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ABSTRACT 
Angiogenesis is a key regulator in over 70 diseases, and it is typically characterized via 
uni-family ligand-receptor interactions—primarily via VEGF-A:VEGFR2 binding. But targeting 
the VEGF family alone has not achieved the promise of stable vascular control, because 
angiogenesis involves other signaling axes, such as the PDGFs. In cancer, for example, anti-
angiogenic therapeutics primarily target the VEGF signaling family, but their success is limited 
by the development of drug resistance. These challenges in VEGF targeting, and recent 
discoveries of VEGF-A:PDGFR binding and signaling, presents a compelling need to shift away 
from a uni-family (e.g., VEGF-alone) towards a multi- and cross-family (e.g., VEGF + PDGF, 
etc.) understanding of angiogenesis.  
VEGFs and PDGFs share significant structural and binding motifs, which could explain 
the new VEGF-A: PDGFR interaction and suggests that additional cross-family VEGF/PDGF 
cross-family binding may occur. To identify and measure new ligand:receptor binding pairs,  I 
utilized a surface plasmon resonance-biosensor based kinetics assay. Here, I present my 
discovery of novel PDGF:VEGFR2 interactions, with: PDGF-AA:R2 KD = 530 nM, PDGF-
AB:R2 KD = 110 pM, PDGF-BB:R2 KD = 40 nM, and PDGF-CC:R2 KD = 70 pM. For the first 
time, I measured the kinetic constants for VEGF-A:PDGFRβ and the canonical PDGF:PDGFR 
interactions. I then construct a model of VEGF-A: and PDGF:VEGFR2 interactions in 
endothelial cells (ECs),and predict that PDGF:VEGFR binding could contribute up to 96% of 
VEGFR2 ligation in healthy conditions and in cancer.  
 Because VEGFR2-mediated signaling drives angiogenic responses, I investigated 
whether PDGF-binding could activate VEGFR2-mediated signaling, and ultimately stimulate EC 
proliferation and migration—steps key in angiogenesis. I found that PDGFs induce significant 
VEGFR2 phosphorylation at tyrosines 951, 1054/59, and 1175. Further, PDGFs activate the 
downstream signaling effectors FAK, PI3K, PLCγ and Src. Remarkably, PDGF-AA promoted a 
1.2-fold larger increase in Y1054/59 phosphorylation than did the canonical VEGF-A. PDGF-
BB stimulates a ~1.3-fold larger increase in FAK phosphorylation than VEGF-A. Furthermore, I 
show the PDGFs stimulate increased EC proliferation, and that only PDGF-AA, -BB, and -CC 
stimulated significant EC migration. Taken together, these findings that PDGFs can stimulate 
VEGFR2 signaling and downstream angiogenic cell responses will break new ground towards 
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modulating angiogenesis in health and disease, offering new hypotheses for why angiogenesis-
targeting therapies have proven unsuccessful. 
VEGF-A165 and its binding to VEGFRs is an important angiogenesis regulator. But 
several additional splice variants play prominent roles in regulating angiogenesis in health and in 
vascular disease, including VEGF-A121 and an anti-angiogenic variant VEGF-A165b. Despite their 
significance to physiological, therapeutic, and pathological angiogenesis, little is known about 
differences in their binding. I measured the binding kinetics for VEGF-A165, -A165b, and -A121 
with VEGFR1 and –R2 using (SPR). I find that the VEGF-A variants differentially bind 
VEGFRs. VEGFR1 binds variants at strengths: VEGF-A165a > -A165b > -A121; and VEGFR2 
binds variants at strengths: VEGF-A165b > -A165a > -A121. Interestingly, my findings suggest that 
the anti-angiogenic VEGF-A165a would preferentially bind VEGFR2, out-competing the pro-
angiogenic isoform. My results suggest VEGF-A splice variants may play an important 
modulatory role in VEGFR-mediated angiogenesis, stressing the need to differentiate VEGF-A 
splice variants in future studies. 
Overall, my results demonstrate that that VEGFR-mediated angiogenesis involves a more 
complex network of ligand:receptor interactions than previously known. Computational 
approaches can provide key insight to detangle these signaling pathways but are limited by the 
sparse knowledge of cross-family interactions. Here, I present a framework for studying known 
and potential non-canonical interactions. I construct generalized models of RTK ligation and 
dimerization for systems of two, three, and four receptor types, and different degrees of cross-
family ligation. Across each model, I develop parameter-space maps that fully determine relative 
receptor activation for any set of ligand:receptor binding kinetics, ligand concentrations, and 
receptor concentrations. My generalized models serve as a powerful reference tool for predicting 
dimerization for known ligand:receptor axes. They also can predict how unknown interactions 
could alter signaling dimerization patterns. Accordingly, they will drive exploration of cross-
family interactions, and help guide therapeutic developments across processes like cancer and 
cardiovascular diseases that depend on RTK-mediated signaling.  
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CHAPTER 1 
INTRODUCTION 
 
 Angiogenesis, the growth of new capillaries from existing microvasculature, is a key 
pathogenic component of at least 70 known diseases, from diabetes to age-related macular 
degeneration to cancers. Angiogenesis is typically characterized via its uni-family ligand-
receptor interactions—i.e. vascular endothelial growth factors (VEGFs) binding and signaling 
via VEGF receptors (VEGFRs). However, targeting VEGF alone has not achieved the promise 
of stable vascular control [1–5]. because angiogenesis involves several other signaling like the 
platelet-derived growth factors, fibroblast growth factors, and the angiopoietins. For example,  
VEGF-A-inhibition in tumor eventually results in anti-angiogenic drug resistance, and involving 
upregulation of ancillary axes, including the PDGFs [6,7].  Furthermore, dual-growth factor 
therapy has resulted in synergistic effects when used to promote vascularization in animal 
ischemia models [8]. These findings present a compelling need to shift away from a uni-family 
(e.g., VEGF-alone) towards a cross-family (e.g., VEGF + PDGF, etc.) understanding of 
angiogenesis.  
 
1.1 The vascular endothelial growth factor family 
The vascular endothelial growth factors (VEGF) are a tyrosine kinase receptor (RTK) 
signaling protein family, and are key regulators of angiogenesis and lymphangiogenesis [9,10]. 
The family is made up by several ligands and receptors. In mammals, the VEGF family includes 
five homodimeric ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor 
(PlGF) [11], three receptor monomers: VEGFR1, VEGFR2, and VEGFR3 [12,13], and two co-
receptors: neuropilins-1 and neuropilins-2. Classically, VEGFs bind VEGFRs with distinct 
interaction patterns: VEGFR1 binds VEGF-A, VEGF-B and PlGF; VEGFR2 binds VEGF-A, 
and VEGF-C and VEGF-D weakly; VEGFR3 binds VEGF-C and VEGF–D [13,14]. Each 
receptor can form homodimers and heterodimers, depending on the bound ligand [15,16].  
Vascular endothelial growth factor A (VEGF-A) and its binding to VEGFR2 is crucial 
for the regulation of angiogenesis. Following VEGF-A ligation and receptor dimerization, 
VEGFR2 signal transduction develops via three key steps: (1) VEGFR2 phosphorylation at 
specific tyrosine residues [17], (2) adapter proteins bind these tyrosine residues and undergo 
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phosphorylation [18], and (3) phosphorylated adapter proteins initiating second-messenger 
signaling cascades [19]. VEGFR2 contains several intracellular tyrosine residues critical to its 
activity, including: Y801 [20,21], Y951 [22], Y1054/5 9[22–24], Y1175 [18,25], and Y1214 
[26,27]; and several with unknown function: Y1223, Y1305, Y1309, and Y1319 [28,29]. Each 
VEGFR2 tyrosine site is associated with specific effector proteins [30–32] and ultimately 
different cell responses [13,18,28,31]. Signaling via Y951, Y1054/59, and Y1175 is especially 
critical to angiogenesis, stimulating endothelial cell survival [33] and permeability [30], and the 
angiogenic hallmarks of cell proliferation and migration [29,30,34]. 
 
1.2 Platelet-derived growth factors 
The PDGF signaling family consists of five ligands: PDGF-AA, -AB, -BB, -CC, and -
DD, and two receptors: PDGFRα and -Rβ [35]. As with the VEGFs, PDGFRs bind the PDGFs 
with a degree of specificity: PDGFRα binds PDGF-AA, -AB, -BB, and -CC; while PDGFRβ 
binds PDGF-AB, -BB, and -DD [35–39]. Like with the VEGFs, the specific ligand-receptor and 
receptor-receptor binding patterns trigger unique downstream signaling, such as the well-
established PI3K/Akt and MER-ERK pathways (reviewed in [19]), resulting in different 
responses. PDGFs also contribute to vascular function. PDGF binding to PDGFRs on pericytes 
maintains and stabilizes endothelial tubes during development [40,41]. PDGFs also promote 
endothelial cell proliferation [42], induce vessel growth [43] and regeneration [44], and induce 
reperfusion after arterial blockage [45].  
 
1.3 VEGF & PDGF similarities suggest further cross-family interactions 
A cross-family understanding of signaling involves examining ligands from one growth 
factor family binding to and signaling through receptor(s) of other families. Indeed, cross-family 
binding and signaling have been observed between the PDGF and VEGF families [35,46–49]. 
Earlier studies revealed that VEGF-A can bind and dose-dependently activate PDGFRs [47] and  
competitively inhibit canonical PDGF:PDGFR binding [49]. Recent measurements of fibroblast 
PDGFRs revealed that VEGF-A165 acts independently of VEGFRs to regulate PDGFR 
concentrations [50]. However, additional cross-family interactions—such as PDGFs to VEGFRs 
and other VEGFs (VEGF-B, -C, and -D) to PDGFRs—have remained unexplored. 
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There are several compelling reasons to suspect that additional cross-family signaling 
interactions may occur. PDGFs and VEGFs—both hailing from the cysteine knot superfamily 
[51]—are similar in quaternary structure: the dimeric form of VEGF-A and PDGFs shows 
significant alignment, with a 1.8 Å root mean square difference despite the low VEGF-PDGF 
sequence homology ( < 20% ) [52,53]. VEGFs and PDGFs also share structural motifs in their 
receptor-binding regions [54]. Domains 2 and 3 in VEGFR2, which are known to be responsible 
for high-affinity VEGF-A:VEGFR1 [55] and VEGF-A:VEGFR2 [56] binding, are highly-
conserved within PDGFRs, where they analogously house its PDGF-binding site. The common 
ligand-binding domains suggests that PDGFs could utilize these sites to bind VEGFRs. 
Furthermore, recent experimental studies established that VEGFR2 and PDGFRβ can form 
complexes on pericytes [57,58], the mural cells that mediate vessel stability [59,60]. Therefore, 
measurement of possible cross-family interactions between the two families could reveal new 
angiogenic mechanisms. Taken together, PDGF and VEGFs are a practical, logical point to begin 
a systematic exploration of potential cross-family interactions.  
 
1.4 VEGF-A splice variants can provide insight into structural motifs key to cross-family 
binding and signaling.  
VEGF-A splice variants are an ideal model for investigating the structural motifs that 
could give insight into PDGF:VEGFR2 binding and their VEGFR2-signaling efficacy.  
Alternative mRNA splicing produces a wide-array of VEGF-A isoforms [61,62], including: 
VEGF-A121, VEGF-A121b, VEGF-A145, VEGF-A145b, VEGF-A165, VEGF-A165b, VEGF-A183, 
VEGF-A189, and VEGF-A206 [34,63] . The splice variants differ in whether they bind certain co-
receptors or extracellular matrix components [64]. For example, exons 6 and 7 encode heparin 
and neuropilin-1 binding motifs [65]. VEGF-A165 includes exon 7 and can bind both [66], while 
VEGF-A121 is generated without exon 6 and 7, binding neither [67]. They also differ in signaling 
capabilities: those denoted as VEGF-AXXX are pro-angiogenic, whereas those designated as 
VEGF-Axxxb are described as anti-angiogenic due to their failure to efficiently activate VEGFRs 
[30,68].  
Despite their significance to physiological, therapeutic, and pathological angiogenesis, 
little is known about differences in their binding kinetics. This is an important area of inquiry 
because recent evidence has revealed shifts in the serum and plasma concentrations for VEGF-
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A165a, -A165b, and –A121 in several pathologies, including: peripheral artery disease, where the 
anti-angiogenic VEGF-A165b is upregulated [69];  cancers [70], where VEGF-A165a is 
upregulated &  VEGF-A165b downregulated, and other pathologies like diabetes [71,72], systemic 
sclerosis [73], and pre-eclampsia [74]. To understand the role these concentration changes may 
play in pathological angiogenesis, we need precise measurements for each splice variants 
binding kinetics. Currently these kinetics remain largely unexplored.  
 
1.5 Kinetics and thermodynamic properties characterize biomolecular interactions 
Biomolecular interaction dynamics are best characterized by: (1) binding kinetics and (2) 
thermodynamic binding affinities [75]. The binding kinetics represent the rate at which the 
proteins chemically couple. For a 1:1 protein interaction, the association constant kon describes 
the rate two proteins couple, forming a complex; the dissociation constant koff, in turn, describes 
the rate that complex [76].  The binding affinity, in contrast, describes the ‘strength’ of the 
protein interaction [77]. Conventionally, binding affinities are expressed as dissociation 
equilibrium constant KD; the higher the KD value, the lower the binding affinity. Conveniently, 
KD can be expressed in terms of the kinetic constants (Equation 1.1).  
(Equation 1.1) = offD
on
k
K
k
 
 
1.6 SPR to identify and measure ligand:receptor binding 
The surface plasmon resonance (SPR)-based assay is an ideal approach for identifying 
and measuring kinetic rate parameters for ligand:receptor interactions, like between VEGFRs 
and VEGF-A splice variants, or cross-family interactions between the PDGFs and VEGFs. SPR-
based biosensors like the BIAcore [78] detect protein-protein interactions utilizing an optical 
phenomenon, surface plasmon resonance, that is sensitive to small changes in mass [79,80]. By 
coupling a target protein on the sensor surface, binding kinetics and affinities can be measured 
by flowing the ligand protein through a flow channel over the sensor surface and recording the 
mass change over time while ligand binds and unbinds the receptor [77,81,82]. Furthermore, 
SPR-based biosensors are capable of probing one ligand against multiple receptors 
simultaneously, enabling faster testing of ligand:receptor pairs [83]. Therefore, SPR-based 
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assays are ideal for systematically identifying and measuring kinetic parameters for potential 
cross-family binding and between VEGF-A splice variants. 
 
1.7 Computational modeling can predict receptor activation due to cross-family binding.  
Computational models of RTKs have examine uni-family receptor activation, including 
EGFs [84], FGFs [85], PDGFs [86], VEGFs [31,87–89]. However, there are no models currently 
that model cross-family interactions (e.g. VEGF-A:PDGFRs), which may be a crucial element to 
accurately predicting the evolution of angiogenic signaling networks. As we continue to expand 
this cross-family paradigm, new models are needed to predict how new cross-family interactions 
will alter signaling patterns within generalized RTK system. Such models will help us answer 
two critical questions: how would cross-family interactions alter signaling activation patterns? 
Are there specific conditions (e.g. upregulated [ligand] in cancers) where cross-family binding 
dominates receptor activation? Generalized modeling, therefore, can offer broad insights across 
different RTK interaction networks. 
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CHAPTER 2 
DISCOVERY OF HIGH-AFFINITY PDGF-VEGFR INTERACTIONS: REDEFINING 
RTK DYNAMICS 1 
 
2.1 Introduction 
The vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR) signaling 
family has been extensively studied, because it is the major regulator of microvascularization 
[19]. VEGF-targeted monoclonal antibodies have been developed to inhibit microvascular 
growth; and VEGF has also been applied to promote vascularization in engineered grafts, 
bioreactors, and tissue [90].  However, anti-angiogenic approaches have not yielded the promise 
of sustained vascular inhibition nor have pro-angiogenic approaches yielded stable blood vessel 
growth [1–5]. This is likely because angiogenesis involves several signaling pathways, in 
addition to VEGF, representing a cross-family signaling complexity that cannot be captured by 
targeting one growth factor alone.  
Increasing evidence suggests that a cross-family view of cell signaling offers promise in 
controlling angiogenesis. For example, VEGF-inhibition eventually results in anti-angiogenic 
resistance and one resistance mechanism involves the upregulation of ancillary axes, including: 
platelet derived growth factors (PDGFs) [6,7], fibroblast growth factor, and angiopoietins [91]. 
Moreover, incorporating a cross-family view of angiogenesis into therapeutics has led to 
synergistic effects and improved blood flow, when dual-growth factor therapy is applied in pre-
clinical ischemia models [8], and improved wound healing, when dual-growth factors are 
coupled to biomaterials for tissue-engineering [92,93]. Together, these cross-family 
compensatory mechanisms and therapeutic advances suggests a need to shift from examining the 
VEGF-family alone toward directed exploration of combined growth factor signaling 
pathways—a cross-family paradigm.  
The canonical angiogenesis philosophy involves uni-family ligand-receptor binding: 
VEGFs bind to VEGFRs, PDGFs bind to PDGFRs, and so on. This paradigm offers numerous 
activation schemes. For example, VEGF-A, -B, -C, -D, & placental growth factor and several 
isoforms produced via alternative splicing [30,64,65,94–96]  bind to selected VEGFRs: 
                                                 
1This chapter was published in Scientific Reports (2017) Volume 7, Issue 1, Article Number: 16439 
doi: 10.1038/s41598-017-16610-z  
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VEGFR1, -R2, -R3 and co-receptors: neuropilin-1 and neuropilin-2 leading to the angiogenic 
hallmarks of endothelial cell proliferation and migration to hypoxic regions [30,97].  PDGFs also 
contribute to vascular function. PDGF-AA, -BB, -AB, -CC, and –DD binding to corresponding 
PDGFRs (α and β) maintains and stabilizes endothelial tubes during development [40,41], 
promotes endothelial cell proliferation [42], induces vessel growth [43] and regeneration [44], 
and induces reperfusion after arterial blockage [45]. (A full schematic detailing the selective 
binding between these ligands and receptors is shown in Figure 2.1.)  
Since VEGFs and PDGFs are both key regulators of angiogenesis, shifting the focus of 
angiogenesis away from a uni-family (VEGF-family alone) and towards a dual-family (VEGF 
and PDGF) focus would be a practical approach in exploring a cross-family angiogenesis 
framework. Indeed, one study of dose-dependent VEGF-A:PDGFR activation [47] has provided 
an example of this new signaling paradigm. They found that VEGF-A directly binds both PDGF 
receptors and induce their phosphorylation in a dose-dependent fashion. However, additional 
cross-family interactions, such as PDGFs to VEGFRs and other VEGFs (VEGF-B, -C, and -D) 
to PDGFRs, remain unexplored.  
There are several, compelling reasons why additional cross-family signaling interactions 
may occur. Structurally, PDGF and VEGF are similar, hailing from the cysteine knot 
superfamily [51]. The dimeric form of VEGF and PDGF shows significant alignment with a 1.8 
Å root mean square difference [53], despite the low VEGF-PDGF sequence homology (<20%). 
Furthermore, recent experimental studies established that VEGFR2 and PDGFRβ can form 
complexes on pericytes [57,58], the mural cells that mediate vessel stability [59,60]. Therefore, 
measurement of possible cross-family interactions could reveal new angiogenic mechanisms.  
Here I identify, measure, and simulate binding across the VEGF and PDGF families. I 
establish new standards for identifying and measuring new protein-protein interaction kinetics. I 
predict the significance of these cross-family binding interactions via computational modeling 
and present evidence that these novel interactions should significantly modulate angiogenic 
signaling, particularly in cancer. Overall, these cross-family interactions offer a shifted paradigm 
for understanding cell signaling with implications to angiogenesis, health, and disease. 
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2.2 Results 
2.2.1 Validation of SPR protocol 
I measured the kinetic rate constants between PDGF ligands and VEGF receptors using a 
surface plasmon resonance (SPR) assay. I injected the ligands at 40, 20 and 10 nM (summarized 
in Figure 2.2) and fit their association and dissociation curves using a 1:1 Langmuir binding 
model. To measure the accuracy of my kinetic analyses, I applied a χ2-to-Rmax ratio heuristic. For 
known interactions, a χ2-to-Rmax value < 0.20, represents a well-established filter for high-quality 
fitting of kinetic parameters obtained via SPR [98–100]. The χ2-to-Rmax ratio can be helpful in 
detecting new 1:1 binding interactions, because this value describes how well the obtained 
sensogram curves fit a 1:1 Langmuir interaction model. When the fitting noise (χ2) exceeds the 
maximal response (Rmax), the interaction cannot be said to follow the binding model. I therefore 
introduce a heuristic where a χ2-to-Rmax ratio ≤ 1.0 is attributed to “true” interactions, and those > 
1.0 are described as non-1:1 Langmuir interactions resulting from non-specific binding.  
To validate the χ2-to-Rmax cut-off approach, I examined ligand:receptor pairs known to 
bind and non-interactions (i.e. pairs known not to bind). The χ2-to-Rmax cut-off approach 
correctly identified well-established VEGF:VEGFR and PDGF:PDGFR ligand:receptor pairs as 
real interactions (χ2-to-Rmax < 1.0), and accurately excluded those known to not interact (χ2-to-
Rmax > 1.0). Specifically, VEGF-A:VEGFR1 and VEGFR2, PDGF-AA:PDGFRa, PDGF-
AB:PDGFRα, PDGF-BB:PDGFRs, and PDGF-CC:PDGFRa were correctly designated as real 
interactions, with χ2-to-Rmax < 1.0 for each (Table A.1). The following known non-binding pairs 
were correctly excluded: VEGF-A:VEGFR3 [101] and PDGF-AA:PDGFRβ [102], with χ2-to-
Rmax ratios 6.0- and 8.6-fold larger than the cut-off. The validation of the heuristic across seven 
ligand:receptor pairs of the VEGFR and PDGFR families offers strong support for its extension 
to cross-family interactions within these families (Figure 2.1 and Table A.1).  
I further validated my experimental approach by reproducing previously measured 
binding affinities. The VEGF-A:VEGFR1 and VEGF-A:VEGFR2 binding affinities (Figure 
2.3A and Table A.2) were both within an order of magnitude of previous SPR measurements, KD 
= 1 pM (Figure 2.3A) versus a previous measured KD = 7.5 pM [103], and KD = 9.8 pM (Figure 
2.3B) versus 52 pM [104], respectively.  
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2.2.2 Establishing kinetic and affinity constants for canonical PDGF:PDGFR interactions. 
I confirmed that the canonical understanding of PDGF:PDGFR holds (Figure 2.1). More 
specifically, PDGF-AA binds only to PDGFRα (Figure 2.4A-B) [105]; both PDGFRs bind 
PDGF-AB (Figure 2.4C-D) [106], -BB (Figure 2.4E-F) [37], and -CC (Figure 4G-H) [107]; and 
PDGF-DD binds only to PDGFRβ (Figure 2.4I-J) [106]. I then compared the obtained affinities, 
when possible, to previously reported affinities. Currently only PDGF-AA and –BB:PDGFR 
interactions have been reported via a study that did not use a reference protein cell (Table A.3). 
As described in the Materials and Methods, I used angiopoietin-4 as a reference protein to 
measure and account for non-specific binding effects that would affect my kinetics. All binding 
affinities values are listed in Table A.2. I measured a PDGF-AA:PDGFRα affinity of the same 
order of magnitude as previously reported (measured KD = 660 nM versus prior 134 nM [108]). I 
determined that PDGF-BB binds both PDGFRα and PDGFRβ with similar affinities KD = 420 
nM and 830 nM, respectively. While these measured affinities were lower than a previous report 
(KD = 150 nM and 1.6 nM for PDGFRα and PDGFRβ, respectively),  these previous studies did 
not use a reference protein [108]. I believe that this difference is critical: without a reference 
protein, these prior studies measure a weaker binding affinity due to an inflated non-specific 
binding reference measurement. Furthermore, the relative strength of binding –BB:Rα > —
BB:Rβ, is observed in both my study and the work of others.   
I further characterized the binding rates and affinities for the canonical PDGF:PDGFR 
interactions lacking kinetic data (-AB, -CC, -DD:Rα and -AB, -CC, -DD:Rβ). I observed that 
PDGF-AB:PDGFRα binding affinity was ~2.6x stronger than PDGF-AB:PDGFRβ, with affinity 
constants of KD = 840 nM versus Kd = 2,200 nM, respectively (Figure 2.5A). I measured strong 
affinities between PDGF-CC:PDGFRα and PDGF-CC:PDGFRβ with KD = 3.4 nM and 1.9 nM, 
(Figure 2.5A) Finally, I observed that PDGF-DD binds PDGFRβ with moderate affinity, KD = 67 
nM (Figure 2.5A). PDGF-DD:PDGFRβ has a 50-fold larger peak association response than its 
binding to PDGFRα, but its kinetic fitting for this interaction produced a χ2-to-Rmax of 2.2 (Table 
A.1). But since it is > 1.0, it displays high noise to signal, which is interpreted to mean it is not a 
1:1 Langmuir interactions.  
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2.2.3 Novel cross-family PDGF:VEGFR2 interactions. 
I identified novel interactions between PDGF-AA, -AB, -BB, and -CC with VEGFR2 
(Figure 2.6A-D, respectively). These interactions all exhibited classic signal responses, 
characterized by a steady signal increase upon ligand injection, association-phase, followed by a 
steady signal decrease during buffer injection, dissociation-phase (Figure 2.6). I show examples 
of this in PDGF:PDGFR binding (Figure 2.5), and all were all found to have χ2-to-Rmax < 1.0, 
indicating true 1:1 Langmuir interactions (Table A.1.) There was no evidence of PDGF 
interactions with VEGFR1 or VEGFR3 (Figure A.1). A summary of the novel interactions 
identified can be found in Figure 2.7. When I quantified kinetic binding rates (ka and kd) and 
affinity constants (KD = kd/ka), I observed that PDGF-CC:VEGFR2 had an affinity constant of 
the same order of magnitude as native VEGF-A:VEGFR2 binding with KD (-CC:R2) ~70 pM 
versus (VEGF-A:R2) ~10 pM. The other PDGFs presented VEGFR2 binding affinities with 
decreasing strength as follows: PDGF-AB>-BB>-AA. Another notable finding was that PDGF-
CC bound VEGFR2 at an affinity greater than or equal its binding to either PDGFR (Figure 
2.5A). PDGF-AA:VEGFR2 was a higher affinity, but similar order of magnitude as PDGF-
AA:PDGFRα binding, KD (-AA:R2) = 100 nM, vs. (-AA:Rα) = 660 nM. PDGF-AB:VEGFR2 
binding was higher affinity than its binding to PDGF-AB:PDGFRs with KD (-AB:R2) = 110 pM 
vs. (AB:PDGFRs) >800 nM. Additionally, PDGF-BB:VEGFR2 binding was higher affinity than 
its binding to PDGFRs, KD (-BB:R2) = 37 nM vs. (-BB:PDGFRs) >400 nM (Figure 2.5A). The 
exact values obtained for binding affinities can be found listed in Table A.2.  
 
2.2.4 Association and dissociation rate constants reveal affinity trends. 
The affinity of the PDGF:VEGFR2 is best understood by examining the association and 
dissociation rate constants. Here I observe that the high-VEGF:VEGFR2 affinity is attributed to 
fast association, ~ 106 M-1 s-1 (Figure 2.5B), and slow dissociation, ~1 day-1 (Figure 2.5C.) Only 
the PDGF-CC:PDGFRβ association nears these VEGF-A:VEGFR2 association dynamics, which 
supports its high-affinity binding to PDGFRβ (Figure 2.5A). All other association dynamics are 
< ~105 M-1 s-1. The slow VEGF:VEGFR2 dissociation rate constant is exceeded by PDGF-
AB:VEGFR2, ~1/7 days (i.e. dissociating on average once per week), explaining its ~100 pM 
binding affinity (Figure 2.5A). All other dissociation rate constants are “faster”—i.e. higher 
values—in the range 1/minutes and 1/hours (i.e. one molecule dissociates on average per minute 
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and per hour, approximately). (Association and dissociation rate constants are summarized in 
Table A.2.)   
 
2.2.5 Model construction and validation. 
To predict the significance of PDGF-VEGFR2 cross-family binding (summarized in 
Figure 2.7), I derived the ordinary differential equations describing these ligand-receptor 
interactions based on the law of mass action. Klipp et al. and Linderman & Lauffenburger offer a 
comprehensive explanation of this approach for representing protein-protein interactions [109–
113]. Towards this goal, I simulated two sets of models governing VEGFR ligation: one 
describing the canonical, uni-family VEGF-A:VEGFR binding and one describing cross-family 
binding that includes both the canonical uni-family VEGF:VEGFR and my newly derived cross-
family PDGF:VEGFR2 binding (PDGF-AA, -AB, and -BB with VEGFR2) (see model 
schematic Figure 2.8).  I do not include PDGF-CC in the model because PDGF-CC has not been 
found to be expressed in humans under healthy or cancer conditions, but is instead observed 
following a an ischemic event like a stroke or myocardial infarction [114]. I recapitulated the 
benchmark, uni-family VEGF-A:VEGFR model by Mac Gabhann [88], showing consistent 
VEGFR1 and VEGFR2 fractional occupancies (Figure 2.9A) and maximal responses (Figure 
2.9B).  
I analyzed these two models for ligand concentrations found in healthy physiology, breast 
cancer, and anti-VEGF-A therapy in breast cancer. Bevacizumab is used as the basis of the anti-
VEGF-A treatment, implemented as a binding interaction between bevacizumab and non-
receptor-bound VEGF-A. Model equations are listed in full in Appendix A.3 and parameters are 
summarized in Table A.4. 
 
2.2.6 Localized PDGF cross-family binding enhances VEGFR2 activation in health and cancer. 
I predict increased VEGFR2 complex formation in every case where PDGF:VEGFR2 
cross-family interactions are considered. First, the cross-family model in comparison to the uni-
family model predicts a 14-fold increase in VEGFR2 ligation under healthy physiology (Figure 
2.10A). Similarly, the cross-family model predicts a 15-fold increase in VEGFR2 ligation in 
breast cancer xenograft-derived endothelial cells over the canonical, uni-family framework 
(Figure 2.10A). Also, I observe that an anti-VEGF drug, like bevacizumab, would only 
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contribute a ~5% decrease in VEGFR2 ligation when cross-family binding is considered in 
breast cancer xenograft-derived endothelial cells (Figure 2.10A). Therefore, I predict that cross-
family interactions may allow VEGFR2 complex formation to remain relatively unchanged when 
bevacizumab is administered, even though PDGFs bind VEGFR2 with affinities ~2 orders of 
magnitude weaker than VEGF-A (Figure 2.10A). 
The increased VEGFR2 ligation that I predict under a cross-family paradigm is attributed 
to the 10- to 100-fold higher PDGF to VEGF concentrations in serum under healthy 
physiological conditions. Indeed, I have included a meta-analysis comparing serum 
concentrations of VEGF-A and PDGFs across healthy and pathological conditions to 
contextualize these differences (Figure 2.11). Such high PDGF concentrations may subsequently 
enable PDGFs to account for up to ~96% of VEGFR2 ligation under healthy conditions (Figure 
2.10B). Similarly, breast cancer patient serum is measured to have 25-to-40-fold higher PDGF 
levels than VEGF (Figure 2.10A), so when considering VEGF-A and PDGFs, I predict up to 
90% steady state ligation by PDGFs in breast cancer and nearly 100% ligation by PDGFs under 
conditions of anti-VEGF therapy (Figure 10B). My model suggests that this buffering of 
angiogenic signaling during anti-VEGF therapy may be mediated as follows: PDGF-AB > 
PDGF-AA > PDGF-BB > VEGF-A (Figure 2.10B).  
As previously described, I do not include PDGF-CC in the model given its limited 
expression pattern (e.g., ischemic event) [114]. However, I expect that PDGF-CC:VEGFR2 will 
dominate VEGFR2 ligation following ischemic damage for two reasons: (1) after ischemic injury 
PDGF-CC has a 150- to 300-fold greater serum concentration than VEGF-A (Figure 2.11), and 
(2) PDGF-CC has similar, high-affinity (~100 pM) VEGFR2 binding as canonical VEGF-
A:VEGFR2. Furthermore, I predict that PDGF-CC:VEGFR2 ligation would dominate whenever 
PDGF-CC serum concentrations are 2-fold greater than VEGF-A. I can extend a similar analysis 
to the other PDGF ligands. my meta-analysis of PDGF and VEGF serum concentrations would 
also suggest that in every case where any PDGF serum concentration is at least 25-fold greater 
than VEGF, then PDGF:VEGFR2 ligation should significantly modulate VEGFR2 signaling. 
This would include in cancer, post-stroke, and during exercise (Figure 2.11). 
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2.3 Discussion 
In this study, I established a χ2-to-Rmax cut-off (where values are < 1.0) for distinguishing 
non-binding and binding interactions, which I used in the discovery of new PDGF-VEGFR 
interactions: (1) PDGF-AA to VEGFR2, (2) PDGF-AB to VEGFR2, (3) PDGF-BB to VEGFR2, 
and (4) PDGF-CC to VEGFR2 (summarized in Figure 2.7).  I measured both the kinetics of these 
new interactions; and for the first time, I measured the kinetics for VEGF-A:PDGFRβ[47] 
binding. In a cross-family signaling system, where several ligands compete to bind with the same 
receptor, the ligand concentrations and ligand-receptor binding kinetics determine which 
ligand(s) dominate signaling. Therefore, my computational analysis provided quantitative 
evidence that PDGF:VEGFR2, cross-family binding should significantly participate in VEGFR2 
ligation under conditions of health physiology, breast cancer, and pathologies where PDGFs 
significantly outnumber VEGFs. Furthermore, my modeling offers predictions on how 
PDGF:VEGFR2 interactions may sustain VEGFR2 ligation when VEGF-A is inhibited (e.g., 
bevacizumab, ziv-aflibercept). Together these findings offer new insight into several fields of 
research, including anti-angiogenic drug development and cancer, which I contextualize herein.  
 
2.3.1 Cross-family interactions may shed new light on anti-angiogenic drug development. 
My discovery of cross-family interactions can advance anti-angiogenic drug 
development, which is currently guided by a uni-family view [115,116]. Anti-VEGF success has 
been limited, due to both intrinsic resistance and acquired resistance (relapse) [117].  Several 
mechanisms have been proposed to explain anti-VEGF resistance, a few include: (1) Increased 
mural cells: some tumors resist anti-angiogenic drug treatment via increased pericyte coverage of 
tumor vessels [117,118], providing a permeability barrier to anti-VEGF therapy. (2) Increased 
tumor invasiveness: tumor undergoes enhanced metastasis into healthy tissue as a means of co-
opting existing vasculature [119]; thereby seeking to avoid hypoxia or nutrient deprivation and 
bypassing anti-VEGF therapy. (3) Ancillary growth factors: some tumors secrete additional 
growth factors, such as PDGFs and fibroblast growth factors [117], which enable ancillary 
angiogenic signaling axes to bypass anti-VEGF therapy. The latter mechanism may be supported 
by my findings if PDGF:VEGFR2 complexes lead to VEGFR2 activation and angiogenic 
signaling. Therefore, future work should determine how PDGF:VEGFR2 ligation regulates 
native VEGFR2 signaling.  
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Cross-family signaling may also aid our understanding of multi-target small molecule 
inhibitors, like sorafenib and sunitinib. Sorafenib inhibits VEGFR2, VEGFR3 and PDGFRβ 
[120,121] , while sunitinib inhibits PDGFRβ and all VEGFRs [122]. When viewed through the 
uni-family signaling lens, these small molecules would only inhibit uni-family interactions, i.e. 
blocking PDGFR autophosphorylation would render PDGF ligands as non-functional. This 
perspective does not explain why patients also relapse on these cross-family anti-angiogenic 
drugs. Under a cross-family paradigm, blocking VEGFR and PDGFR would shift VEGF and 
PDGF binding to receptors of other signaling families. Some possibilities could be other, 
structurally similar tyrosine kinase receptors with angiogenic function, such as: nerve, fibroblast, 
and transforming growth factor receptors [123–125]. My work suggests that drug resistance to 
multi-target therapeutics can be better informed and overcome by identifying the extent of cross-
family binding. 
 
2.3.2 The tip of the iceberg? Structural analysis can guide further cross-family discovery. 
These results open the possibility that that other cross-family interactions exist but remain 
undiscovered. Experimentally screening for interactions between every known cytokine with 
every known receptor would be cost- and time-prohibitive. Instead, structural analysis of shared 
ligand and receptor structural motifs can guide further discovery. For example, VEGFRs and 
PDGFRs are tyrosine kinase receptors: PDGFRs have 5 extracellular immunoglobulin-like (IgG-
like) domains [35] and VEGFRs have 7 extracellular IgG-like domains in VEGFRs [54]. Of 
these, domains 2-3 are responsible for high-affinity binding of VEGF-A:VEGFR1 [55] and 
VEGF-A:VEGFR2 [56]. Domains 2-3 are highly-conserved within PDGFRs, where they play an 
identical role of housing the PDGF binding site. The common ligand-binding domains suggests 
that PDGFs could utilize these sites to bind VEGFRs. Moreover, VEGF and PDGF are similar in 
quaternary structure: VEGF and PDGF have only a 1.93 Å root mean square difference between 
overlapping structures [52] (Figure 2.1B). VEGFs and PDGFs also share structural motifs in 
their receptor-binding regions [54]. In fact, PDGF ligands have been superimposed within the 
VEGF-A:VEGFR2 binding domains, illuminating the possible confirmations for the interactions 
I report [53]. Additionally, VEGFRs and PDGFRs have a similar intracellular structure: having 
an intracellular split tyrosine-kinase domain [36,126]. Such a feature may lend the possibility of 
agonist or partial agonist action via cross-family binding.  
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Cysteine knot ligands [52,127] with some of these VEGF-PDGF structural properties 
should also be investigated; these include: nerve growth factors, fibroblast growth factors, 
transforming growth factors, and even glycoprotein hormones, due to their structural similarity to 
PDGF [52]. Examining other receptors that exhibit multi-ligand binding would offer a good 
template for understanding the possibilities in cross-family binding. For example, early work by 
Pennock et al. explored whether VEGF-A served as a cross-family agonist or antagonist for the 
PDGF receptors, finding the ligand acted antagonistically [49]. Outside the VEGFs and PDGFs, 
the nicotinic acetylcholine receptor is well known for having several possibilities for receptor 
assembly, and several molecules, other than nicotine that can bind with agonist-partial agonist-
antagonist affect (e.g., epibatidine, choline, etc.) [128]. The transforming growth factor-β 
superfamily also offers a good template to examine multi-binding interactions, where extensive 
cross-family ligand:receptor binding between the subgroups, transforming growth factor-βs, 
bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and the 
activin/inhibins [129] are responsible for maintaining a complicated regulatory network [130]. 
Structural analysis, therefore, can enable a focused screening of likely cross-family binding 
partners.  
 
2.3.3 Computational modeling will drive conceptual understanding of cross-family signaling.  
Computational modeling has provided new insight into the uni-family activation of 
several growth factor-receptor families, including EGF ([131]), FGF ([85]), PDGF ([86]), and 
VEGF [1,113,132–136]. This PDGF:VEGFR2 modeling and analysis predicted conditions where 
PDGF:VEGFR2 binding prevails, which included normal physiological conditions. While I do 
find the high-affinity of these cross-family interactions surprising, I do not find the modeling 
results to be surprising. It follows that when incorporating when incorporating a new population 
of ligands—at concentrations higher than VEGF-A, and which bind the same receptor at 
affinities either slightly lower or similar to VEGF-A—the receptor would be substantially ligated 
by these new ligands. I expect that these patterns of ligated-receptor dominance could change 
when different healthy biological conditions are considered, such as when receptor trafficking 
rates are altered by changes in blood flowrate-induced sheer stresses [137]. As we continue 
exploring this new paradigm, additional models will need to determine how cross-family 
receptor occupancy translates to various receptor activation landscapes. An elegant 
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computational framework for examining the possible receptor landscapes is the recent work on 
how bone morphogenetic proteins (BMP) and their receptors achieve multiple activation profiles 
[138]. I expect that further computational modeling of cross-family signaling will enable a 
similar understanding of receptor activation landscapes (full-agonist, partial-agonist, partial 
antagonist, and full-antagonist), receptor activation dynamics (fast/burst, slow/sustained, etc.), 
and effector efficiencies. 
Another computational approach that should be enlisted for understanding maximal 
canonical signaling is the recent “meta-model” from my laboratory, which modeled receptor 
activation across eight, canonical ligand-receptor pairs [139].  This meta-model offered ranked 
predictions of receptor signaling, based on the integrated receptor activation response: PDGFRβ 
> IGFR1 > EGFR > PDGFRα > VEGFR1 > VEGFR2 > Tie2 > FGFR1. Because these receptors 
activate similar second messengers, this ranking of canonical (uni-axis) signaling provided the 
first guide for manipulating signaling in cells carrying combinations of these receptors. The 
envisioned multi-family model would extend the foundational model presented here to 
incorporate signaling landscapes [138], and growth factor receptor hierarchy [139]. Such models 
will offer novel predictions for maximally tuning signaling. Furthermore, I will test more 
conditions than are accessible by experiment to understand the multiple cross-family signaling 
permutations.  
 
2.3.4 Future studies: Filtering novel interactions via the χ2-to-Rmax heuristic  
Once structural analysis predicts additional cross-family partners, validation can use a 
similar SPR approach, as I established here. Towards such goals, researchers may apply the χ2-
to-Rmax ratio that I discuss to designate “true” interactions from non-specific, non-1:1 Langmuir 
interactions. Indeed, SPR can often produce large response curves that suggest binding, even 
where no interaction exists. Such curves are primarily due to two types of non-specific binding: 
(1) sensor-ligand interactions [140] and (2) receptor-ligand interactions [141]. The former can be 
corrected by coating a flow cell with a non-binding reference protein. Without the use of a 
reference protein, non-specific effects would artificially inflate the observed binding affinity 
strength (lower KD). For this study I used angiopoietin-4 as a reference (see Materials and 
Methods), thus minimizing non-specific interactions between ligand and chip. However, 
previous SPR measurements of PDGF:PDGFR interactions, did not use a reference protein 
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[108]. I believe this critical difference explains my different affinities, with prior studies 
measuring a weaker binding affinity. Non-specific ligand-receptor interactions can also be 
accounted for when you consider that such interactions would not likely follow a 1:1 Langmuir 
binding model. This is due to the fact that many non-specific interactions are mediated by 
transient electrostatic attractions between amino acid residues on the ligand and receptor. These 
transiently-interacting residues can be distributed throughout both proteins—are therefore not 
site-specific—and should not follow a 1:1 interaction pattern [83,141,142] indicated by the χ2-to-
Rmax ratio. Future measurements of cross-family binding should apply my finding that χ2-to-Rmax 
ratio > 1.0 is attributed to non-specific binding.  
 
2.3.5 Conclusion 
These studies offer new interpretations of tyrosine kinase receptor signaling: a cross-
family paradigm. I provide standards for kinetic analyses of novel interactions with broad 
implications for tyrosine kinase receptor signaling. Through computational modeling, I further 
predict that cross-family interactions may significantly alter signaling. From these results, I 
propose a new mechanism for anti-angiogenic drug resistance, which may aid drug development.  
In addition to the applications of this work for tumor angiogenesis, PDGF-VEGF cross-
family signaling should affect my understanding of cardiovascular-dependent diseases, governed 
by angiogenic signaling, including: wound healing [93], exercise [143], and other cardiovascular 
pathologies [4,144]. Moreover, it should enable improved vascularization in the areas of tissue 
engineering and regenerative medicine [143,145–147]. 
Finally, my work suggests that structural similarities in signaling ligands and receptors 
could indicate cross-family binding patterns and that this phenomenon could be common across 
cell signaling (e.g., agonist/partial agonist paradigm). These and any new interactions can and 
should be illuminated through structural analysis and computational modeling. 
 
2.4 Materials and Methods 
2.4.1 Surface plasmon resonance (SPR) 
All SPR studies were performed with the BIAcore 3000 instrument (Biacore International 
AB, Uppsala, Sweden) at 25°C on dextran-coated gold sensor chips (CM5, Research grade, GE 
Healthcare Bio-sciences AB, Uppsala). The BIAcore 3000 divides CM5 sensor chips into four 
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separate flow cells. I immobilized a different receptor protein in each flow cell: The first cell was 
reserved for measuring non-specific binding by immobilizing recombinant angiopoietin-4 (Cat. 
#964-AN-025/CF, R&D Systems) to a flow cell: it has no known interaction with VEGFs or 
PDGFs. Three different receptors were immobilized to the three remaining flow cells. Running 
buffer: 1x HBS-EP pH 7.4 (10 mM HEPES, 3 mM EDTA, 150 mM NaCl, 0.005 % TWEEN-20, 
cat. # BR100188, GE Life Sciences). 
 
2.4.2 Optimizing immobilization conditions 
Human recombinant VEGFR1 (Cat. #321-FL-050/CF, R&D Systems), VEGFR2 (Cat. 
#357-KD-050/CF, R&D Systems), VEGFR3 (Cat. #349-F4-050, R&D Systems), PDGFRα (Cat 
#322-PR-050/CF, R&D Systems) and PDGFRβ (Cat. #385-PR-100/CF, R&D Systems) were 
immobilized on flow cells by first performing pre-concentration studies to determine optimal 
receptor-immobilization pH as follows: 20 µg/mL receptor + 10 mM acetate buffers ranging 
from pH 3.5 to 0.5 - 1.0 below the protein isoelectric point (Table A.6) were prepared. Known 
receptor-ligand was introduced at 5 µL/min (association), followed by 5-µL injection of 
ethanolamine-HCL (GE Healthcare AB, Uppsala, Sweden) to clear the surface. I selected the 
optimal acetate buffer pH for each protein based on (1) the maximum level of protein 
immobilization reached and (2) the rate of immobilization observed in the pre-concentration 
study sensograms.  
 
2.4.3 Protein immobilization 
Receptor proteins were immobilized to the sensor dextran matrix via amine coupling. 
Flow cells were activated by injecting 35 μL of a 1:1 volumetric mixture of 0.05 M NHS (N-
hydroxysuccinimide) and 0.2 M EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride) at 5 μL/min. 20 µg/mL of the aforementioned recombinant receptor in 10 mM 
acetate buffer at its optimal pH was injected at 5 µL/min until the target level was reached 
(approximately 200-500 R.U. of immobilized receptor.) After sufficient protein coupling (~200-
500 R.U. immobilized protein), the surface was de-activated by 35 μL ethanolamine 
(ethanolamine hydrochloride-NaOH pH 8.5, GE Healthcare AB) (Figure A.2). 
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2.4.4 Ligand-receptor association and dissociation kinetics  
Fresh ligand solutions were prepared at 40, 20 and 10 nM in HBS-EP running buffer each 
experimental day, including: human recombinant VEGFA (R&D Systems, Cat. #293-VE-010), 
PDGF-AA (Cat. #221-AA-050), -AB (Cat. #222-AB-050), -BB (Cat. #220-BB-050), -CC (Cat. 
#1687-CC-025) and -DD (Cat. #1159-SB-025) (Note: All ligands were obtained from R&D 
Systems and were human recombinant proteins). 120 μL of each ligand solution was injected 
into flow cells containing immobilized receptor and Ang-4—a reference for non-specific 
binding—at 30 μL/min (association). This was followed by a 10 min running-buffer injection 
(dissociation). Between each sample, I injected, in series, 5 μL of 5 mM HCl and 5 μL of 10 mM 
NaOH at 5 μL/min to remove any remaining bound ligand. I repeated this cycle for each 
concentration tested (40, 20, and 10 nM, summarized in Figure 2.2). Each concentration series 
were performed in triplicate.  
 
2.4.5 Kinetic analysis 
The raw ligand:receptor sensograms were aligned and the background, non-specific 
binding was subtracted using the sensogram trace from the ligand:Ang-4 flow cell (Figure A.3). 
Both the raw ligand:receptor and ligand:Ang-4 sensogram curves were obtained within the 
BIAcore 3000’s detection window (10-70,000 R.U.) for all interactions [148] to ensure detected 
interactions did not represent system noise. Post-subtraction sensograms with a negative-sloped 
association phase were excluded from global kinetic fitting and not considered interactions. 
BIAevaluation removes momentary signal spikes resulting from transient air bubbles.  
Global analysis is considered to produce more accurate results than fitting of a single 
response curve, so global fitting was performed with BIAevaluation software (Version 4.1.1, GE 
Healthcare), which follows 1:1 Langmuir adsorption isotherm (Equation 2.1) [149]. The software 
applies nonlinear least squares analysis to determine association (ka) and dissociation (kd) rates 
fitting best to multiple response curves simultaneously. Additionally, the software provides the 
goodness-of-fit parameter χ2 and the peak magnitude of the signal response, Rmax. 
(Equation 2.1) a
d
k
k
R L R:L→←+  
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2.4.6 Classifying binding 
Both the instrument manufacturer (BIAcore) and previous researchers have suggested 
that when fitting kinetic rate constants using global analysis, a χ2-to-Rmax value (a measure of 
noise-to-signal) < 0.2 is ideal for confidence in the kinetic parameters obtained when studying 
known interactions [99,100,150]. A low noise-to-signal indicates that the sensogram signal 
includes minimal contributions from the following three noise-factors: (1) overall instrument 
noise, (2) heterogeneities in immobilized receptor or ligand, and (3) non-specific interactions. 
Using ligand:receptor pairs with known interactions and pairs known not to interact, I established 
a cut-off value of χ2-to-Rmax < 1.0 that differentiates real, 1:1 Langmuir interactions, from 
predominantly non-specific interactions, where χ2-to-Rmax > 1.0.  I arrived at this via 
experimentally fitting known interactions and non-interactions (Table A.1). I then applied the χ2-
to-Rmax < 1.0 heuristic to classifying the interactions observed in PDGF:VEGFR binding. 
 
2.4.7. Single-cell model of membrane receptor activation 
I recapitulated the uni-family (VEGF:VEGFR) single cell model described by Mac 
Gabhann et al, consisting of 7 ordinary differential equations (ODEs) derived using the law of 
mass action. The cell is represented as a single compartment [88] that represents both the 
extracellular space and plasma membrane. I extended this to a dual-family model, including the 7 
ODEs describing VEGF:VEGFR ligation plus an additional 8 ODEs describing PDGF:VEGFR2 
signaling. The model equations and parameters are implemented in MATLAB using the 
SimBiology toolbox. Steady-state and dynamic solutions are computed using the ode15 solver 
for 24 simulated hours. (A complete description of model equations for both uni-family and 
dual-family models are provided in Appendix A.3.) 
 
2.4.8 Model parameters 
Parameters are based upon 7 guidelines. (1) VEGFR1 and VEGFR2 are inserted into the 
plasma membranes at fixed rates [88]. (2) Ligand-free receptors and ligand-bound receptors are 
internalized from the plasma membrane at fixed rates [151] (see Table A.4 for full summary of 
kinetic parameters). (3) VEGFR dimerization is not modeled explicitly, reflecting recent work 
that suggests VEGF receptors are initially pre-dimerized, and ligand-binding initiates a 
conformational change that enables phosphorylation and down-stream signaling events [152]. (4) 
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Ligand secretion and ligand clearance are not modeled to better represent a localized cell 
environment without the influence of the systemic dynamics [88]. (5) Ligand concentrations are 
derived from known serum concentrations (Table A.5). (6) Benchmark kinetic and concentration 
parameters are used only to recapitulate the benchmark. (7) The cross-family model applied 
updated kinetic parameters via SPR studies (Table A.2) and updated VEGFR concentrations 
from recent quantitative flow (qFlow) cytometry measurements [50,153–155]. All model 
parameters, their descriptions, and their values are provided in Table A.4. 
I modeled anti-angiogenic drug treatment by incorporating the anti-VEGF-A antibody, 
bevacizumab. In the model, bevacizumab reversibly binds free VEGF-A, with kinetic constants 
previously-determined via SPR [156]. Drug treatment was modeled as a single, initial 
bevacizumab dose. The dose concentration used was adopted from an earlier VEGF 
computational model that based the dosage on patient plasma concentrations following the 
administration of bevacizumab in advanced cancer treatment [89,157]. Thus, this value correlates 
with the systemic level of bevacizumab. I excluded bevacizumab clearance and ‘secretion’ (the 
movement of bevacizumab from plasma into the area around endothelial cells), to examine the 
concentrations individual endothelial cells would experience. 
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2.5 Figures 
 
Figure 2.1. VEGF and PDGF ligand receptor interactions. (A) Schematic summarizes known 
receptors that bind VEGF-A and PDGFs. (B) Structural alignment of VEGF-A165 (blue, PDB ID: 
2VPF) and PDGF-BB (red, PDB ID: 3MJG) proteins displayed from two rotational perspective.  
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Figure 2.2. Surface plasmon resonance (SPR) workflow.  Using a dextran-coated gold (CM5)-
type sensor chip, SPR is performed as follows: (I) Carboxymethyl groups on the sensor surface 
are activated with NHS:EDC, enabling (II) amine-coupling between target (receptor or reference 
protein, Ang-4) and the dextran matrix semi-permanently. Such binding allows multiple kinetic 
cycles to be performed without requiring remobilization of the target. In a kinetic study cycle, 
(III) ligand is injected across the bound target; called the association phase, binding events are 
sensed and detected in real-time. (IV) Next running buffer (HBS-EP) alone is injected. In this 
dissociation phase, the instrument detects only the dissociation of ligand from the target. (V) A 
regeneration solution is injected to clear any remaining bound ligands before another kinetic 
study is performed. 
 
 
 
Figure 2.3. VEGF to VEGFR association and dissociation signal. BIAcore signal response 
kinetics studies of interactions between (A) VEGFA and immobilized VEGFR1 (B) VEGFA and 
VEGFR2 and (C) VEGFA and VEGFR3. 
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Figure 2.4. PDGF to PDGFR association and dissociation signal. BIAcore signal response 
kinetics studies of interactions between (A) PDGFAA and PDGFRα (B) PDGFAA and PDGFRβ 
(C) PDGFAB and PDGFRα (D) PDGFAB and PDGFRβ (E) PDGFBB and immobilized 
PDGFRα (F) PDGFBB and immobilized PDGFRβ (G) PDGFCC and immobilized PDGFRα (H) 
PDGFCC and immobilized PDGFRβ (I) PDGFDD and immobilized PDGFRα (J) PDGFDD and 
immobilized PDGFRβ.  
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Figure 2.5. Binding kinetics and affinities for VEGF and PDGF interactions with PDGFRs 
and VEGFR2. (A) Binding affinity KD between each ligand and receptor. (B) Association rate 
(in M-1 s-1) and (C) dissociation rate (s-1). 
 
 
Figure 2.6. PDGF to VEGFR association and dissociation signal. BIAcore signal response 
kinetics studies of interactions between (A) PDGFAA and VEGFR2 (B) PDGFAB and VEGFR2 
(C) PDGFBB and VEGFR2 and (D) PDGFCC and VEGFR2. 
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Figure 2.7. Summary of novel cross-family VEGF and PDGF ligand-receptor interactions. 
Schematic illustrates an updated view of the VEGF and PDGF ligand-receptor binding patterns, 
adding newly discovered PDGF-VEGFR interactions. Specifically, only new interactions where 
the kinetic analysis fit χ2-to-Rmax ratio < 1.0 were included. Previously-known interactions are 
indicated with grey lines, and newly-found interactions are indicated with red lines. 
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Figure 2.8. Qualitative model of endothelial cell VEGF and PDGF ligand-receptor binding. 
Schematic illustrates basic structure of computational model of VEGF-A:VEGFR and 
PDGF:VEGFR2 signaling for endothelial cells. Non-ligated dimers of VEGFR1 and VEGFR2 
are inserted and internalized at a constant rate (kins and kint, respectively). Ligand-receptor 
binding for VEGFs and PDGFs as found in this study are incorporated. Ligated-receptor 
complexes are internalized at a constant rate kint. 
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Figure 2.9. Recapitulation of VEGF-A:VEGFR benchmark model. All rate parameters and 
species concentrations taken from original study. (A) Number of VEGFA-receptor complexes 
formed over time) and (B) Fractional receptor occupancy for VEGFR1 and VEGFR2 over time, 
defined as: (# VEGFR1 complexes)/(total # VEGFR1) and (# VEGFR2 complexes)/(total # 
VEGFR2) respectively. 
 
Figure 2.10. VEGF and PDGF ligation of VEGFR2 ligation in healthy, cancer, and anti-
VEGF treated cancer conditions. (A) Fold-change in maximal ligand-VEGFR2 binding in 
different physiological conditions with and without PDGF-VEGFR interactions. Physiological 
conditions use VEGFA, PDGF-AA, -AB, -BB, VEGFR1 and VEGFR levels found in serum and 
healthy endothelial cells. Cancer conditions use serum levels and tumor endothelial cell levels 
found in breast cancer. Anti-VEGF treated cells use cancer conditions in addition to the 
introduction of bevacizumab, a monoclonal antibody targeting VEGF-A. (B) Ligand proportional 
composition in VEGF and PDGF cross-family model  
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Figure 2.11. Meta-analysis of healthy and pathological VEGF and PDGF serum 
concentrations. A summary of known serum values for VEGF-A, PDGF-AA, -AB, -BB, -CC 
and –DD under healthy, breast cancer, and post-stroke (both at 0 hr and following 24 hr) 
conditions, wound fluid, and post-exercise. See Table A.5 for a complete summary of measured 
serum concentration values with references to the original studies. 
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CHAPTER 3 
DISCOVERY OF CROSS-FAMILY PDGF:VEGFR2 SIGNALING 
 
3.1 Introduction 
Angiogenesis is a key pathogenic component of at least 70 known diseases, from Crohn’s 
disease to age-related macular degeneration to cancers [158], and it is primarily driven by the 
vascular endothelial growth factor receptor (VEGFR) and its family of VEGF ligands [159]. 
However, targeting VEGF alone has not achieved the promise of stable vascular control [1–5]. I 
now know that is because angiogenesis involves several signaling axes in addition to VEGF, 
representing a complexity that cannot be captured by targeting one growth factor alone. In fact, 
VEGF-inhibition in tumor eventually results in anti-angiogenic resistance, involving 
upregulation of ancillary axes, including: platelet derived growth factors (PDGFs) [6,7], 
fibroblast growth factors [160], and angiopoietins [161]. Furthermore, dual-growth factor 
therapy has resulted in synergistic effects when used to promote vascularization in animal 
ischemia models[8]. These findings present a compelling need to shift our pedagogy: away from 
a uni-family understanding of vascularization (e.g. VEGF-alone) towards a cross-family 
understanding (e.g., VEGF + PDGF, etc.). 
The canonical, uni-family view is defined by VEGF binding to VEGFRs, PDGF binding 
to PDGFRs [35], and so on. This paradigm offers numerous activation schemes. For example, 
VEGF-A, -B, -C, -D, & placental growth factor and several isoforms produced via alternative 
splicing [30,64,65,94–96]  bind to selected VEGFRs: VEGFR1, -R2, -R3 and co-receptors: 
neuropilin-1 and neuropilin-2 [162], leading to the angiogenic hallmarks of endothelial cell 
proliferation and migration to hypoxic regions [30,97]. 
A cross-family understanding of signaling involves examining ligands from one growth 
factor family binding to and signaling through receptor(s) of other families. Indeed, cross-family 
signaling has been observed between the PDGF and VEGF families [35,46–49]. VEGF-A binds 
and activates PDGFRs in a dose-dependent manner [47]. These VEGF-A:PDGFR interactions 
have been shown to affect PDGFR signaling through different mechanisms. VEGF-A binding 
outcompetes PDGFs in PDGFR-binding, inhibiting PDGF-dependent downstream signaling and 
PDGF-induced PDGFR internalization [49]. Additionally, VEGF-A:PDGFRα binding has been 
shown to block signaling pathways stimulated by PDGF:PDGFRα, while allowing binding by 
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unidentified non-PDGF ligands and enabling stimulation of their associated downstream 
signaling pathways [48], a mechanism shown to improve cell viability under hypoxia [46]. My 
measurements of PDGFRs on fibroblasts revealed that the dominant VEGF isoform, VEGF-A165, 
acts independently of VEGFRs to regulate PDGFR concentrations on the plasma membrane [50]. 
Moreover, my previous studies demonstrated high-affinity PDGF binding to VEGFR2 [163], 
suggesting a PDGF role in VEGFR2 activation. [See Figure 3.1 for a summary of the recently-
discovered PDGF:VEGFR2 interactions (Figure 3.1A) and their binding affinities (Figure 
3.1B)]. Computational modeling demonstrated that these PDGF:VEGFR2 interactions could 
constitute a significant proportion of VEGFR2-ligand complexes formed [163] for serum 
[VEGF-A]/[PDGFs] and EC [VEGFRs] measured in certain physiological and breast cancer 
conditions. Therefore, I predict that these PDGF:VEGFR2 interactions would play a significant 
role in modulating VEGFR2 signaling.  
Experimental examination of cross-family signaling in the context of VEGFR2 is a 
crucial starting point because many angiogenesis-associated cell behaviors are regulated largely 
by VEGFR2 complex formation. Following VEGF-A ligation, VEGFR2 signal transduction 
develops via three key steps: (1) VEGFR2 phosphorylation at specific tyrosine residues, (2) 
adaptor proteins bind these tyrosine residues and undergo phosphorylation [18], and (3) 
phosphorylated adaptor proteins initiating second-messenger signaling cascades [19]. VEGFR2 
contains several intracellular tyrosine residues critical to its activity, including: Y801 [20,21], 
Y951 [22], Y1054/59 [22–24], Y1175 [18,25], and Y1214 [26,27],; and several with unknown 
function: Y1223, Y1305, Y1309, and Y1319 [28,29]. Each VEGFR2 tyrosine site is associated 
with specific adaptor proteins [30–32] and ultimately different cell responses [13,18,28,31]. 
Signaling via Y951, Y1054/59, and Y1175 is especially critical to angiogenesis, stimulating 
endothelial cell survival [33] and permeability [30], and the angiogenic hallmarks of cell 
proliferation and migration (see Figure 3.2 for summary schematic) [29,30,34] Therefore, 
measuring any PDGF-mediated VEGFR2 activation at these tyrosine sites would identify 
whether cross-family binding leads to functional receptor signaling.  
Because of the novelty of PDGF:VEGFR2 binding, PDGF-mediated VEGFR2 receptor 
activation, adaptor signaling, and other second messenger signaling must be explored. I 
characterize the signaling capacities of PDGF:VEGFR2 complexes. I measure PDGF-induced 
VEGFR2 phosphorylation for three major tyrosine residues—Y951, Y1054/59, and Y1175—and 
32 
four associated adaptor proteins—cellular Src kinase (c-Src; henceforth, I will refer to this as 
Src), focal adhesion kinase (FAK), phospholipase-Cγ (PLCγ), and phosphoinositide 3-kinase 
(PI3K)—that represent different hallmark cellular responses of angiogenesis: cell migration, 
proliferation, survival, and vascular permeability. I compare PDGF-induced signaling patterns to 
the native ligand VEGF-A to establish the unique VEGFR2 activation patterns each PDGF 
ligand produces.  
 
3.2 Results 
3.2.1 PDGF binding stimulates VEGFR2 tyrosine phosphorylation comparable to VEGF-A 
To determine whether PDGF-binding leads to VEGFR2 signaling, I measured VEGFR2 
phosphorylation at three tyrosine residues critical in angiogenic signaling: Y951, Y1054/59, and 
Y1175. At identical ligand doses, the five PDGF isoforms tested stimulated VEGFR2 
phosphorylation at one or more tyrosine residues (Figure 3.3). Generally, PDGF stimulation 
induced VEGFR2 phosphorylation greater than or equal to VEGF-A165-induced levels. . More 
specifically, PDGFs –AB, –BB, and –CC induced ~40-60% higher phosphorylation of Y951 
compared to VEGF-A165 (Figure 3.3A). PDGF-AA stimulated a 2.0-fold increase, or a ~15% 
greater phosphorylation of Y1054/59 than VEGF-A165 (Figure 3.3B). Whereas, I observe 
statistically similar phosphorylation of Y1175 by each PDGF and VEGF-A165 (p < 0.05, two-
tailed Student’s t test, Figure 3.3C).  
 
3.2.2 PDGF binding selectively primes VEGFR2 for signaling 
Each PDGF ligand preferentially activates specific VEGFR2 tyrosine residues, thereby 
priming VEGFR2 to activate particular signaling pathways preferentially, with unique pattern of 
activation levels. PDGF-AA had no significant (p = 0.85) effect on Y951 phosphorylation 
(Figure 3A) but did significantly increase Y1059 (Figure 3.3B) and Y1175 (Figure 3.3C) 
phosphorylation (2.0-fold and 1.2-fold, respectively). PDGF-AB increased phosphorylation at 
Y951 and Y1175, 1.4-fold each, but it did not significantly increase Y1059 phosphorylation (p = 
0.09) (Figure 3.3B). Likewise, PDGF-BB preferentially stimulated Y951 and Y1175 
phosphorylation to increase ~1.4-fold and ~1.3-fold, respectively, and no significant effect on 
Y1059 (p = 0.07). Like –AB and –BB, PDGF-CC increased Y951 and Y1175 phosphorylation 
(1.5-fold and 1.3-fold, respectively), and not Y1059 (p = 0.47). Finally, I observed that—despite 
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previous research demonstrating no PDGF-DD:VEGFR2 binding occurs—PDGF-DD 
nonetheless produced a 1.3-fold increase in Y1175 phosphorylation (Figure 3.3C); however, -DD 
had no effect at Y951 or Y1059 (p = 0.73 and 0.90, respectively). Taken together, the PDGFs 
activate VEGFR2 with complex patterns of specificity, activating critical tyrosine residues with 
isoform-specific effectiveness, thereby priming VEGFR2 for signaling via the signaling 
pathways associated with these tyrosines. 
 
3.2.3 PDGF-activated VEGFR2 phosphorylate downstream signaling proteins. 
PDGF-induced activation of VEGFR2 tyrosine residues represents the first step in signal 
transduction. To characterize PDGFs effect on downstream processes, I measured whether 
PDGFs induced phosphorylation of three adaptor proteins—Src, FAK, and PLCγ, PI3K—known 
to be bound and phosphorylated by VEGFR2 tyrosine sites directly or, like PI3K, also indirectly 
activated downstream of Y1175 [19,30]. Additionally, these adaptor proteins are associated with 
the angiogenic hallmarks of migration, survival, and proliferation. At identical ligand doses, 
most PDGFs induced adaptor phosphorylation that was greater than or equivalent to VEGF-A165-
induced phosphorylation. The two exceptions to this were: PDGF-CC, which did not increase 
PLCγ activation, as well as PDGF-DD, which activated FAK but had no effect on PI3K, PLCγ, 
and Src. PDGF-BB stimulated the largest fold-increase in PI3K phosphorylation, having an 
effect 32% larger than VEGF-A (Figure 3.4A). Every PDGF isoform could produce increased 
activation of FAK, including PDGF-DD (Figure 3.4B). PDGF-AA, -AB, and -BB increased 
PLCγ phosphorylation ~1.4 fold, like VEGF-A (Figure 3.4C). I found PDGF-BB to stimulate the 
largest increase in Src phosphorylation, producing a ~1.4-fold increase versus the ~1.1-fold 
increase via VEGF-A (Figure 3.4D). The PDGF family, therefore, can stimulate activation of the 
signaling pathways downstream of VEGFR2.  
 
3.2.4 PDGFs induce endothelial cell proliferation in dose-dependent manner 
I next investigated whether PDGF:VEGFR2 binding and signaling could stimulate 
endothelial cell proliferation and migration—key steps in angiogenesis—and characterized the 
dose-relationship. VEGF-A treatment ( > 1 ng/mL) stimulated EC proliferation in a dose-
dependent manner, producing up to a 1.4-fold increase over untreated cells, and stimulating a 
half-maximal response at EC50 =  ~80 ng/mL (Figure 3.5A). I found that each PDGF stimulated 
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significant increases in HUVEC proliferation. In general, PDGFs stimulated weaker increases in 
proliferation but had different potencies (i.e. different half-maximal responses, or EC50). PDGF-
AA stimulated a dose-dependent increase in proliferation at doses >= 63 ng/mL but with a 
weaker potency (EC50 = 103 ng/mL) and weaker effect (maximum 1.25-fold proliferation 
increase) than VEGF-A (Figure 3.5B.) PDGF-AB (Figure 3.5C) and PDGF-BB (Figure 3.5D) 
stimulated fold-increases (1.23- and 1.20-fold maximum responses, respectively), but were more 
potent than VEGF-A, with EC50 = 2.3 and 2.6 ng/mL vs ~80 ng/mL. PDGF-CC stimulated the 
weakest response, resulting in a 1.15-fold increase, but with the highest potency (EC50 = 0.17 
ng/mL) (Figure 3.5E). PDGF-DD, despite not binding VEGFR2, stimulated up to a 1.2-fold 
increase in EC proliferation, with a similar high potency as -AB and -BB (EC50 = 4.2 ng/mL) 
(Figure 3.5F). Overall, I determined that PDGFs stimulate a moderate proliferative response in 
ECs.  
 
3.2.5 PDGF-AA, -BB, and –CC stimulate endothelial cell migration 
I next investigated whether PDGF binding would stimulate endothelial cell migration, 
another hallmark of angiogenic responses, via a wound-healing assay. I compared the change in 
wound area after 24 hr. growth factor treatment vs. untreated controls (Figure 3.6A). I found that 
PDGF-AA, -BB, and –CC each produced a significant increase in wound area closure relative to 
untreated cells (Figure 3.6A). PDGF-AA treatment, remarkably, stimulated a response 
comparable to VEGF-A, with a 2.2-fold increase in wound closure (Figure 3.6B). Canonical 
VEGF-A stimulated a ~2.5-fold increase, for comparison, a statistically insignificant difference 
(p = 0.225; Figure 3.6B). PDGF-BB and -CC treatments produced a weaker 1.8- and 1.9-fold 
migration response. In contrast, neither PDGF-AB nor PDGF-DD stimulation produced 
significant EC migration. The PDGF family, therefore, can stimulate both endothelial cell 
migration and proliferation responses, the key angiogenic responses mediated by VEGFR2 
signaling. 
 
3.3 Discussion 
3.3.1 PDGFs may directly promote angiogenic cell behaviors via VEGFR2 signaling. 
My results demonstrate that PDGF:VEGFR2 binding stimulates VEGFR2 
phosphorylation, activates signaling pathways key in regulating hallmarks of angiogenesis, and 
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ultimately induce two major hallmark behaviors: endothelial cell proliferation and migration. 
VEGFR2 control over angiogenesis is dependent on autophosphorylation at the key tyrosine 
Y951, Y1054/59, and Y1175, and their activation of downstream signaling. Once 
phosphorylated, these tyrosines can directly bind and activate Src homology 2 (SH2) domain-
containing proteins [164], or indirectly through SH2 adaptor proteins [165] resulting in the 
activation of additional effectors and second messengers. Each tyrosine associates with specific 
adaptor proteins [31,34,166–168]. There is both experimental evidence and my validated 
computational modeling [31] that indicates that each adaptor is involved in signaling cascades 
regulating specific cell responses: the Y951 phosphorylation results in PLCγ [25,31,166,167], 
VEGF-receptor associated protein (VRAP) [30,31,168] and PI3K activation [29], and regulates 
endothelial cell survival, migration and vascular permeability [31,33,169]. Y1054/59 
phosphorylation activates Src [170] and PLCγ [24,31], and regulates cell migration and 
proliferation [33]. Finally, Y1175 phosphorylation activates PLCγ, Src, and, indirectly, FAK and 
PI3K [19,30], promoting cell migration, proliferation, and cell survival [29,30,33]. Further 
research should identify whether the activation of these sites and adaptors regulates other 
angiogenic hallmarks independent of VEGF-A, like cell survival and vascular permeability. If 
this is the case, then PDGFs would serve a direct pro-angiogenic role. 
 
3.3.2 Post-ischemic PDGF-CC upregulation can directly induce VEGFR2-mediated angiogenesis 
in hypoxic tissue. 
My discovery of PDGF-CC-induced VEGFR2 signaling may indicate a direct 
angiogenesis mechanism in ischemic injury. PDGF-CC is not present in serum in normal 
physiological conditions, but it is secreted following a major ischemic injury like myocardial 
infarction or stroke [114]. It is known to play a pro-angiogenic role in the ischemic tissue [171] 
promoting mural cell recruitment to developing vessels [172]. Furthermore, PDGF-CC has been 
shown to promote HUVEC migration by myself and others [173],  but because HUVECs  do not 
express PDGFRs [155,173,174], the mechanism by which PDGF-CC affects EC behavior 
remained unclear. The VEGFR2 tyrosine and signaling protein phosphorylation I observed, 
however, may provide an explanation: PDGF-CC stimulate EC migration by activating the same 
VEGFR2 tyrosine sites and signaling pathways associated with VEGF-A binding. Following 
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ischemic injury, PDGF-CC expression and upregulation may supplement VEGF-A:VEGFR2 in 
promoting angiogenesis and re-vascularizing the ischemic tissue.  
 
3.3.3 Indirect PDGF-DD-mediated VEGFR2 phosphorylation: a possible role for –
DD:neuropilin-1 complexes? 
My results suggest a possible role for the recently identified PDGF-DD:neuropilin-1 
(NRP1) interaction. Because PDGF-DD has not been observed to bind VEGFR2 directly [163], 
my observation of PDGF-DD-induced VEGFR2 phosphorylation suggests that PDGF-DD acts 
on VEGFR2 indirectly. One such indirect mechanism was suggested by a recent study [175] that 
revealed PDGF-DD can form complexes with NRP1—a VEGFR2 co-receptor, highly expressed 
in ECs (35,000–73,000 receptors/cell [153]) that is known to enhance VEGFR2 phosphorylation 
[176]. This suggests, therefore, that PDGF-DD may alter VEGFR2 phosphorylation via its NRP1 
interaction, instead of through direct binding. Further experimental work should explore whether 
PDGF-DD requires neuropilin-1 to induce VEGFR2 phosphorylation. 
 
3.3.4 Structural analysis of growth factors can predict cross-family binding and signaling. 
My results open the possibility that additional cross-family interactions may exist and can 
activate receptor signaling pathways. Therefore, identifying these interactions, is key to 
understanding biological processes. Experimentally screening every known cytokine for an 
effect on a particular signaling pathway, via a brute-force approach, however, would be 
impractical, costly, and time-prohibitive. Instead, comparative analysis of ligands and receptors 
that share structural and functional motifs can more effectively guide further discoveries. For 
example, VEGFRs and PDGFRs are tyrosine kinase receptors: PDGFRs have 5 extracellular 
immunoglobulin-like (IgG-like) domains [35] and VEGFRs have 7 extracellular IgG-like 
domains in VEGFRs [54]. Of these, domains 2-3 are responsible for high-affinity binding of 
VEGF-A:VEGFR1 [55] and VEGF-A:VEGFR2 [56] and are highly conserved within PDGFRs, 
where they play an identical role in determining PDGF binding. Additionally, VEGFRs and 
PDGFRs have a similar intracellular structure: having an intracellular split tyrosine-kinase 
domain [36,126]. Moreover, VEGF and PDGF are similar in quaternary structure: VEGF and 
PDGF have only a 1.93 Å root mean square difference between overlapping structures [52]. 
VEGFs and PDGFs also share structural motifs in their receptor-binding regions [54]. In fact, 
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PDGF ligands have been superimposed within the VEGF-A:VEGFR2 binding domains, 
illuminating the possible confirmations for the interactions I report [53]. My observations that 
PDGFs can induce VEGFR2 phosphorylation and signaling, may be understood by these 
similarities in ligand and receptor structure.  
Ligands and receptors that share similar structural and functional motifs should be further 
explored for potential cross-family binding and signaling. For example, VEGF and PDGF are 
part of the cysteine knot family [52,127], which share a conserved core domain of ~90-amino 
acid residues within the signature cysteine knot domain [127]. Other ligands in this family 
include: nerve growth factors, fibroblast growth factors, transforming growth factors, and even 
glycoprotein hormones [52]. So, examining these structurally similar ligands would be a 
promising approach.  
Explorations of possible cross-family interactions can be performed on the structural 
level via molecular dynamics identification of how cross-family binding stabilizes protein 
structure. Recent advances in structural determination of membrane proteins has resulted in high 
resolution structures of many biological systems that can be simulated. Such simulations can 
show how protein architecture, interactions and dynamics influence signaling mechanisms, 
molecularly [177]. In particular, one can identify if there are key amino acid residues that 
stabilize binding via analysis of canonical VEGF–VEGFR2 structures in comparison to newly 
discovered PDGF–VEGFR2 binding. One can predict how these new cross-family binding 
interactions influence the larger protein confirmation—giving clues to receptor activation. Such 
insight will expand the arena for manipulating growth factor-receptor signaling.  
Once possible cross-family interactions are predicted via molecular dynamics analysis, 
kinetic analyses can identify those that exhibit cross-family binding [163], and phosphorylation 
studies can identify those that stimulate downstream signaling activation, as I show here. 
Receptors that exhibit multi-ligand binding could reveal several landscapes of signaling. For 
example, the nicotinic acetylcholine receptor is well known for having several possibilities for 
receptor assembly, and several molecules, other than nicotine, that can bind and signal with 
functional selectivity (e.g., epibatidine, choline, etc.) [128]. As such, combining structural 
analysis, kinetic analysis, and receptor phosphorylation/signaling assays would provide a 
framework for systematically identifying the signaling landscapes elicited by receptors.  
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Additionally, cross-family signaling can open new doors in protein engineering. Indeed, 
in vitro evolution is widely used to engineer proteins with enhanced or new functions. In vitro 
evolution also allows for the relative phenotypic fitness of all mutants in an evolving population 
to be compared simultaneously in a single experiment [178,179]. By applying different evolution 
strategies one can tease out sequence features associated with folding [180], ligand or receptor 
interactions [181,182], and specificity [183,184]. An emerging approach to achieve protein 
evolution is deep mutational scanning. The major advantage of deep mutational scanning is that 
it can rapidly screen up to tens of thousands of mutations in an unbiased manner to give a global 
perspective of a protein’s mutational tolerance, which directly contrasts with classical 
mutagenesis methods. This combined evolution and deep sequencing strategy has been applied 
in recent years to a variety of systems, especially in bacteria and yeast [181,182,184–186]. I 
expect that applying these novel in vitro evolution approaches to engineer new PDGFs and 
VEGFs would enable new insight into aspects of ligand sequence that are associated with 
physiological function while providing new signaling landscapes.  
 
3.3.5 Conclusions 
I previously demonstrated that PDGF ligands bind VEGFR2. Here, I show that in binding 
VEGFR2, the PDGFs stimulate signaling through the receptor, manifested via phosphorylation 
of key tyrosine residues on VEGFR2 and adaptor-effector proteins associated with VEGFR2. 
Further, I show that PDGFs stimulate cell migration and proliferation—crucial steps in inducing 
angiogenesis activated by the VEGFR2 pathway. Since VEGFR2 is a key pro-angiogenic 
signaling receptor, these findings provide new targets for tuning angiogenesis via VEGFR2. 
Furthermore, my findings strongly challenge the uni-family view of cell signaling, which I am 
showing is not restricted to protein families. Instead, my results suggest that cell signaling should 
be understood through systems of interacting ligands and receptors that, through binding, act 
with a varying degree of agonism or antagonism on different downstream pathways. Together, 
this new paradigm provides a general framework, and in the future, when combined with 
computational modeling [31,113,139,163,187], should enable an improved understanding of 
physiological systems and pathologies. 
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3.4 Materials and Methods 
3.4.1 Materials 
Protein phosphorylation studies were performed using colorimetric cell-based ELISA kits 
obtained from Assay Biotechnology. The following kits were used: VEGFR2 (phospho-Tyr951, 
#CBP1707), VEGFR2 (phospho-Tyr1059, #CBP1230), VEGFR2 (phospho-Tyr1175, 
#CBP1705), Src (phospho-Tyr216, #CBP1793), FAK (phospho-Tyr407, #CBP1154), PLCγ1 
(phopho-Tyr1253, #CBP1202), and PI3-Kinase P85Alpha/Gamma (PI3K) (phosphor-
Tyr467/199, #CBP1475). Ligand proteins were obtained from R&D Systems, including: human 
recombinant VEGFA (R&D Systems, Cat. #293-VE-010), PDGF-AA (Cat. #221-AA-050), -AB 
(Cat. #222-AB-050), -BB (Cat. #220-BB-050), -CC (Cat. #1687-CC-025) and -DD (Cat. #1159-
SB-025). 
 
3.4.2 Cell culture 
Human umbilical vein endothelial cells (HUVECs) were cultured in endothelial cell 
growth medium (EGM-2), composed of endothelial cell basal medium (EBM-2) and EGM-2 
bullet kit containing 2% fetal bovine serum (FBS) (Lonza). All cells were maintained in a 
humidified incubator at 37°C with 5% CO2.  
 
3.4.3 Measuring ligand-induced protein phosphorylation 
Cellular phosphorylation levels were determined by ELISAs for VEGFR2 tyrosine 
residues Y951, Y1059, and Y1175, and for downstream signaling proteins Src, FAK, PLCγ, and 
PI3K. HUVECs were seeded into a 96-well plate and grown to ~75% confluence in normal 
culture media. Cells were serum-starved overnight in EGM-2 with 0.1% FBS. The cells were 
then stimulated for 8 minutes with 50 ng/mL of either VEGF-A165, PDGF-AA, -AB, -BB, -CC, -
DD, or serum-starved media alone (“Untreated”). Stimulation was halted by washing the cells 
twice in ice-cold TBS solution. Cells were then fixed, quenched, blocked, and incubated at 4oC 
overnight with primary antibodies specific for phosphorylated- and pan-Src, FAK, PLCγ, PI3K, 
and VEGFR2 (residues Y951, Y1059, and Y1175), and for GAPDH as a positive control. 
Corresponding HRP-conjugated secondary antibodies were added to the cells, treated with 
substrate, and absorbance in each well was read at 450 nm with a Synergy HTX multi-mode 
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reader (BioTek U.S., Vermont, United States) to measure protein concentration. Experiments 
were performed with 8 independent replicates. 
 
3.4.4 Quantifying endothelial cell proliferation 
Endothelial cell proliferation was determined by an XTT Proliferation Assay. HUVECs 
were seeded into a 96-well plate at 5,000 cells/well and grown to ~50% confluence in EGM-2. 
Cells were then serum-starved overnight in EBM-2 with 0.1% FBS. The cells were then 
stimulated for 24 hours of either VEGF-A165, PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, or 
serum-starved media alone (“Untreated”) at 500 ng/mL, 250 ng/mL, 125 ng/mL, 62.5 ng/mL, 
31.3 ng/mL, 15.6 ng/mL, 7.8 ng/mL, 3.9 ng/mL, 2.0 ng/mL, 1.0 ng/mL, and 0.5 ng/mL, in order 
to establish a dose-response relationship. After stimulation, cell proliferation was evaluated by 
the 2,3-bis(2-methoxy-4-nitro-5sulfophenyl)5[(phenylamino)carbonyl)2H-tetrazolium hydroxide 
(XTT) assay. Activated XTT reagent was added to each well and incubated for 5 hours. A 
spectrophotometric absorbance measurement was taken of each well at 450 nm, with a 650 nm 
reference wavelength. Experiments were performed with 5 independent replicates. 
 
3.4.5 Endothelial cell wound healing assays 
Endothelial cell migration following VEGF-A and PDGF stimulation was measured 
using a wound healing migration assay. HUVECs were seeded at 6 * 104 cells/well in 12-well 
plates and grown to ~90% confluence. I serum-starved the cells overnight with EBM-2 with 1% 
FBS [188]. I generated a wound for each well by scratching a horizontal line across the cell 
monolayer using a sterile P-200 micropipette tip. Floating cells and debris were removed by 
aspirating the cell media and rinsing twice with 1x sterile PBS. Wells were then treated with 50 
ng/mL of either VEGF-A165, PDGF-AA, -AB, -BB, -CC, -DD, or serum-starved media alone 
(“Untreated”). Bright-field images were captured at three locations along each scratch (Leica 
DMI-4000B inverted microscope.) Experiments were performed in triplicate. Wound areas for 
each time-point were measured in the captured images using the TScratch automated wound-
healing assay analysis toolkit [189]. Cell migration was quantified as the percent change in 
wound area (or the % wound closure) for each experimental condition. 
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3.4.6 Data analysis 
Data is normalized to the cell-density in each well, found by measuring 595 nm 
absorbance following crystal violet staining. I removed background signaling by subtracting the 
average absorbance measured for blank wells (containing cells not labeled with primary 
antibodies.) from the raw absorbance values containing cells. Experiments were independently 
carried out in quadruplicate. Data is represented as the mean phosphorylated over mean total 
protein (p/t) ratio, normalized to the housekeeper GAPDH absorbance values +/- the standard 
error of the mean (SEM) for each treatment condition. Phosphorylation fold-changes were then 
determined by further normalizing ligand-treated responses to untreated response.  
 
3.4.7 Statistical analysis 
Values are given as the mean fold-change (Rf.c.) ± standard error of the mean (SEM). 
Response fold-changes were calculated relative to the untreated controls (Equation 3.1) where 
Runtreated and Rtreated are the mean normalized absorption signals for the non-treated control and 
ligand-treated wells. The fold-change standard errors (Sf.c.) were determined via error 
propagation (Equation 3.2), where Suntreated and Streated are the standard errors of the untreated and 
treated responses , respectively [190,191]. 
 
(Equation 3.1) treatedf.c.
untreated
RR
R
=  
 
(Equation 3.2) 
2 2
untreated treated
f.c. f.c.
untreated treated
S SS R
R R
   
= +   
   
 
 
Fold-change differences were assessed for significance via a two-tailed Student’s t-test. 
Statistically significant P-values are represented as * P < 0.05, ** P < 0.01, and *** P < 0.005.   
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3.5 Figures 
 
 
 
Figure 3.1. PDGF ligands bind cross-family with VEGFR2. Summary of (A) interactions 
between VEGFRs and VEGF-A/PDGF-family ligands and (B) VEGF & PDGF:VEGFR2 
binding affinities. 
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Figure 3.2. Signal transduction through VEGFR2 tyrosine sites and associated adapter 
proteins. Schematic depicts VEGFR2 tyrosine sites critical to angiogenic cell behaviors, a 
summary of adapter proteins associated with each residue, and the cell responses prompted. 
Phosphorylation at tyrosine sites Y951, Y1054/59, & Y1175, and adapter proteins PLCγ, Src, 
PI3K, & FAK were investigated (indicated in green). 
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Figure 3.3. VEGFR2 tyrosine site phosphorylation following VEGF-A and PDGF 
treatment. ELISA studies were performed measuring VEGFR2 phosphorylation at tyrosine sites 
(A) Y951, (B) Y1054/59, and (C) Y1175 in HUVECs following an 8 min. ligand stimulation, 
using 50 ng/mL VEGF-A, PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. The 
relative VEGFR2 phosphorylation values were calculated by normalizing the phosphorylated 
VEGFR2 levels by the total VEGFR2 signal, and to cell density via crystal violet staining (595 
nm absorbance). The housekeeping protein GAPDH is presented as a positive control. All values 
are presented as the arithmetic mean ± standard error of the mean (SEM). (n = 8; *p < 0.05, **p 
< 0.01, ***p < 0.001)  
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Figure 3.4. VEGFR2-associated adapter protein phosphorylation following VEGF-A and 
PDGF treatment. ELISA studies were performed to measure phosphorylation of VEGFR2-
associated adapter proteins (A) PI3K, (B) FAK, (C) PLCγ, and (D) Src in HUVECs following an 
8 min. ligand stimulation with 50 ng/mL VEGF-A, PDGF-AA, PDGF-AB, PDGF-BB, PDGF-
CC, and PDGF-DD. The phosphorylated adapter protein per cell values were calculated by 
normalizing the phospho-protein signal to cell density via crystal violet staining (595 nm 
absorbance). The housekeeping protein GAPDH is presented as a positive control. All values are 
presented as the arithmetic mean ± standard error of the mean (SEM). (n = 8 *p < 0.05, **p < 
0.01, ***p < 0.001) 
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Figure 3.5. VEGF-A and PDGFs stimulate EC proliferation. HUVECs were seeded at 3.2 * 
104 cells/mL, incubated 24 hours in EGM-2 with BulletKit growth supplement for 24 hrs. The 
cells were serum starved (EBM-2, 0.1% FBS) overnight, then treated for 24 hr with each growth 
factor at concentrations ranging from 500 ng/mL to 0.5 ng/mL, and 0 ng/mL as a control. 
Absorbance measured at 450 nm and off-peak at 630 nm. Absorbance values are normalized to 
untreated cell proliferation. Dose-response results for (A) VEGF-A, (B) PDGF-AA, (C) PDGF-
AB, (D) PDGF-BB, (E) PDGF-CC and (F) PDGF-DD were fit to a dose-response function 
(dashed red line) to calculate EC50 values. The fitting confidence range (CI = 95%) is indicated 
by the pink area. Values are presented as the arithmetic mean ± standard error of the mean 
(SEM). (n=4, *p < 0.05, **p < 0.01, ***p < 0.001 relative to untreated controls).  
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Figure 3.6. VEGF-A and PDGF-stimulated HUVEC wound healing. HUVECs were seeded 
in 12-well plates at 6 * 104 cells/well and grown to confluence in EGM-2 with 2% FBS and 
BulletKit growth factor supplements. Cells were serum-starved overnight (EBM-2, 1.0% FBS), 
scratched with P-200 pipette tip, rinsed twice in PBS, and treated with VEGF-A, PDGF-AA, -
AB, -BB, -CC, -DD or serum-starved media alone for 24 hours. (A) Scratch area was 
photographed at 0 hr and 24 hrs and (B) the relative cell migration was quantified using the 
TScratch image analysis software. Values are presented as the arithmetic mean ± standard error 
of the mean (SEM). (n=4, *p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
  
48 
CHAPTER 4 
MAPPING RTK DIMERIZATION TO RECEPTOR EXPRESSION AND LIGAND 
AFFINITIES 
  
4.1 Introduction 
Tyrosine kinase receptors (RTK) and their ligands are key to regulating growth, motility 
and differentiation processes, including: fibroblast growth factors (FGFs), epidermal growth 
factors (EGFs), vascular endothelial growth factors (VEGFs) and platelet-derived growth factors 
(PDGFs) [192–197]. RTKs are transmembrane proteins which transduce external signals to 
internal transduction pathways when an external ligand molecule binds a receptor to induce 
dimerization [192,198,199]. Different ligands can induce unique receptor conformational 
changes that are key to allowing downstream signaling activation [152]. Likewise, RTKs can 
form dimers with identical or different receptor monomers, each activating unique downstream 
pathways [200]. Therefore, mapping RTK ligation and dimerization patterns across conditions 
offers a promising means to understanding and manipulating key critical physiological processes.  
One critical process governed by RTK ligand:receptor dynamics [158] is angiogenesis, 
the process of new blood vessel formation from existing vasculature. Angiogenesis plays a 
critical role in normal physiological functions as well as in diseases, such as peripheral artery 
disease and cancers [201,202]. Multiple families of RTKs and their ligands are known to 
modulate angiogenic behavior, including the vascular endothelial growth factors (VEGFs) and 
the platelet-derived growth factors (PDGFs) [171,172,203]. However, VEGF- or PDGF-targeted 
therapies are not clinically effective for many patients or angiogenesis-dependent diseases [204–
206]. As such, there is a further need to further understand how VEGF- and PDGF-promoted 
angiogenesis can be mechanistically controlled to improve the efficacy of current angiogenic 
treatments. Therefore, quantitatively mapping VEGF and PDGF binding distributions would 
predict angiogenic responses, allowing higher efficacy angiogenesis therapeutics to be 
developed.  
Two primary challenges impede our ability to map ligand:receptor binding distributions 
in RTK systems like the VEGF/PDGF signaling axes quantitatively. Firstly, each RTK signaling 
family involves an array of ligand:receptor interactions between multiple ligands and receptors. 
The vascular endothelial growth factor (VEGF) family is composed of five ligands, VEGF-A, -
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B, -C, -D, and placental growth factor (PlGF), and three receptor tyrosine kinase monomers: 
VEGF-R1, -R2, and -R3 [12] that canonically interact thus: VEGFR1 binds VEGF-A and -B; 
VEGFR2 binds VEGF-A, -C, and -D [13]; and VEGFR3 binds VEGF-C and -D [13,14]. 
However, the VEGFR monomers can homodimerize, bind the same monomer type, and 
heterodimerize, bind different monomer types, enabling differential VEGF binding distributions 
with varying degrees of specificity. VEGFR1-VEGFR2 heterodimers can form through VEGF-A 
binding, while VEGFR1-VEGFR3 heterodimers can form with VEGF-C and VEGF-D [15,16]. 
Likewise, the PDGF signaling family consists of five ligands: PDGF-AA, -AB, -BB, -CC, and -
DD, and two receptors: PDGFRα and -Rβ [35]. PDGF proteins show ligand-receptor and 
receptor-receptor binding patterns similar to the VEGF family, reviewed in [35–39]. These 
specific ligand-receptor and receptor-receptor binding patterns trigger unique downstream 
signaling, such as the well-established PI3K/Akt and MER-ERK pathways (reviewed in [19]), 
resulting in different angiogenic responses. Mapping these pathways requires a modeling 
approach to detangling the effects of each interaction. 
The second challenge limiting attempts to fully-characterize RTK dimerization is the 
prevalence of cross-family interactions. Cross-family or non-canonical interactions—binding of 
ligands and receptor from different, distinct growth factor families—have been increasingly 
identified recently in RTK signaling systems. For example, direct interactions between VEGF 
and PDGF ligands and receptors have recently been identified. Studies have demonstrated that 
VEGFR2 forms heterodimers with PDGFRβ [47,203] and that VEGF-A can directly bind and 
signal through both PDGFRs [47]. Additionally, recent work from this lab has demonstrated that 
several PDGF ligands—PDGF-AA, -AB, -BB, and –CC—can directly bind VEGFR2 [163]. 
These cross-family interactions could play a significant role in modulating angiogenesis. 
Therefore, characterizing how cross-family interaction alter dimerization distributions will be 
key to developing angiogenesis therapeutics. Cross-family ligand:receptor binding and cross-
family dimerization patterns introduce a degree of complexity to modeling RTK signaling 
systems that is rendered especially difficult where the existence of these interactions remains 
unknown.  
Our capacity to model RTK ligand:receptor signaling systems, therefore, is limited by the 
unknown extent of cross-family binding and sparse experimental kinetics data. This goal to 
predict key cross-family interactions can be obtained through fundamental models that map the 
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space where important interactions may occur and correlates that space to real ligands and 
receptors. Experiments are increasingly revealing an expanding set of cross-family 
interactions—and therefore increasing the number of ligands and receptors within a signaling 
network [47,163,200,207].Thus, there is a pressing need for a theoretical foundation that 
generalizes RTK ligand:receptor binding and dimerization patterns across increasingly complex 
systems—not just for the VEGF-PDGF axis, but for any RTK signaling network.  
Here, I present a theoretical framework of ligand-receptor binding, generalized for any 
RTK family. I apply this framework to show how potential cross-family interactions shift 
signaling potential. I examine how cross-family interactions affect dimerization patterns across 
systems of (1) multiple receptors that form heterodimerization pairs, (2) multiple ligands with 
variable degrees of cross-receptor binding. Within these systems, I computationally predict how 
differing kinetic parameter ranges directs receptor dimerization as a proxy for receptor 
activation. This framework allows us to predict key interaction spaces, thereby directing 
experimental investigation and therapeutic options for controlling angiogenesis. 
 
4.2 Materials and Methods 
4.2.1 Ligand-induced dimerization reaction scheme 
Multiple generalized models were constructed for RTK ligand-induced homo- and 
heterodimerization in systems of variable numbers of unique ligand and receptor types. Receptor 
ligation and dimerization were mathematically modeled based upon a common mechanism 
(Figure 4.1): (1) model interactions occur within a single compartment that represents (a) the 
surface of the cell membrane where receptors, receptor complexes, and receptor dimers are 
found, and (b) the extracellular space where unbound ligand molecules are present. (2) Ligand-
induced dimerization begins with a free ligand (L) binding a single unbound receptor (R) to form 
a ligand-receptor complex (CL). (3) A ligand-receptor ligand complex can then bind another free 
receptor monomer to form a receptor dimer (D). The interactions in each model class are 
represented as a set of ordinary differential equations (ODEs) derived using the law of mass 
action [110]. (See Appendix B.2 for a complete list of model ODEs.) The model equations and 
parameters are implemented in MATLAB using the SimBiology toolbox. Steady-state and 
dynamic solutions are computed using the sundials ODE solver for 24 simulated hours. 
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4.2.2 Model parameters 
For each model class, I investigated how relative dimerization patterns respond to 
changes in two physiological parameters known to vary between proteins—relative ligand and 
receptor concentrations (referred henceforth as ni and Ri, where i indicates the specific ligand or 
receptor class—and between interactions pairs—the ligand-receptor on-rates (kL), and ligand-
receptor off-rates (akL). In this exploratory model, I model dimerization using a single, static set 
of dimerization kinetic rate (kdim/akdim) between all homo- and heterodimer pairs, which was 
adapted from a previous model of EGF/EGFR ligand-receptor interactions. Relative [ligand] and 
[receptor] concentrations are varied from a baseline concentration of 1 nM and 1000 
receptors/cell respectively, based on physiological values found for RTK systems [88]. (See 
Table B.1 for a complete list of model parameters and their sources.) I compare the sensitivity in 
dimerization across binding on-rates, ligand concentrations (in the generalized multi-ligand 
models), or receptor concentrations (in the generalized multi-receptor models) for each model by 
evaluating simulations for different set value ratios (summarized in Table B.2.). 
Dimerization is compared between conditions using the relative steady-state dimer, 
referred to here as the dimer fraction fDi (Equation 4.1). The dimer fraction is defined as the ratio 
of the number of steady-state dimer Di molecules (ni) to the total number of all steady-state 
dimer molecules in the simulation. 
(Equation 4.1) = ∑i
i
D
j
j
nf
n  
4.2.3 Generalized multi-receptor models 
I explored the impact the introduction of additional ligand-binding and 
heterodimerization-partner receptor types had on dimerization patterns by constructing separate 
models including two, three, and four unique receptor monomers. These generalized receptor 
models were all constructed under the following restrictions: (1) one unique ligand was available 
for receptor binding; (2) each unique receptor monomer can bind ligand; (3) a ligand-receptor 
complex of any receptor type can either form a homodimer with a free monomer of the same 
type or heterodimer with a monomer of another type. Each additional monomer type increased 
the number of dimer types produced, e.g. three different dimers can result from the generalized 
two-receptor model: homodimers of each receptor, D11 and D22, and one heterodimer, D12 
(Figure 4.2), while six unique dimers (three homodimers, three heterodimers) can result in the 
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three-receptor model (Figure 4.3). For each model, simulations were performed for all 
combinations of different configurations of relative on-binding rates and relative receptor 
concentrations (summarized in Table B.2). The model equations governing each model 
configuration are described in Appendix B.2. 
 
4.2.4 Generalized multi-ligand models 
Cross-family interactions, such as those found between the VEGF and PDGF families, 
can involve binding of multiple unique ligands to one or more common receptor type. I explored 
the dimerization patterns resulting from different binding configurations between two ligands 
and one- and two-receptors: (A) two unique ligands interacting with a single receptor; (B) two 
receptors that each bind a unique ligand, with no cross-interactions—I.e. Ligand A binds 
Receptor 1, Ligand B binds Receptor 2); (C) Two receptors and two ligands, with cross-family 
competition over one receptor—i.e. Ligand A binds Receptors 1 and 2, Ligand B binds Receptor 
2; and (C) two ligands both bind each of two receptors—Ligand A binds both R1 and R2, and 
Ligand B also binds R1 and R2. Each model scheme is summarized in Figure 4.4; binding rates in 
red indicate those varied across simulations. I maintained constant and equal receptor 
concentrations to focus on how different [ligand] configurations and binding rates affected 
dimerization patterns across different cross-family configurations. I performed steady-state 
simulations across each [ligand] and kA configuration.  
 
4.3 Results 
I constructed models for several physiologically-relevant ligand:receptor configurations: 
where one ligand binds two, three, and four unique receptor monomer types that can homo- and 
heterodimerize (representing uni-family binding systems). I explored different cross-family 
schemes by building models of two ligands and two receptors, either having (a) no overlap in 
target receptors, (b) one overlapping interaction, or (c) two overlapping interactions (Figure 
4.4A-D). For each model, I performed simulations while varying two major properties: across 
different ligand-to-ligand relative concentrations or receptor-to-receptor concentrations; and 
across different relative binding rates between two ligand:receptor interactions. I compiled the 
simulation results to generate a complete reference table, with which one predict the evolution of 
any existing physiological system of ligand:receptor interactions and look-up the likely 
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ligand:receptor complexes that would dominate under different conditions (i.e. healthy vs disease 
serum levels).  
  
4.3.1 A guided tour across RTKs: generalized two-receptor model demonstrates how cross-
family heterodimerization complicates the ligand:receptor binding distributions. 
I constructed a model of the least complex case of cross-family heterodimerization: the 
two-receptor, one-ligand model (2R1L) (Figure 4.2). I ‘mapped out’ the relative homo- and 
hetero-dimers predicted to form under every combination of initial kL1/kL2 and nR1/nR2 
configurations (Figure 4.5A). I examine its predictions in detail to illustrate how these 
generalized RTK models offer insight into how signaling system behavior shifts across different 
physiological conditions. I first examined ‘slices’ of this parameter space for specific ratios of 
ligand:receptor binding affinities (i.e. for constant kL1/kL2, the relative kinetic association 
constants for L:R1 vs L:R2 binding) to observe how physiological changes to [R1] and [R2] 
(parameters n1 and n2)influence homo- and hetero-dimer formation, and can therefore alter 
dominant signaling pathways activated. When the ligand L binds R1 and R2 and equal affinities 
(kL1 = kL2), I observe two significant findings: (1) No receptor concentration configuration 
results in heterodimer (D12) domination (Figure 4.4A); only when [R1] and [R2] are equal (where 
nR1 = nR2) do heterodimer concentrations equal to the homodimers D11 and D22 (~33% for D11, 
D22, and D12). (2) The homodimer predominantly formed is determined by the highest-
concentration monomer. For example, where nR1 > nR2, its corresponding homodimer D11 
predominates. Vice-versa, where nR2 > nR1, D11 formation dominates, making up ~90% of all 
dimers.  
While the predictions made for identical binding rates (kL1 = kL2) are intuitive, my 
simulations also explored less intuitive scenarios where a common ligand binds receptor 
monomers with different affinities—conditions common in RTK binding, such as VEGF-A 
binding VEGFR1 vs VEGFR2 [163]—and investigated how this altered the relationship between 
receptor concentrations and homo- and heterodimerization formation patterns. For example, I 
observe these relationships where kL1 = 100 * kL2. Here, the stronger L:R1 binding results in 
diminished D11 formation across all relative receptor configurations (Figure 4.5B). This behavior 
appears to be as a result of the effective negative cooperation known in VEGFR and other RTKs; 
when L predominantly binds free R1, leaving few free R1 molecules available to complete 
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dimerization [17,208], enabling D22 dimers to dominate. As nR1 increases, D22 decreases while 
D11 and D12 increase. Notably, once nR1 ≥ 2 * nR2, I see the D12 heterodimer become the 
dominate dimer formed (Figure 4.5B). 
I find that the nR1/nR2 concentration ratio modulates the sensitivity of the system to 
changes in the relative kinetic rate constants changes. I observe two distinct behaviors, or 
responses to kinetic rate changes that emerge depending upon the relative initial number of 
receptors. Where nR1 < nR2, when I vary kL1/kL2 from 10-3 to 103, I do not observe any changes to 
the order of receptor dominance (Figure 4.5C). In contrast, this behavior changes entirely where 
nR1 ≥ nR2. Where nR1 = 2 * nR2, for instance, when I increase kL1/kL2, from 10-3 to 103 the 
dominant dimer changes from D11 to the heterodimeric D12, with the transition occurring 
approximately where kL1 = kL2 (Figure 4.5D). 
In summary, the 2R1L model serves to illustrate that cross-family interactions introduce 
complex dynamics relationship between which signaling dimers form and the binding 
kinetics/cell receptor concentrations particular to the specific RTK family. This model—as will 
the other generalized models—can serve as a reference table for researchers to predict 
dimerization profiles. (Further parameter slices can be found in Appendix B.4. A tabulated 
summary of relative dimer formation vs. initial parameter configurations is provided in Table 
B.4) 
 
4.3.2 [R]-kL1 Relationships Mapped for Higher-Order Models 
Ligand:receptor interaction schemes in RTK signaling systems can involve three, four, or 
more unique receptor monomers, each expressed at different relative concentrations, and each 
binding at different affinities. I expanded my model to include systems of three and four receptor 
monomers and repeated my analysis whereby steady-state dimer levels were predicted for 
different receptor concentrations and different binding affinities (Figure B.1). I observe that 
hetero-and homo-dimerization patterns follow more complicated trends than for the two-
receptor, one-ligand model. Nevertheless, my modeling produced an expanded prediction dataset 
that enables the use of this tool to quickly identify the predicted dimer distribution for an 
arbitrary RTK system of multiple receptor monomers (summarized in Tables B.5 and B.6). 
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4.3.3 Dimerization predictions expanded for cross-family ligand:receptor interaction systems  
In addition to cross-family heterodimerization, there have been increasing occurrences of 
cross-family ligand interactions that overlap in target receptors. I expanded my model sets to 
include systems of two ligands with varying degrees of cross-binding to a common set of 
receptors and analyze how dimerization patterns change for different ligand:receptor binding 
affinities and ligand concentrations. In the simplest case, when two ligands both bind and 
compete for one receptor (i.e. in the two-ligand, one-receptor (2L1R) model), I observe a 
symmetric relationship across both binding kinetics and ligand concentrations (Figure 4.6). First, 
when both ligand concentrations and binding kinetics are equal, I observe equal formation of LA-
bound dimers and LB-bound dimers (50% DA and 50% DB). Within this single receptor system, I 
observe that ligand-specific dimer formation is equally sensitive to ligand concentrations and 
ligand:receptor binding kinetics. When LA is increased relative to LB or when kA1 is larger than 
kB1, DA formation increases.  
The presence of cross-family ligand:receptor interactions introduces more complex 
effects in systems where two ligands each bind a native a receptor while cross-family bind with 
varying degrees of ‘overlap’ or number of cross-family interactions to their non-native target 
receptor. I further analyzed the dimer formation patterns to observe how altering the relative 
binding affinity each ligand has for the cross-family interaction and the relative ligand 
concentrations results in different degrees of homo- and hetero-dimer formation (summarized in 
Figure 4.7; see Figures B.2-5 and Tables B.6-B9 for a detailed breakdown of each parameter 
space map). 
 
4.4 Discussion 
I constructed models that generalize both simple, single-protein family RTK signaling 
pathways and progressively more complex systems incorporating multiple signaling families. (1) 
I modeled generalized systems of two-, three-, and four-receptor homo- and heterodimerization 
patterns. I further modeled two-receptor systems with none, one, and two degrees of cross-family 
interactions. (2) I analyzed the parameter space of receptor concentrations, ligand concentrations, 
ligand-receptor binding kinetics, and degrees of cross-family ligand:receptor binding, mapping 
out how the system evolves under different configuration. (3) Furthermore, we identified critical 
points within this parameter space where switches in the dominant pathway occur. The parameter 
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space mappings produced from this modeling provide a novel framework enabling researchers to 
investigate for investigating the physiological significance of new or suspected cross-family 
interactions.  
 
4.4.1 Generalized modeling predictions guide exploration of specific RTK systems 
My generalized models of RTK ligation and dimerization provide a novel framework that 
enables researchers to investigate ligand:receptor systems of new or suspected cross-family 
interactions. Tyrosine kinase receptor signaling systems like the VEGFs, PDGFs 
[36,159,207,209–212], and FGFs [120] involve complex interactions between multiple ligand 
and receptors.  Different degrees of homo- and heterodimerization are observed, so, detangling 
the influence of individual interactions is rendered difficult by these complexities. Furthermore, 
cross-family interactions have been observed in fibroblast growth factor/bone morphological 
protein signaling [138] and between the PDGF/VEGF signaling [39,47,163]. These discoveries 
highlight the need to predict the impact these existing or newly-discovered non-canonical 
interactions would have on dimerization and receptor activation patterns.  
The results produced from my generalized modeling framework provide an easy-to-use 
reference for predicting steady-state dimerization patterns for any system of RTK ligand:receptor 
interactions without needing to construct and evaluate simulations. When studying a specific 
system, researchers can consult the predictions made for my model for a specified configuration 
to estimate how the system would evolve. Further, my framework allows researchers to quickly 
evaluate under what conditions the system would evolve towards a different dominant signaling 
pathway. For example, we can use these predictions to identify the [L1]/[L2] conditions where 
homodimers vs. heterodimers dominate for a particular ligand:receptor RTK system. Likewise, 
we can consult the model predicts to determine the relative binding affinity a suspected cross-
family ligand:receptor interaction would be required to alter the dominant signaling dimers 
formed. Together, my generalized modeling of dimerization and ligation provide a framework 
for studying cross-family and inter-family interactions. 
 
4.4.2 Generalized models predict dimerization patterns observed across RTK systems 
My results expand upon earlier growth factor family-specific models that explored how 
homo- and heterodimerization patterns. Homo- and heterodimerization have been explored 
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previously for several RTKs, including: epithelial growth factor receptor [84,213–216] (EGFR) 
and vascular endothelial growth factor receptors [32] (VEGFRs). These previous models studied 
how dimerization depended upon receptor concentrations within the scope of the specific 
receptor tyrosine kinase family. Hendriks et al., for instance, characterized how homo-and 
heterodimerization patterns between EGFR and HER2 shifted with changes to either receptor 
concentrations, in a family-specific version of my two-receptor, one-ligand (2R1L) model. Their 
model observed a shift from predominantly EGFR-homodimers to HER2 homo- and hetero-
dimers as [HER2] increased above [EGFR], as I observed where nR1 >> nR2 in the 2R1L model 
(Figure 4.5A) [84]. In their VEGFR dimerization model, Mac Gabhann demonstrated how 
VEGFR1 and VEGFR2 homo- and heterodimerization formation changed across different initial 
ligand and receptor concentrations. Their results predicting that increasing 
[VEGFR1]/[VEGFR2] from 1:1 to 10:1 would result in VEGFR1 becoming the pre-dominant 
dimer formed, just as predicted in the 2R1L model (Figure 4.5A)  [32].  
Both models demonstrated the predictive power of dimerization models for their 
respective signaling family. However, their results could not be generalized to predict 
dimerization for any RTK ligand:receptor system. They were instead limited to the kinetics and 
interaction patterns of the specific RTK family being explored—i.e. using binding patterns and 
kinetics specifics known for EGF:EGFR/HER2 and VEGF-A:VEGFRs. My generalized 
modeling approach—by instead exploring abstractions of different RTK configurations--can 
predict dimerization patterns for any system. Therefore, they can provide insight into any RTK 
system of interest by simply plugging in the relevant kinetic and concentration measurements.  
 
4.4.3 Generalized models improve model reusability 
Generalizing systems increases model modularity—and thus, the ability of researchers to 
mix-and-match or recombine—by reducing them to discrete units stripped of system-specific 
mechanistic details. The use of modeling has become a key approach towards studying biological 
and biochemical systems [217,218]. Through computational systems biology approaches, models 
have been constructed to study a wide-array of biochemical processes such as VEGF signaling 
[31,134,163,187,219,220]. Recent advances in standardizing model formats have offered the 
promise of integrating existing models, including the Systems Biology Markup Language 
(SBML) [221] and CellML [222]. Nevertheless, several hurdles remain to effective 
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interoperability between models of related biological systems, such as biological network data 
for biological pathways, as well as modeling of systems at different scales [223,224].  
One major hurdle is the highly-specific, model-specific definitions of different biological 
networks [224]. For example, individual computational models of systems often employ model-
specific schemes for naming molecules types—e.g. ligands vs. receptors—or molecules in 
different states—such as phosphorylation status. Additionally, different biological models can 
depict interaction networks with different degrees of detail. Together, these differences in detail 
leave few common interfaces to link models. Semantic annotation approaches offer promising 
solutions this impediment, but such solutions increase the complexity of constructing models of 
even simple systems [223,225,226]. In contrast, constructing models that generalize systems—
such as RTK ligation and dimerization—biological models are reduced to their basic 
components—i.e. ligands, receptors, and dimers. These reduced models generalize the 
interaction scheme, enabling them to serve as self-sufficient ‘modules’ to be combined at ease. 
For example, the different ligand:receptor interaction pattern models I constructed can serve as 
‘dimerization modules’ to be linked with downstream signaling cascade modules. Therefore, 
generalized models provide a simpler approach for constructing module representations of 
biological systems that can be combined with ease. 
 
4.4.4 Generalized model enables exploration of cross-family interactions in human disease 
My generalized framework for studying cross-family interactions can be applied to 
explore how cross-family interactions alter signaling activation in processes important in human 
disease. For example, angiogenesis is regulated by a complicated signaling network involving 
both cross-family dimerization and cross-family ligand:receptor interactions: the pro-angiogenic 
vascular endothelial growth factor receptor 2 (VEGFR2) hetero-dimerizes with a platelet-derived 
growth factor receptor (PDGFRβ)  [57], and recent work by this lab has shown several PDGF 
ligands (PDGF-AA, -AB, -BB, and –CC) bind VEGFR2 [163]. Fully-characterizing 
angiogenesis requires untangling the influence each VEGF-PDGF cross-family interaction has 
on VEGFR2 signaling. These models provide a framework to achieve this aim. By using these 
model predictions, I can determine which cross-family interactions significantly impact the 
dimerization and activation of VEGFR receptors equipped with parameters known 
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experimentally, such as the ligand:receptor binding affinities [103,163], receptor concentrations 
[227,228], and ligand concentrations [163].  
 
4.4.5 Simplifying models enables larger picture insights of complex biological systems 
My generalized modeling of RTK ligand:receptor interactions furthers recent 
demonstrations that simple, more generalized models can be powerful tools to understanding 
biological networks. Detailed and complex models—like the recent model of VEGFR1 signaling 
[31]—are powerful tools for characterizing signal transduction networks. Such model 
construction, however, requires detailed knowledge of (a) the biological interaction network and 
(b) kinetics and concentration measurements for each component [224], Early and recent work, 
however, has demonstrated the insights provided by smaller, simpler models that represent the 
more complex system. Models of EGFR:HER2 ligation and dimerization provided key insights 
as to how internalization dynamics affected dimer formation patterns, which served as proxies 
for predicting downstream signaling activation [84,213]. Likewise, simple mechanistic models 
VEGFR ligation demonstrated how PlGF concentrations affected VEGF-A:VEGFR ligation 
rates, and that VEGFR1/VEGFR2 concentrations determined homo- and heterodimerization 
patterns [32]. Recently, a compact ligand:receptor binding model suggested a key compensatory 
role for cross-family PDGF:VEGFR2 interactions in anti-VEGF-A drug resistance [163]. These 
focused, compact models provided key insight into the larger output of the signaling systems.  
My generalized models expand on the predictive power of these earlier simple models. 
Rules-based modeling approaches have also been employed recently to simplify modeling of 
interaction networks. Under this scheme, biological interaction networks are generalized by local 
‘rules’ that describe general interactions available for a specific molecule (e.g. ligand-binding, 
dimerization, phosphorylation, or signal transduction activation) without providing explicit 
chemical reaction schemes for every combination of molecular state [229,230]. Models defined 
using a rules-based approach are ‘simplified’ by removing the need to define vast arrays of 
chemical reactions to describe specific biological processes [226,231]. Together, earlier compact 
mechanistic models, and the newer approaches to simplify model definitions have enabled key 
insights. My generalized approach to modeling mirrors these approaches by reducing multiple 
systems to their common interaction mechanism and exploring how different variations would 
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alter their evolution. Therefore, my generalized models further demonstrate the insights that can 
be gained by reducing the complexity of biological models.  
 
4.5 Conclusion 
RTKs including the VEGFRs, FGFRs, PDGFRs, and EGFRs mediate signaling crucial in 
regulating physiological processes critical to human health. I here presented a generalized 
framework for studying any arbitrary RTK network. The generalized models I developed can 
represent and simulate ligation and dimerization for any RTK networks, knowing their kinetics 
and concentrations. Critically, I provide a framework for exploring how different cross-family 
interaction schemes alter receptor dimerization patterns. As additional cross-family interactions 
are discovered, the model predictions will be crucial for determining how these interactions alter 
receptor activation within these processes. Furthermore, we can further study which cross-family 
interaction parameters provide a targetable ‘dial’ that allows for manipulating the process 
towards pro- or anti-angiogenic therapeutic effects. Researchers can further to determine 
adjustments needed to adapting therapeutics to the different ligand and receptor concentration 
conditions found in different angiogenesis-related conditions, such as cancers, cardiovascular 
diseases, and diabetes [159]. By applying my generalized modeling approach to specific 
conditions, my results enable exploring cross-family interactions across different biological 
processes critical to human health.  
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4.6 Figures 
 
 
Figure 4.1. Receptor dimerization reaction scheme. Dimerization includes the following 
reactions for any two receptor monomers with indices i and j: ligand L binds a non-ligated 
receptor monomer Ri, with on-rate kLi and off-rate akLi, forming a ligand-receptor complex CLi. 
This complex can then dimerize with another un-ligated receptor monomer Rj, with forward rate 
kdim and reverse rate akdim, to form the dimer Dij. Note that i = j indicates a homodimer and i ≠ j 
indicates a heterodimer.  
 
Figure 4.2. Two-receptor, one-ligand (2R1L) dimerization model schematic. Two receptor 
monomers, R1 and R2, bind ligand L and form dimers Dij, where i and j represent receptor 
monomers. Thus, D11 is a homodimer containing two R1, D12 is a heterodimer containing one R1 
and one R2, and D22 is a homodimer containing two R2. 
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Figure 4.3. Three-receptor, one-ligand (3R1L) dimerization model schematic. Three receptor 
monomers, R1, R2, and R3, bind ligand L and form dimers Dij, where i and j represent receptor 
monomers. Thus, D11 is a homodimer containing two R1, D12 is a heterodimer containing one R1, 
etc. 
 
 
Figure 4.4. Generalized multi-ligand model schemes. (A) Two-ligand, one-receptor (2L1R). 
(B) Two-ligand, two-receptor, no overlap (2L2R0X). (C) Two-ligand, two-receptor, one overlap 
(2L2R1X) (D) Two-ligand, two-receptor, two overlaps (2L2R2X).
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Figure 4.5. Two-receptor, one-ligand model parameter mapping. Predicted steady-state dimer formation across relative affinity- 
and concentration parameter spaces, depicting changes in fraction dimer expression: across  a range  of nR1 concentrations for (A) 
equal receptor binding affinities and (B) where L binds nR1 > nR2; further, how relative binding rates altered fraction dimer expression 
where (C) nR1 > nR2 and (D) when nR1 < nR2  
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Figure 4.6. Two-ligand, one-receptor model parameter space. The fraction of dimers formed 
bound with ligand LA versus bound to ligand LB shifts as a function of the relative 
ligand:receptor binding kinetics kA1/kA2 and the relative ligand concentrations [LA]/[LB]. 
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Figure 4.7. Multi-ligand, two-receptor model dimerization patterns across relative affinity- and concentration parameter 
spaces, for the following configurations:  (A) Two-ligand, two-receptor, no overlap (2L2R0X). (B) Two-ligand, two-receptor, one 
overlap (2L2R1X) (C) Two-ligand, two-receptor, two overlaps (2L2R2X).
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CHAPTER 5 
VEGF-A SPLICE VARIANTS BIND VEGFRS WITH DIFFERENTIAL AFFINITIES 
 
5.1 Introduction 
The vascular endothelial growth factors have been extensively studied as signaling 
molecules in angiogenesis [30,67], and their signaling comprises several components. The 
mammalian VEGF family includes five homodimeric ligands: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and placental growth factor (PlGF) [11]. The most well-studied ligand is VEGF-A 
[232]. VEGF-A has a wide array of isoforms produced through alternative mRNA splicing 
[61,62], including: VEGF-A121, VEGF-A121b, VEGF-A145, VEGF-A145b, VEGF-A165, VEGF-
A165b, VEGF-A183, VEGF-A189, and VEGF-A206. Members of the VEGF-AXXX family are pro-
angiogenic, whereas those designated as VEGF-Axxxb are described as anti-angiogenic due to 
their failure to efficiently activate VEGFRs [30,64].  Given this modulatory signaling role, 
several of these VEGF-Axxxb isoforms have been proposed as targets for treating such 
angiogenic-dependent diseases as diabetic retinopathy [233], peripheral vascular disease [69], 
and cancers [70]. 
Developing tailored treatment to angiogenesis-related diseases, such as in tumors or 
ischemia, can be enhanced by the use computational modeling. Computational modeling offers a 
systemic approach for optimizing ligand, receptor, and signaling targeting. It has predicted how 
anti-VEGF drug efficacy may depend on VEGFR1 concentrations on tumor endothelial cells 
[113]. It has provided predictions on anti-VEGF pharmacodynamics and pharmacokinetics in the 
body [64]. It has provided systematic analysis comparing the roles of heparin-binding and non-
heparin-binding VEGF-A isoforms in tumors. The advantage of these computational approaches 
is that predictions are defined by protein concentrations and kinetics (e.g. protein-protein-
interactions). I can similarly apply computational modeling towards investigating how best to 
target these VEGF-Axxxb isoforms. Such modeling models will require not only quantitative 
insight into the relative concentrations for each isoform but also insights into their binding 
characteristics with the VEGF receptors, i.e. ligand:receptor kinetic rate constants and binding 
affinities.  
Developing computational models requires precise measurements of the protein-protein 
interactions involved in the systems. Computational modeling has, therefore, been limited by 
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VEGF-A splice variant kinetic binding data availability. More broadly speaking, though, precise 
measurements of ligand:receptor binding affinities and kinetics are crucial to understanding the 
systems at play: determining whether pro- or anti-angiogenic splice variants dominate the 
signaling axis is based both on the ligand concentrations and their binding affinities. Current 
evaluations of anti-angiogenic VEGF-A165b, in diseases like peripheral artery disease (PAD) for 
example, have operated under the assumption that both splice variants bind receptors with 
identical affinities [234].  
The conclusions reached, therefore, are highly-dependent on whether VEGF-A splice 
variants truly bind their receptors with identical binding affinities. Previously, only a small 
subset of the pro-angiogenic isoforms, VEGF-A165a, -A121, and –A183 have had their binding 
affinities measured, and only VEGF-A165a has binding kinetic constants (ka and kd) measured 
[235]. The binding affinities (e.g., KD =  kd/ka) of the anti-angiogenic VEGF-A165b and VEGF-
A165a to VEGFRs were previously compared qualitatively via a radiolabeled-ligand binding assay 
[236], concluding that VEGF-A165b and VEGF-A165a bind with similar affinities, but also without 
providing quantitative measurements of the binding affinity (KD). However, these previous 
studies provided insufficient evidence for identical VEGFR binding affinities for two reasons: 
(1) Radiolabeled-ligand binding assays are unable to compare differences in ligand-binding 
kinetics constants (ka and kd) and only provide binding data at equilibrium conditions (e.g., KD). 
However, binding affinity KD values were not quantified, rendering it difficult to compare 
binding for VEGFR1, where VEGF-A165b saturated the receptor at a higher concentration. (2) 
The concentration range was limited. The lowest dose explored was sufficient to saturate 
VEGFR2 for both splice variants, demonstrating that VEGF-A165b does not bind VEGFR2 with a 
weaker affinity than VEGF-165a, while leaving open whether it binds with a stronger affinity than 
VEGF-A165a. Differentiating whether VEGF–A165b binds with identical affinity vs greater affinity 
than VEGF-A165a would require testing doses below the receptor-saturating concentrations for 
both VEGF-A165a and VEGF-A165b.  
Surface plasmon resonance (SPR) is an ideal approach for addressing the unanswered 
questions of (a) whether VEGF-A165a, VEGF-A165b, and VEGF-A121 bound VEGFR1 and 
VEGFR2 with identical binding affinities and (b) the kinetic binding kinetic rate constants for 
each interaction. SPR measures binding kinetics (ka and kd) by detecting biomolecular 
interactions in real-time with high sensitivity [79,237]. Recent work has further advanced 
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reference signal choice to minimize the detection of non-specific artefacts while measuring 
ligand:receptor kinetic constants for VEGF family receptors specifically [163]. Recently, the 
SPR-based approach has been applied to compare pro- and anti-angiogenic binding properties, 
but these studies only qualitatively reported that the isoforms bound VEGFRs with binding 
affinities within 2 orders of magnitude of each other [235], and these studies were performed 
before new reference subtraction methods were demonstrated [163] . Kinetic rate constants have 
been reported only for VEGF-A165:VEGFR interactions [103,163,235]. These currently-
unknown binding characteristics are needed to develop physiologically-accurate and predictive 
computational models.  
Here I apply surface plasmon resonance (SPR) to measure the unknown VEGF-
Axxxa:VEGFR1 and –Axxxb  binding kinetics. I observe differential binding that should lead to 
differential activation of the VEGFRs. These results will enable the construction of detailed, 
accurate computational models to help further my understanding of angiogenic signaling in 
human health and pathology. 
 
5.2 Results 
5.2.1 Establishing VEGFR binding kinetics for VEGF-A splice variants  
I utilized the SPR biosensor-based assay to measure the unknown kinetics for VEGF-A121 
and VEGF-A165b binding to VEGFR1 and VEGFR2. I confirmed that the canonical view of 
VEGFR:VEGF-A splice variant binding holds: VEGF-A165a, -A165b, and –A121 bind both 
VEGFR1 and VEGFR2 (Figure 5.1) [65]. I validated the method with VEGF-A165a binding 
kinetics [103,163]. Previously, I measured a VEGF–A165a:VEGFR1 binding affinity (Figure 
5.1A and Table C.1) binding affinity of KD = 1 pM; which is consistent with a prior SPR affinity 
of KD = 7.5 pM [103]).  I measured a VEGF–A165a:VEGFR2 binding affinity of KD = 9.8 pM, 
which is within an order of magnitude of a previous SPR measurement found by Tiedemann et 
al. (KD = 52 pM [104]). Here, I observe that VEGF-A165a binds VEGFR1 with 3-orders of 
magnitude stronger affinity than either the anti-angiogenic –A165b or –A121: VEGF-A165a binds 
VEGFR1 with KD = 1.0 pM. VEGF-A165b, however, binds VEGFR1 with a KD = 1.4 nM. 
VEGF–A121 binds VEGFR1 with the weakest affinity of the three isoforms with a KD = 3.7 nM. 
(Figure 5.2A, and Table C.1). In contrast, I observe that the –A165b variant binds VEGFR2 10x 
stronger than the -A165a variant with a VEGF–A165b:VEGFR2 KD = 0.81 pM versus a VEGF-
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A165a:VEGFR2 KD = 9.8 pM. In contrast, VEGF-A121:VEGFR2 binding occurred with the 
weakest strength, with an affinity constant KD = 660 nM (Figure 5.2A, and Table C.1).  
 
5.2.2 Association and dissociation rate constants reveal affinity trends 
I can further understand the VEGF-Axxx:VEGFR interaction affinities via their 
association and dissociation rate constants (Figure 5.2B-C). Here I observe that the differences in 
–A165a and –A165b binding affinities with VEGFR2 are attributed primarily to differences 
between their dissociation kinetics. VEGF-A165a and VEGF–A165b bind VEGFR2 with similar 
association rates—i.e. ka ≃ 106 M-1 s-1; however, A165a:VEGFR2 has a dissociation rate 50-fold 
faster than does –A165b:VEGFR2, resulting in the higher binding affinity between the latter pair 
(Figure 5.2B-C). In contrast, –A165b:VEGFR1 dissociates ~30-fold faster than does VEGF-
A165a:VEGFR1, but with an association rate ~2 orders of magnitude slower than for VEGF-
A165a:VEGFR1 (ka ≃ 4.9 * 103 vs 4.0 * 105), which together results in a 1000-fold weaker –
A165b:VEGFR1 interaction. In contrast to the variation in dissociation rates, I observed minor 
association rate variation. For both VEGFR1 and VEGFR2, the splice variants association rates 
varied within an order of magnitude. VEGF-A121 bound VEGFR1 with an association rate within 
an order of magnitude of VEGF-A165a and -A165b. Likewise, all three variants bound VEGFR2 
with association rates within an order of magnitude (Figure 5.2B). However, VEGF-A121 
dissociates from VEGFR1 and VEGFR2 faster than either other splice variant, with a kd > 1/1hr, 
which is over an order of magnitude faster than the next fastest dissociating splice variants—
VEGF-A165b for VEGFR1 and VEGF-A165a for VEGFR2 (Figure 5.2C). 
 
5.3 Discussion 
I have shown (A) differential binding between VEGFRs and three most common 
[68,95,238] VEGF-A splice variants, VEGF-A165a, VEGF-A121, and VEGF-A165b (B) measured 
the kinetics and affinities for each interaction. The differential VEGFR binding is key to 
understanding VEGF-Axxx protein expression patterns in numerous pathologies, including: (1) 
peripheral artery disease (PAD), (2) cancers, and (3) other disorders including systemic sclerosis. 
I summarize the functional and therapeutic impact in each case.  
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5.3.1 Anti-angiogenic VEGF-Axxxb splice variants in human disease 
The preceding discovery of VEGF-A165b preferentially binding VEGFR2 suggests an 
important role in regulating human disease. Anti-angiogenic -Axxxb variants were initially 
investigated by Bates et al. with their discovery of VEGF-A165b in 2002 [95]. The so-called anti-
angiogenic splice variants, denoted VEGF-Axxxb, which are differentiated from the pro-
angiogenic VEGF-A variants by the inclusion of an alternate form of exon 8 [68]. Since their 
publication, interest has boomed. To date, PubMed lists over 200 citations for “anti-angiogenic 
VEGF isoforms”, and over 100 citations for “VEGF165b” and “VEGF-A165b” [239]. These 
subsequent studies have observed significant shifts in the anti-angiogenic VEGF-A165b 
concentrations across important angiogenesis-related pathologies, including: peripheral artery 
disease (PAD) [234,240], cancer [62], diabetes [71,72], systemic sclerosis (SSc) [73], pre-
eclampsia [74], and Denys-Drash syndrome (DDS) [241], to name a few [74]. In these 
pathologies, VEGF-A splice variant concentration shifts change the angiogenic “agonist” and 
“antagonistic’ balance. Taken together, these studies have highlighted the importance that these 
anti-angiogenic isoforms play in regulating angiogenesis in human disease. Specifically, I 
discuss how my binding measurement results are key to understanding how these isoform shifts 
result in impaired or pathologic angiogenesis and highlight how splice variant expression can 
regulate human pathologies. 
 
5.3.2 VEGF-A165b:VEGF-A165a differential binding contextualizes expression patterns observed 
in pro- and anti-angiogenic pathologies 
My measurement of strong VEGF-A165b:VEGFR2 binding helps explain a recent 
paradox: VEGF-A165b disrupts angiogenesis in a number of pathologies while its absence 
enhances angiogenesis in others. Recent evidence resolving this apparent paradox demonstrated 
that VEGF-A165b specifically was selectively upregulated in SSc patients to serve an antagonistic 
role [73]. Angiogenesis impairment is a feature of SSc, so this VEGF-A upregulation means pro-
angiogenic VEGF-A165a is not upregulated sufficiently to outcompete VEGF-A165b despite 
measuring VEGF-A165a tissue protein upregulation [242]. In another example of the antagonist 
isoform activity, VEGF-A165b upregulation and VEGF-A165a downregulation in peripheral artery 
disease (PAD) is linked to angiogenesis impairment that limits re-vascularization [234,240]. 
However, the isoform balance is shifted towards agonist isoforms in renal cell carcinoma, where 
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VEGF-A165b is down-regulated, removing an inhibitory block to tumor angiogenesis [95]. A 
similar pattern of VEGF-A165b downregulation alongside overall VEGF-A upregulation during 
the first trimester is predictive of pre-eclampsia in pregnancy [243,244]. In diabetes, a similar 
shift towards agonist isoforms occurs within the vitreous humor. In healthy patients, both pro- 
and anti-angiogenic isoforms appear at similar concentrations; in diabetes, however, pro-
angiogenic VEGF-A165a is significantly upregulated while VEGF-A165b is not [72].  VEGF-A165b 
binds VEGFR2 selectively and with a stronger affinity than –A165a, therefore, my results suggest 
that -A165b upregulation could easily compete with –A165a for VEGFR2 binding and inhibit 
angiogenic signaling. The strong –A165b:VEGFR2 binding affinity measured here suggests that 
pathologies promoting angiogenesis require both upregulating –A165a and down-regulating the 
inhibitory and competitive –A165b isoform. My results demonstrating that VEGF-A165b binds 
VEGFR2 selectively with stronger affinity than –A165a, therefore, explains why isoform specific 
up-regulation and down-regulation could have either pro- or anti-angiogenic results in different 
pathologies for different isoforms. 
 
5.3.3 VEGF-A165x:VEGFR2 differential binding may regulate peripheral artery disease. 
My results revealing that the anti-angiogenic VEGF-A165a binds VEGFR2 with a higher 
affinity than VEGF-A165b suggests the interaction would dominate in the high [-A165a] conditions 
found in peripheral artery disease [240]. Peripheral artery disease patients develop tissue 
ischemia when collateral vessel formation is insufficient around formed arterial occlusions [245]. 
The improper revascularization occurs despite increased serum [VEGF-A] levels [246]. Recent 
work demonstrated that this increase in serum [VEGF-A] is due to increased anti-angiogenic 
[VEGF-A165b] while pro-angiogenic [VEGF-A165a] levels decrease [240]. Recent computational 
modeling predicted that the decreased [-A165a]—not competition for VEGFR2 binding between 
the pro- and anti-angiogenic variants accounts for the limited VEGFR2 signaling. However, this 
prediction was predicated on -A165a & -A165b binding VEGFRs with identical affinities. My 
results demonstrating stronger -A165b:VEGFR2 binding, however, suggests competitive VEGFR2 
binding between the pro- and anti-angiogenic forms could be key conditions for inhibiting 
VEGFR2 signaling at PAD [VEGF-Axxx]. 
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5.3.4 Pro-angiogenic treatments for peripheral artery disease should be coupled with anti-VEGF-
Axxxb therapies. 
My measurements of strong –A165b:VEGFR2 binding suggests that future pro-angiogenic 
treatments for peripheral artery disease should couple pro-angiogenic VEGF-A165a treatments 
with anti-A165b treatments. Pro-angiogenic therapies developed for PAD focus on increase pro-
angiogenic serum [VEGF-A165], however these approaches have failed to promote sufficient 
revascularization [246]. Recent work has demonstrated that PAD patients are characterized by 
high anti-angiogenic [VEGF-A165b] in serum, which inhibit VEGFR2 signaling when bound. My 
results revealed that this upregulated variant can bind VEGFR2 with a higher affinity than the 
administered pro-angiogenic variant, which could limit the treatment efficacy. Further, 
experimental studies have demonstrated that –A165b-related inhibited angiogenesis is reversed by 
inhibiting –A165b [73]. Additionally, quantitative flow cytometry (qFlow) results revealed 
receptor expression trends that reinforce this mechanism: early on in hind-limb ischemia, 
VEGFR1 is upregulated, while VEGFR2 is downregulated [227]. This VEGFR1 upregulation 
increases the higher-affinity binding sites available to VEGF-A165a, limiting the effect of the 
isoform in treatment. My results therefore further support the inhibitory action of –A165b in PAD, 
and suggest future treatments focus on inhibiting its binding.  
 
5.3.5 VEGF-A splice variant-specific regulation in tumors: differential binding may regulate 
tumor angiogenesis. 
My results demonstrating that –A165b binds VEGFR2 stronger than –A165a offers a 
possible explanation for the –A165b down-regulation observed in tumors. For instance, the anti-
angiogenic splice variant VEGF-A165b has been found to be down-regulated or absent in renal 
cell carcinoma and prostate tumor patients where the pro-angiogenic –A165a splice variant is 
upregulated in tumor tissues. Further, the restoration of –A165b corresponds to inhibited tumor 
growth [95,247].  Additionally, qFlow analyzes of VEGFR expression levels in tumor xenograft 
models [154] as well as on tumor EC-like cells in glioblastoma [228] revealed high heterogeneity 
in VEGFRs, including a large subpopulation (~35%) with strong VEGFR2 upregulation, 
increasing the amount of pro-angiogenic receptors available for VEGF-A165a binding. My results 
suggest that increased pro-angiogenic –A165a levels without downregulating –A165b, would not 
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sufficiently out-compete the remaining inhibitory –A165b due to its stronger –A165b:VEGFR2 
binding.  
 
5.3.6 VEGF-Axxxb-versus-VEGF-Axxx differential binding may shed new light on anti-angiogenic 
drug development. 
My discovery that anti-angiogenic VEGF-A165b binds VEGFR2 with a higher affinity 
than the pro-angiogenic –A165a can advance anti-angiogenic drug approaches in cancer. 
Currently, three broad approaches are applied to inhibit VEGFR2-mediated angiogenic signaling 
in cancer: (1) blocking VEGFR2 signaling via broad RTK inhibitors, such as sunitinib [248] and 
sorafenib [121], (2) VEGF-A sequestration via anti-VEGF-A antibodies like bevacizumab [156], 
and recently (3) blocking VEGFR2 binding via monoclonal antibodies like ramucirumab that 
block the receptor ligand-binding domain [249,250] These current approaches have several 
limitations: anti-VEGF-A treatments like bevacizumab are plagued by intrinsic and acquired 
drug resistance [91], which recent work suggests could be driven by cross-family 
PDGF:VEGFR2 binding in the absence of VEGF-Axxx [163]; small molecule RTK inhibitors also 
suffer from resistance, but, more significantly, broadly inhibit multiple classes of RTKs resulting 
in extensive side effects [251]; and anti-VEGFR2 binding antibodies like DC101 (in mice) and 
ramucirumab bind VEGFR2 with nanomolar-scale affinities [250,252,253]. These monoclonal 
antibody treatments, however, still allow a degree of uni- and cross-family binding by VEGF-A, 
PDGF-AB and –CC, ligands which bind VEGFR2 at sub-nM affinities [163]. VEGF-A165b, 
therefore, could serve as an alternative anti-angiogenic approach that overcomes each of these 
limitations: it outcompetes all currently known VEGFR2-binding growth factors and anti-
VEGFR2 antibodies, preventing a cross-family VEGFR2 mechanism, while inhibiting VEGFR2 
signaling without the broad-class inhibition afforded by sunitinib and sorafenib [120–122]. 
Indeed, studies in mice have demonstrated that treatment with –A165b inhibited tumor growth 
[247], My discovery of high-affinity VEGF-A165b:VEGFR2 binding, therefore, offers a uniquely 
advantageous approach towards anti-angiogenic therapies that could overcome current 
limitations. 
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5.3.7 VEGF-Axxx:VEGFR differential binding suggest differential binding in cross-family 
interactions. 
My results of differential binding between VEGF-A splice variants and VEGFRs suggest 
that differential binding—and therefore differential activation—may occur in VEGF-A cross-
family interactions with PDGFRs. These results have focused on the established uni-family 
interactions, i.e. VEGF-A binding VEGF receptors, but splice variants may also bind 
differentially to cross-family targets, i.e. receptors of different signaling families. The VEGF 
family has demonstrated several cross-family interactions. VEGF-A165a has been shown to bind 
and activate both PDGFRα and PDGFRβ [47]. Recently, VEGFRs have been found to exhibit 
cross-family interactions: notably, the PDGF-AA, -AB, -BB and –CC were found to bind 
VEGFR2 with strong affinities [163]. This evidence of differential VEGF-Axxx:VEGFR binding 
underscores a need for future studies to determine whether VEGF-Axxx:PDGFR interactions 
occur with differential binding or activation.  
 
5.3.8 VEGF-Axxx:VEGFR2 kinetics measurements enable more precise computational models. 
My measurements of VEGF-Axxx:VEGFR kinetics will enable more precise 
computational model construction of VEGF-A splice variants in angiogenesis. Computational 
modeling is powerful tool for understanding complex signaling systems, like those regulating 
angiogenesis, and enables us to probe for important regulators in disease processes. Current 
computational models of angiogenesis have focused on the role played by VEGF-A165a:VEGFR 
interactions in competition with other related growth factors like PlGF [88], its role in whole-
body disease processes like cancer following drug treatments [64,69,238,254], the role VEGFR 
heterogeneity plays in VEGF-A binding [113], and how cross-family binding competition 
contributes to receptor binding [163]. These models, however, are limited by their focus on 
VEGF-A165a, their exclusion of VEGF-A165b, or because they treat VEGF-A121 and VEGF-A165a 
binding kinetics as identical. Recently, a computational model of peripheral artery disease 
explored the competition between VEGF-A165a and VEGF-A165b in peripheral artery disease 
(PAD) [234]. However, this model too is limited because differential binding kinetics were 
previously unknown for VEGF-A165b. Understanding of VEGF-A in disease processes has been 
advanced by computational models, but they are limited by the previous lack of quantitative 
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measurements of splice variant binding kinetics. Future modeling, therefore, will incorporate my 
new kinetics measurements in addition to splice variant concentration measurements.  
 
5.3.9 How alternative splicing is achieved: opportunities for future manipulation of VEGF-A 
splice variant signaling. 
My discovery that VEGF-A variants bind VEGFRs with different affinities suggests that 
manipulating exon splicing could provide a new mechanism for manipulating pro- and anti-
angiogenic responses clinically. The VEGF-A variants are produced by alternative splicing, a 
process by which the cell can generate alternate protein forms, with potentially different binding 
characteristics, from the same gene [65,255]. Splicing occurs between DNA transcription and 
RNA translation when the cell removes gene introns and selects which exons will be translated 
[256]. Alternative splicing has been estimated to be involved in as many as 95% of human genes, 
and has been shown to produce proteins with largely differing properties and interactions [257]. 
While the removal of introns is a form of splicing, alternative splicing occurs with the removal of 
certain exons, which can result in significantly different protein products [258]. This process is 
catalyzed by molecules known as spliceosomes, complexes that consists of five small nuclear 
ribonucleic proteins (snRNPs) and other proteins [259]. Spliceosomes regulate the exclusion of 
introns and exons from the final mRNA by their base-pair specific binding [260]. Two 
components of the spliceosome bind either end of a RNA section, which is removed following a 
series of spliceosome conformational changes [261].  
The regulation of spliceosome production, and therefore alternative splicing itself, is 
manipulated by a variety of complex mechanisms that aren’t fully understood, including in 
VEGF-A alternative splicing [258]. VEGF-A splice variants are drawn from eight exons, with 
exons 6 and 8 have alternate forms [262]. All splice variants are formed by preferring one exon 
variant or excluding exons. For example, VEGF-Axxxb anti-angiogenic variants are formed 
through preferring the alternative form of exon 8 [62].  Exon exclusion, however, defines the 
differences between all other VEGF-A splice variants. For example, VEGF-A121 is formed by the 
exclusion of exons 6 and 7, both of which are key for binding extracellular matrix heparin while 
exon 7 is required for binding neuropilins [61]. The mechanisms regulating these exon deletions 
remain unclear in VEGF-A synthesis. Because VEGF-A splice variants have unique binding 
patterns, and unique effects on VEGFR signaling, future investigations are needed to understand 
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the regulatory mechanisms that control which splice variants are produced, enabling future 
therapeutics to differentially promote pro- and anti-angiogenic VEGF-A variants. 
 
5.3.10 Conclusion 
Alternative splicing produces VEGF-A variants with different binding partners, and as I 
show for the first time, different binding kinetics. As recent evidence has pointed to important 
roles the pro- and anti-angiogenic variants can play in human pathology, it is crucial for 
researchers to not only have access to differences in their expression, but these differences I have 
identified in their binding kinetics. Cell signaling systems, like the VEGF-A-axis regulating 
angiogenesis, are complex: receptors activate a multitude independent and overlapping 
downstream pathways, with dozens of growth factors binding receptors, either activating, 
inhibiting, or modulating their downstream action. Deconvolving the contributions that any one 
molecule makes requires the experimental tools provided for by systems biology. Only by having 
a complete picture of VEGF-A in regulating angiogenesis are I able to truly start developing 
effective therapeutic interventions for angiogenesis-related pathologies. 
 
5.4 Materials and Methods 
5.4.1 Surface plasmon resonance kinetic studies with dextran-coated gold sensors 
SPR studies were performed with the BIAcore 3000 instrument (Biacore International 
AB, Uppsala, Sweden) at 25°C on dextran-coated gold sensor chips (CM5, Research grade, GE 
Healthcare Bio-sciences AB, Uppsala). The BIAcore 3000 divides CM5 sensor chips into four 
separate flow cells. I immobilized a different receptor protein in each flow cell: The first cell was 
reserved for measuring non-specific binding by immobilizing recombinant angiopoietin-4 (Cat. 
#964-AN-025/CF, R&D Systems) to a flow cell: it has no known interaction with VEGF-A 
splice variants. VEGFR1 and VEGFR2 were immobilized in two of the remaining flow cells. 
Running buffer: 1x HBS-EP pH 7.4 (10 mM HEPES, 3 mM EDTA, 150 mM NaCl, 0.005 % 
TWEEN-20, cat. # BR100188, GE Life Sciences). 
 
5.4.2 Protein immobilization 
Pre-concentration studies were performed as previously described [163]mameto 
determine optimal pH conditions for protein immobilization to ensure target levels of 
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immobilized protein can be achieved precisely and to conserve protein. 10 mM acetate buffers 
were prepared ranging from pH 3.5 to 0.5 - 1.0 below the protein’s isoelectric point. Receptor 
solutions were prepared at 20 µg/mL with each acetate buffer. I injected 20 µL of each pH 
solution at a flow rate of 5 µL/min, followed by a 5-µL injection of ethanolamine-HCL (GE 
Healthcare AB, Uppsala, Sweden) to clear the surface. I selected the optimal acetate buffer pH 
for each protein based on (1) the maximum level of protein immobilization reached and (2) the 
rate of immobilization observed in the pre-concentration study sensograms.  
Recombinant VEGFR1 (Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein, CF, 
Cat. #321-FL-050/CF, R&D Systems) and VEGFR2 (Recombinant Human VEGF R2/KDR Fc 
Chimera Protein, CF, Cat. #357-KD-050/CF, R&D Systems) were immobilized irreversibly to 
separate flow cells via amine coupling with the dextran matrix. Additionally, I immobilized 
angiopoietin-4 (Recombinant Human Angiopoietin-4 Protein, CF, Cat. #964-AN-025/CF, R&D 
Systems), a protein with no known interaction with any VEGF-A splice variant, to a flow cell as 
a reference signal protein to subtract the effects of non-specific interactions. The surface was 
activated by injecting 35 μL of a 1:1 volumetric mixture of 0.05 M NHS (N-
hydroxysuccinimide, GE Healthcare AB) and 0.2 M EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride GE Healthcare AB) at a flow rate of 5 μL/min. Each receptor was 
dissolved in 20 µg/mL of the 10 mM acetate buffer at its optimal pH and injected at 5 µL/min 
until the target level was reached (approximately 200-500 R.U. of immobilized receptor.) After 
sufficient protein was coupled, the surface was de-activated by injecting 35 μL ethanolamine 
(ethanolamine hydrochloride-NaOH pH 8.5, GE Healthcare AB.)  
 
5.4.3 Ligand-receptor kinetics measurements 
Fresh ligand solutions were prepared at 40, 20 and 10 nM in HBS-EP running buffer each 
experimental day, including: human recombinant VEGF-A (R&D Systems, Cat. #293-VE-010), 
VEGF-A121, and VEGF-A165b (Note: All ligands were obtained as recombinant human proteins 
from R&D Systems). 120 μL of each ligand solution was injected into flow cells containing 
immobilized receptor and Ang-4—a reference for non-specific binding—at 30 μL/min 
(association). This was followed by a 10 min running-buffer injection (dissociation). Between 
each sample, I injected, in series, 5 μL of 5 mM HCl and 5 μL of 10 mM NaOH at 5 μL/min to 
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remove any remaining bound ligand. I repeated this cycle for each concentration tested (40, 20, 
and 10 nM.) Each concentration series was performed in triplicate.  
 
5.4.4 Kinetic analysis 
The raw ligand:receptor sensograms were aligned and the background, non-specific 
binding was subtracted using the sensogram trace from the ligand:Ang-4 flow cell (as previously 
described [163]). Both the raw ligand:receptor and ligand:Ang-4 sensogram curves were 
obtained within the BIAcore 3000’s detection window (10-70,000 R.U.) for all interactions [148] 
to ensure detected interactions did not represent system noise. BIAevaluation removes 
momentary signal spikes resulting from transient air bubbles.  
Global analysis is considered to produce more accurate results than fitting of a single 
response curve, so global fitting was performed with BIAevaluation software (Version 4.1.1, GE 
Healthcare) following a 1:1 Langmuir adsorption isotherm (Equation 5.1) [149]. The software 
applies nonlinear least squares analysis to determine association (ka) and dissociation (kd) rates 
fitting best to multiple response curves simultaneously. Additionally, the software provides the 
goodness-of-fit parameter χ2 and the peak magnitude of the signal response, Rmax. 
(Equation 5.1) a
d
k
k
R L R:L→←+  
 
5.4.5 Classifying binding 
Both the instrument manufacturer (BIAcore) and previous researchers have suggested 
that when fitting kinetic rate constants using global analysis, a χ2-to-Rmax value (a measure of 
noise-to-signal) < 0.2 is ideal for confidence in the kinetic parameters obtained when studying 
known interactions [99,100,150]. A low noise-to-signal indicates that the sensogram signal 
includes minimal contributions from the following three noise-factors: (1) overall instrument 
noise, (2) heterogeneities in immobilized receptor or ligand, and (3) non-specific interactions. I 
applied a cut-off value I established previously [163] of χ2-to-Rmax < 1.0 that differentiates real, 
1:1 Langmuir interactions, from predominantly non-specific interactions, where χ2-to-Rmax > 1.0 
to confirm that detected interactions represented true receptor binding.  
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5.5 Figures 
 
 
 
Figure 5.1. Structural and functional differences of VEGF-A alternative splice variants.  
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Figure 5.2. Binding kinetics and affinities for VEGFR1 and VEGFR2 interactions with VEGFA splice variants. (A) Binding 
affinity KD between each ligand and receptor, (B) association rate (in M-1 s-1) and (C) dissociation rate (s-1). 
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Figure 5.3. SPR sensograms for VEGFA165a, –A121, and –A165b binding VEGFR1 and VEGFR2. (A) Kinetic response curve of 
VEGFA165a—VEGFR1 and (D) —VEGFR2 binding confirmed previous high affinity measurements to both receptors. (B) Both 
VEGFA121 and the anti-angiogenic VEGFA165b variants bind VEGFR1 with affinities 3 orders of magnitude weaker than VEGFA165a. 
(E) VEGFA121 binds VEGFR2 with the weakest affinity, and (F) the anti-angiogenic VEGFA165b binds VEGFR2 with a strong affinity 
that could displace the angiogenic form. Receptors were immobilized on BIAcore CM5 sensors. All kinetic studies were obtained by 
simultaneously injecting ligand across VEGFR1, VEGFR2, and Angiopoietin-4, a non-VEGFA binding protein used for reference 
subtraction. The following curves were obtained by subtracting this reference signal from the raw receptor-ligand interaction curve, 
removing signals associated with non-specific interactions.
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APPENDIX A 
SUPPLEMENTAL – PDGF:VEGFR INTERACTIONS 
A.1 Supplementary Discussion 
A.1.1 Functional role of cross family binding in vascular structure: PDGF-BB may serve an 
autocrine regulatory role enhancing endothelial cell (EC) stability 
The novel PDGF-VEGFR2 interactions suggest that local autocrine and paracrine 
signaling toward the promotion and maintenance of vascular structure is robust to major changes 
in serum VEGF-A levels. Angiogenic endothelial cells (ECs) are known to communicate with 
mural cells, specifically pericytes, for microvasculature via a form of paracrine signaling 
involving PDGF-BB and PDGFRβ [41,263]: Angiogenic ECs such as those in angiogenic 
sprouts or in remodeling arteries [264] secrete PDGF-BB, which binds to pericyte-expressed 
PDGFRβ [265] resulting in pericyte recruitment to newly-formed vessels [266]. This signaling is 
critical to angiogenesis and vascular stability [264,267]. Our discovery of a novel PDGF-BB—
VEGFR2 interaction suggests that PDGF-BB secretion by angiogenic ECs could play an 
additional autocrine role in promoting angiogenesis. Secreted PDGF-BB could bind EC-
expressed VEGFR2, promoting further angiogenic behavior. However, the lower relative affinity 
observed with VEGFR2 suggests that any autocrine PDGF-BB signaling would be relatively 
minor compared to VEGF-A:VEGFR2 signaling, even when considering the higher serum PDGF 
levels in healthy and in exercise conditions.  
 
A.1.2 Functional implications of cross family binding in wound healing  
Under the PDGF-rich conditions found during the wound healing process (Table 4), the 
novel PDGF—VEGFR2 complex may form at higher levels than VEGF-A—VEGFR2, 
providing a PDGF-dominated pathway for neovascularization in wound healing. Once a wound 
has formed, the repair requires the coordination of multiple cellular processes: cell proliferation, 
migration and angiogenic neovascularization [268]. Wound healing is the confluence of these 
processes and their respective regulatory cytokines—of which the PDGFs play several critical, 
well-established roles including clot formation, ECM production and collagen removal 
[194,269–271]. Following injury, there is a larger upregulation of PDGFs in the wound fluid 
relative to upregulation of VEGF-A: VEGF-A wound fluid concentrations are 10-fold higher 
[272] than normal serum levels [273,274], whereas PDGF-AA and -AB wound fluid 
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concentrations increase to concentrations that are 5-to-40-fold higher [272] than normal (Table 
3). Under normal physiological conditions, VEGF-A binding with the VEGFR2 expressed on 
endothelial cell surfaces is the primary mechanism for inducing an angiogenic response, while 
PDGF-VEGFR2 interactions remain insignificant due to the weaker binding affinity (Table 2.) 
However, with this shift in PDGF-VEGF-A concentration balance, the PDGF—VEGFR2 
interaction may outcompete VEGF-A—VEGFR2 formation despite the binding disparity and 
may become the primary regulator of the VEGFR2 angiogenic signaling pathway. Therefore, the 
novel cross-family PDGF—VEGFR2 interactions found in this study would play the primary 
role in regulating the neovascularization in the wound healing process. 
 
A.1.3 Functional implications of cross family binding in cellular tissue engineering: PDGF-
VEGFR2 should be exploited for engineered tissue vascularization 
Our identification of new cross-family interactions will provide the basis of new 
guidelines for vascular development in tissue engineering. Encouraging vascularization within 
new tissue is inherently difficult and a major challenge to graft development [275–277]. Efforts 
in artificial organ development are limited by the need to vascularize the engineered tissues 
[278,279]. One existing method is the tube-formation assay on Matrigel and other substrates. 
These experiments commonly use human umbilical vein endothelial cells (HUVECs), which do 
not express either PDGFR normally; but as the assay progresses and tubes form over time, the 
HUVECs begin to express PDGFRβ [202]. Their malleable receptor expression patterns 
combined with the newly discovered cross-family receptor activation patterns together suggest 
that the behavior of HUVECs could be readily manipulated to improve vascularization of 
artificially developed tissue grafts and organs. Other methods to induce vasculature development 
include 2-D co-culture studies [202,280] and the use of 3-D environments or scaffolds for tissue 
growth [281,282]. These methods typically use a combination of ECs and fibroblast cells (FCs), 
the latter of which express virtually no VEGFRs [283]. Our results indicate that these models 
could be improved by exploiting these novel cross-family receptor interactions. Growth media 
compositions can be adjusted to optimize the amounts of VEGF and PDGF ligands to improve 
EC proliferation and migration responses [50] and to encourage fibroblast recruitment to the 
development of blood vessels. These new interactions offer new mechanisms to manipulate these 
cell types in hopes of better vascularizing artificial grafts and organs.  
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A.2 Supplementary Tables 
 
Table A.1. Classification of true and false interactions via χ2-to-Rmax. The ratio reflects how 
well a global kinetic analysis of a multi-concentration sensogram series can fit to a simple 1:1 
Langmuir interaction model can fit. True interactions were distinguished from those due to non-
specific binding patterns where χ2-to-Rmax < 1.0 (indicated by green shading and polka dot 
texturing). Fitted curves where χ2-to-Rmax > 1.0 (in red-shaded, grid-pattern textured cells) were 
considered to be dominated by non-specific binding. Ligand-receptor pairs that produced 
negative association curves were not analyzed with global fitting (indicated by “NI” for no 
interaction). 
  VEGFR1 VEGFR2 VEGFR3 PDGFRα PDGFRβ 
VEGFA 0.17 0.52 6.03 34.4 0.95 
PDGFAA NI 0.082 NI 0.023 8.6 
PDGFAB NI 0.29 NI 0.0042 0.19 
PDGFBB NI 0.029 NI 0.0082 0.0064 
PDGFCC NI 0.33 NI 0.43 0.58 
PDGFDD NI NI NI 1130 2.2 
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Table A.2. VEGF and PDGF binding kinetics and affinities.  Sensograms for ligand injections at 10 nM, 20 nM, and 40 nM, three 
replicates each, for each ligand-receptor pair. Kinetic constants were obtained by performing global kinetic analysis using the 
BIAevaluation software across several kinetic binding sensograms. Affinity constants were calculated as the ratio of the association 
and dissociation rates. Rate constants where the χ2-to-Rmax ratio exceeds 1.0 are shown in italics, indicating interactions that are 
dominated by non-specific interactions. Ligand-receptor pairs that produced negative association curves were not analyzed with global 
fitting (indicated by “NI” for no interaction). Mean values are reported for each kinetic fit for N=3. Uncertainty presented using the 
standard error of the mean. 
 
 
VEGFR1 VEGFR2 
ka (M
-1 s-1) kd (s
-1) KD (M) ka (M
-1 s-1) kd (s
-1) KD (M) 
VEGFA 54.0 0.04 10± ∗  74.0 0.1 10−± ∗  121.0 0.03 10−± ∗  59.7 100.3∗±  69.5 100.2 −∗±  129.8 100.4 −∗±  
PDGFAA NI NI NI 31.6 0.1 10± ∗  48.6 0.1 10−± ∗  75.3 0.4 10−± ∗  
PDGFAB NI NI NI 41.4 0.3 10± ∗  61.6 0.6 10−± ∗  101.1 0.5 10−± ∗  
PDGFBB NI NI NI 33.5 0.7 10± ∗  41.3 0.1 10−± ∗  83.7 0.9 10−± ∗  
PDGFCC NI NI NI 43.6 0.2 10± ∗  62.5 0.3 10−± ∗  117.0 0.9 10−± ∗  
PDGFDD NI NI NI NI NI NI 
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Table A.2. (cont) 
 
VEGFR3 
ka (M
-1 s-1) kd (s
-1) KD (M) 
VEGFA .2 2  . 51 3 10−∗  . 65 2 10−∗  
PDGFAA NI NI NI 
PDGFAB NI NI NI 
PDGFBB NI NI NI 
PDGFCC NI NI NI 
PDGFDD NI NI NI 
 
 
 
 
 
PDGFRα PDGFRβ 
ka (M
-1 s-1) kd (s
-1) KD (M) ka (M
-1 s-1) kd (s
-1) KD (M) 
VEGFA . 31 1 10∗  . 52 7 10−∗  . 82 6 10−∗  41.2 0.1 10± ∗  64.0 0.5 10−± ∗  103.4 0.5 10−± ∗  
PDGFAA 26.8 1.3 10± ∗  44.5 1.3 10−± ∗  76.6 2.3 10−± ∗  38.8 0.4 10± ∗  41.5 0.4 10−± ∗  81.7 0.4 10−± ∗  
PDGFAB 31.2 0.1 10± ∗  31.0 0.2 10−± ∗  78.4 1.7 10−± ∗  31.3 0.3 10± ∗  32.9 0.7 10−± ∗  62.2 0.7 10−± ∗  
PDGFBB 42.0 0.1 10± ∗  38.6 0.1 10−± ∗  74.2 0.3 10−± ∗  31.9 0.1 10± ∗  31.6 0.2 10−± ∗  78.3 1.3 10−± ∗  
PDGFCC 35.0 1.6 10± ∗  41.7 0.1 10−± ∗  93.4 1.8 10−± ∗  57.4 0.4 10± ∗  31.4 0.06 10−± ∗  91.9 0.1 10−± ∗  
PDGFDD .18 8  . 51 0 10−∗  . 75 4 10−∗  . 43 8 10∗  . 32 6 10−∗  . 86 7 10−∗  
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Table A.3. Literature mined VEGF and PDGF from SPR and cell-based assays. Values 
determined with cell assays indicated with † and SPR indicated with an asterisk*. Currently, few 
interaction kinetics have been determined. 
 
Interaction Measured KD (M) 
VEGF-A:VEGFR1 117.4 10−∗ *- 127.5 10−∗ M ([103])† 
VEGF-A:VEGFR2 115.2 10−∗ M ([103]) † 
PDGF-AA:PDGFRα 81.34 10−∗ M ([108])* 
PDGF-AA:PDGFRβ 74.53 10−∗ M ([108])* 
PDGF-BB:PDGFRα 71.5 10−∗ M ([108])* 
PDGF-BB:PDGFRβ 91.6 10−∗ M ([108])* 
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Table A.4. Model kinetic parameters and initial values. 
 
  
 Benchmark Healthy Cancer Units 
VEGFA:VEGFR1 coupling  
k1,f (coupling) 3.8 * 106 ([88]) 4.0 * 105 (via SPR) M-1 s-1 
k1,r (decoupling) 95 * 10-6 ([88]) 4.0 * 10-7 (via SPR) s-1 
VEGFA:VEGFR2 coupling  
k2,f (coupling) 1.2 * 106 ([88]) 9.7 * 105 (via SPR) M-1 s-1 
K2,r (decoupling) 410 * 10-6 ([88]) 9.5 * 10-6 (via SPR) s-1 
PDGF:VEGFR2 coupling N/A See Table  1 
Receptor and ligand-receptor 
complex internalization  
kint 10-5 ([88]) s-1 
Receptor insertion  
kinsert,R1 0.8 ([88]) s-1 
kinsert,R2 2.3 ([88]) s-1 
Extracellular volume  
Vmem 10-10 ([284]) L 
VEGFA-bevacizumab coupling  
k7,f 4.10 × 10
7  
([64]) 5.3 * 10
5  ([156]) M-1 s-1 
k7,r 2.01 × 10
-5 
([64]) 3.1 * 10
-5 ([156]) s-1 
VEGFR1 concentration/EC  
D11 80,000 ([88])  990 ([50]) 8200 ([154]) receptors 
VEGFR2 concentration/EC  
D22 230,000 ([88])  1890 ([50]) 1100 ([154]) receptors 
Healthy serum concentrations  
VA 2.2 ([88]) 
See Table  3 
nM 
PAA N/A nM 
PAB N/A nM 
PBB N/A nM 
PCC N/A nM 
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Table A.5. Serum concentrations for VEGF-A and PDGFs under physiological and pathological conditions. All values are 
means (± SD where provided) unless otherwise noted. 
 [VEGF-A] [PDGF-AA] [PDGF-AB] [PDGF-BB] [PDGF-CC] [PDGF-DD] 
Normal 
(serum) 
81.7-91.83 
pg/m[273,274] 
250.0-1700 pg/mL 
[274,285,286] 
250.0-2830 
pg/mL[285] 
8506 ± 550 
pg/mL[287] None 
1170 ± 460 
pg/mL[288] 
Exercise 
(serum) 
165.61 
pg/mL[274] 
4640 pg/mL 
[274]     
Wound fluid 1033 pg/mL[272] 8604 pg/mL [272]   
Stroke (0hr) 
(serum) 
410 ± 71 
pg/mL[289] 
7300 ± 5100 
pg/mL[114] 
52600 ± 18900 
pg/mL[114] 
10100 ± 7700 
pg/mL[114] 
66900 ± 41200 
pg/mL[114]  
Stroke (24hr) 
(serum) 
416 ± 64 
pg/mL[289] 
5500 ± 3900 
pg/mL[114] 
48000 ± 16400 
pg/mL[114] 
7000 ± 4700 
pg/mL[114] 
123600 ± 64000 
pg/mL[114]  
Breast Cancer 
(serum) 
305.9 
pg/mL[290] 
11900 ± 5100 
pg/mL[291] 
11900 ± 5100 
pg/mL[291] 7623 pg/mL [292]  7500 pg/m L[293] 
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Table A.6. Isoelectric points of immobilized proteins and optimal immobilization pHs.  
Protein pI Optimal pH 
VEGFR1 8.7 [294] 3.7 
VEGFR2 5.6 [295] 4.0 
VEGFR3 5.9 [296] 5.0 
PDGFRα 5.0 [297] 4.5 
PDGFRβ 4.9 [298] 3.7 
Angiopoietin-4 9.1 [299] 4.0 
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A.3 Supplementary Figures 
 
 
Figure A.1. Non-specific signal example—PDGF-AA:VEGFR3. Sensogram depicts example 
negative reference-subtracted curve produced when subtracting Ang-4 reference signal from 
binding signal. The negative response signal suggests than non-specific binding effects are 
greater than specific, ‘true’ binding effects.  
 
 
Figure A.2. SPR immobilization example—PDGFRα binding to the dextran matrix. Surface 
activated by injecting 35 µL 1:1 NHS:EDC solution at flow rate of 5 µL min-1. Injected 20 µg 
mL-1 PDGFRα in 10mM pH 3.7 acetate buffer until 310 R.U. of receptor immobilized. Surface 
deactivated by injecting 5 µL ethanolamine-HCL at 5 µL min-1. 
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Figure A.3. Non-specific binding reference signal subtraction. Sensogram depicts the 
injection of 40 nM PDGFAA across immobilized angiopoietin-4 and PDGFRα simultaneously. 
Ang-4, a protein with no known interaction with either PDGF or VEGF ligands, was 
immobilized at levels similar to the receptors as a background reference signal. The reference 
subtracted curve was obtained by subtracting this reference signal from the raw receptor-ligand 
interaction curve, removing signals associated with non-specific interactions.  
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A.4 Model Equations 
A.4.1 Model 1: VEGF-A:VEGFR2 Uni-Axis Model 
 
(1) 
1,f 11 1,r 11,A 2,f 22 2,r 22,A 7,r
mem
7,f
d[VA] 1 (k [VA]D k D k [VA]D k D ) k [bev:VA]
dt V
k [bev][VA]
= − + − + +
−
   
(2) 11 ins 1,f 11 1,r 11,A int 11
dD k (k [VA]D k D ) k D
dt
= − − −   
(3) 11,A
1,f 11 1,r 11,A int 11,A
dD
k [VA]D k D k D
dt
= − −   
(4) . 22 ins 2,f 22 2,r 22,A int 22
dD k (k [VA]D k D ) k D
dt
= − − − .  
(5) 22,A
2,f 22 2,r 22,A int 22,A
dD
k [VA]D k D k D
dt
= − −   
 (6) 7,f 7,r
d[bev : VA] k [bev][VA] k [bev : VA]
dt
= −   
 
A.4.2 Model 2: VEGF-A:VEGFR2 and PDGF:VEGFR2 Cross-talk Model 
 
(1) 
1,f 11 1,r 11,A 2,f 22 2,r 22,A 7,r
mem
7,f
d[VA] 1 (k [VA]D k D k [VA]D k D ) k [bev:VA]
dt V
k [bev][VA]
= − + − + +
−
   
(2) 11 ins 1,f 11 1,r 11,A int 11
dD k (k [VA]D k D ) k D
dt
= − − −   
(3) 11,A
1,f 11 1,r 11,A int 11,A
dD
k [VA]D k D k D
dt
= − −   
(4) 
AA
AB BB
CC
22
ins 2,f 22 2,r 22,A 3,f AA 22 3,r 22,P
4,f AB 22 4,r 22,P 5,f BB 22 5,r 22,P
6,f CC 22 6,r 22,P int 22
dD k (k [VA]D k D ) (k [P ]D k D )
dt
(k [P ]D k D ) (k [P ]D k D )
(k [P ]D k D ) k D
= − − − −
− − − −
− − −
  
(5) 22,A
2,f 22 2,r 22,A int 22,A
dD
k [VA]D k D k D
dt
= − −   
 
(6) 
AA
AA
3,f AA 22 3,r 22,P
mem
d[P ] 1 (k [P ]D k D )
dt V
= − −   
(7) 
AA
22,AA
3,f AA 22 3,r 22,P int 22,AA
dD
k [P ]D k D k D
dt
= − −   
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(8) 
AB4,f AB 22 4,r 22,P
mem
d[PAB] 1 (k [P ]D k D )
dt V
= − −    
(9) 
AB
22,AB
4,f AB 22 4,r 22,P int 22,AB
dD
k [P ]D k D k D
dt
= − −   
(10) 
BB5,f BB 22 5,r 22,P
mem
d[PBB] 1 (k [P ]D k D )
dt V
= − −   
(11) 
BB
22,BB
5,f BB 22 5,r 22,P int 22,BB
dD
k [P ]D k D k D
dt
= − −   
(12) 
CC6,f CC 22 6,r 22,P
mem
d[PCC] 1 (k [P ]D k D )
dt V
= − −   
(13) 
CC
22,CC
6,f CC 22 6,r 22,P int 22,CC
dD
k [P ]D k D k D
dt
= − −   
(14) 7,f 7,r
d[bev : VA] k [bev][VA] k [bev : VA]
dt
= −   
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APPENDIX B 
SUPPLEMENTAL – GENERALIZED RTK MODELS 
 
B.1 Supplementary Tables 
 
 
Table B.1. Generalized two, three, and four receptor models default parameter values 
applied  
 
Parameter Value Units 
Vext 1.26 x 10-12  [300] L 
[L]0 1.0 x 10-9 M 
R1 1000 molecules 
R2 1000 molecules 
R3 1000 molecules 
kL1 1.0 x 106 M-1 s-1 
akL1 1.0 x 10-7 s-1 
kL2 1.0 x 106 M-1 s-1 
akL2 1.0 x 10-7 s-1 
kL3 1.0 x 106 M-1 s-1 
akL3 1.0 x 10-7 s-1 
kL4 1.0 x 106 M-1 s-1 
akL4 1.0 x 10-7 s-1 
kdim 8.3 x 10-7 [301] molecule-1 s-1 
akdim 1.0 [301] s-1 
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Table B.2. Generalized two, three, and four receptor model parameter variation values 
applied 
 
Two Receptor Model 
Parameter Ratios 
R1 / R2 0.1—10.0  
kL1 / kL2 10-3—10+3 
Three Receptor Model 
Parameter Ratios 
R1:R2:R3 1:1:1, 1:2:1, 2:1:1 
kL1 / kL2 10-3—10+3 
kL2 / kL3 10-2—10+2 
Four Receptor Model 
Parameter Ratios 
R1:R2:R3:R4 
1:1:1:1, 1:2:1:1, 1:2:2:2, 1:10:1:1, 
1:10:2:1, 1:10:2:2, 2:1:1:1, 2:2:1:1, 
2:10:1:1, 2:10:2:2 
kL1/kL2 10-3—10+3 
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Table B.3. Two-receptor, one-ligand (2R1L) model predictions. Tabulated model predictions 
across system configurations. Predictions reported as % of total dimers formed at steady-state.   
Input Parameter Model Predictions 
[R1]/[R2] kL1 /kL2 D11 (%) D12 (%) D22 (%) 
0.1 1.00E-03 7.4 40.3 52.3 
0.1 4.64E-03 7.4 40.2 52.4 
0.1 2.15E-02 7.3 39.5 53.2 
0.1 1.00E-01 6.6 36.0 57.4 
0.1 4.64E-01 2.5 16.4 81.2 
0.1 2.15E+00 0.5 7.0 92.5 
0.1 1.00E+01 0.1 5.3 94.6 
0.1 4.64E+01 0.0 4.9 95.1 
0.1 2.15E+02 0.0 4.8 95.2 
0.1 1.00E+03 0.0 4.8 95.2 
0.2 1.00E-03 12.1 41.0 46.8 
0.2 4.64E-03 12.1 40.9 47.0 
0.2 2.15E-02 12.0 40.5 47.6 
0.2 1.00E-01 11.2 38.0 50.9 
0.2 4.64E-01 5.6 22.6 71.8 
0.2 2.15E+00 1.3 11.1 87.6 
0.2 1.00E+01 0.3 8.6 91.1 
0.2 4.64E+01 0.1 7.9 92.0 
0.2 2.15E+02 0.0 7.7 92.2 
0.2 1.00E+03 0.0 7.7 92.3 
0.3 1.00E-03 19.2 40.9 39.9 
0.3 4.64E-03 19.2 40.8 40.0 
0.3 2.15E-02 19.0 40.5 40.5 
0.3 1.00E-01 18.2 38.9 42.9 
0.3 4.64E-01 11.5 28.9 59.6 
0.3 2.15E+00 3.3 17.1 79.6 
0.3 1.00E+01 0.9 13.5 85.5 
0.3 4.64E+01 0.2 12.5 87.3 
0.3 2.15E+02 0.0 12.3 87.7 
0.3 1.00E+03 0.0 12.2 87.8 
0.5 1.00E-03 29.0 39.4 31.6 
0.5 4.64E-03 29.0 39.3 31.7 
0.5 2.15E-02 28.9 39.1 31.9 
0.5 1.00E-01 28.1 38.3 33.6 
0.5 4.64E-01 21.3 33.4 45.3 
0.5 2.15E+00 8.2 24.4 67.4 
0.5 1.00E+01 2.5 20.5 77.0 
0.5 4.64E+01 0.6 19.2 80.2 
0.5 2.15E+02 0.1 18.9 81.0 
0.5 1.00E+03 0.0 18.9 81.1 
0.8 1.00E-03 41.2 36.1 22.7 
0.8 4.64E-03 41.2 36.1 22.7 
0.8 2.15E-02 41.2 36.0 22.8 
0.8 1.00E-01 40.6 35.6 23.8 
0.8 4.64E-01 34.8 34.3 30.8 
0.8 2.15E+00 18.1 31.3 50.7 
0.8 1.00E+01 6.3 29.1 64.6 
0.8 4.64E+01 1.5 28.2 70.3 
0.8 2.15E+02 0.3 28.0 71.7 
0.8 1.00E+03 0.1 27.9 72.0 
1.3 1.00E-03 54.4 31.1 14.5 
1.3 4.64E-03 54.4 31.1 14.5 
1.3 2.15E-02 54.4 31.0 14.6 
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Table B.3 cont. 
[R1]/[R2] kL2 /kL1 D11 (%) D12 (%) D22 (%) 
1.3 4.64E-01 50.2 31.3 18.5 
1.3 2.15E+00 33.8 33.9 32.3 
1.3 1.00E+01 14.5 37.0 48.5 
1.3 4.64E+01 4.0 38.6 57.4 
1.3 2.15E+02 0.9 39.1 60.0 
1.3 1.00E+03 0.2 39.2 60.6 
2.2 1.00E-03 66.8 24.9 8.3 
2.2 4.64E-03 66.8 24.9 8.3 
2.2 2.15E-02 67.0 24.8 8.2 
2.2 1.00E-01 67.0 24.7 8.3 
2.2 4.64E-01 64.8 25.5 9.8 
2.2 2.15E+00 52.6 30.4 16.9 
2.2 1.00E+01 29.4 39.9 30.7 
2.2 4.64E+01 9.7 47.9 42.4 
2.2 2.15E+02 2.3 50.9 46.7 
2.2 1.00E+03 0.5 51.7 47.8 
3.6 1.00E-03 77.0 18.7 4.2 
3.6 4.64E-03 77.1 18.7 4.2 
3.6 2.15E-02 77.2 18.6 4.2 
3.6 1.00E-01 77.5 18.4 4.2 
3.6 4.64E-01 76.5 18.9 4.6 
3.6 2.15E+00 69.5 23.1 7.5 
3.6 1.00E+01 49.8 34.7 15.5 
3.6 4.64E+01 21.5 51.5 27.0 
3.6 2.15E+02 5.9 60.7 33.3 
3.6 1.00E+03 1.4 63.4 35.2 
6.0 1.00E-03 84.7 13.3 2.0 
6.0 4.64E-03 84.7 13.3 2.0 
6.0 2.15E-02 84.9 13.1 2.0 
6.0 1.00E-01 85.2 12.9 1.9 
6.0 4.64E-01 84.9 13.1 2.0 
6.0 2.15E+00 81.6 15.5 2.9 
6.0 1.00E+01 69.5 24.3 6.2 
6.0 4.64E+01 41.2 45.0 13.9 
6.0 2.15E+02 14.2 64.6 21.2 
6.0 1.00E+03 3.5 72.4 24.1 
10.0 1.00E-03 90.1 9.0 0.9 
10.0 4.64E-03 90.1 9.0 0.9 
10.0 2.15E-02 90.3 8.9 0.9 
10.0 1.00E-01 90.6 8.6 0.8 
10.0 4.64E-01 90.6 8.6 0.8 
10.0 2.15E+00 89.2 9.7 1.1 
10.0 1.00E+01 83.4 14.5 2.1 
10.0 4.64E+01 64.0 30.5 5.5 
10.0 2.15E+02 30.8 57.9 11.3 
10.0 1.00E+03 9.0 75.9 15.1 
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Table B.4. Three-receptor, one-ligand (3R1L) model predictions. Tabulated model predictions across system configurations. 
Predictions reported as % of total dimers formed at steady-state.   
Input Parameter Model Predictions 
n1:n2:n3 kL1/kL2 kL2/kL3 D11 D12 D13 D22 D23 D33 
1:1:1 0.001 0.1 20.2% 19.4% 15.7% 18.7% 14.9% 11.2% 
1:1:1 0.01 0.1 20.1% 19.4% 15.7% 18.7% 14.9% 11.2% 
1:1:1 0.1 0.1 20.1% 19.4% 15.6% 18.7% 15.0% 11.2% 
1:1:1 1 0.1 19.2% 19.2% 15.4% 19.2% 15.4% 11.5% 
1:1:1 10 0.1 13.6% 18.2% 13.6% 22.7% 18.2% 13.6% 
1:1:1 100 0.1 3.5% 16.3% 10.5% 29.1% 23.3% 17.4% 
1:1:1 1000 0.1 0.4% 15.7% 9.5% 31.0% 24.8% 18.6% 
1:1:1 0.001 1 23.7% 18.4% 18.4% 13.2% 13.2% 13.2% 
1:1:1 0.01 1 23.6% 18.4% 18.4% 13.2% 13.2% 13.2% 
1:1:1 0.1 1 22.7% 18.2% 18.2% 13.6% 13.6% 13.6% 
1:1:1 1 1 16.7% 16.7% 16.7% 16.7% 16.7% 16.7% 
1:1:1 10 1 4.5% 13.6% 13.6% 22.7% 22.7% 22.7% 
1:1:1 100 1 0.5% 12.6% 12.6% 24.7% 24.7% 24.7% 
1:1:1 1000 1 0.1% 12.5% 12.5% 25.0% 25.0% 25.0% 
1:1:1 0.001 10 29.9% 16.6% 23.3% 3.3% 10.0% 16.7% 
1:1:1 0.01 10 29.1% 16.3% 23.3% 3.5% 10.5% 17.4% 
1:1:1 0.1 10 22.7% 13.6% 22.7% 4.5% 13.6% 22.7% 
1:1:1 1 10 7.1% 7.1% 21.4% 7.1% 21.4% 35.7% 
1:1:1 10 10 0.9% 4.5% 20.9% 8.2% 24.6% 40.9% 
1:1:1 100 10 0.1% 4.2% 20.8% 8.3% 25.0% 41.6% 
1:1:1 1000 10 0.0% 4.2% 20.8% 8.3% 25.0% 41.7% 
1:2:1 0.001 0.1 10.3% 20.0% 8.4% 38.8% 16.1% 6.4% 
1:2:1 0.01 0.1 10.3% 20.0% 8.4% 38.8% 16.1% 6.4% 
1:2:1 0.1 0.1 10.2% 20.0% 8.3% 38.9% 16.2% 6.4% 
1:2:1 1 0.1 9.8% 19.7% 8.2% 39.4% 16.4% 6.5% 
1:2:1 10 0.1 7.1% 17.9% 7.1% 43.0% 17.9% 7.1% 
1:2:1 100 0.1 1.9% 14.3% 5.1% 49.8% 20.7% 8.2% 
1:2:1 1000 0.1 0.2% 13.2% 4.4% 51.9% 21.6% 8.6% 
1:2:1 0.001 1 12.8% 20.8% 10.4% 32.0% 16.0% 8.0% 
1:2:1 0.01 1 12.7% 20.8% 10.4% 32.1% 16.0% 8.0% 
1:2:1 0.1 1 12.3% 20.4% 10.2% 32.6% 16.3% 8.1% 
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Table B.4. (cont.) 
1:2:1 1 1 9.1% 18.2% 9.1% 36.4% 18.2% 9.1% 
1:2:1 10 1 2.5% 13.5% 6.8% 44.1% 22.0% 11.0% 
1:2:1 100 1 0.3% 12.0% 6.0% 46.7% 23.3% 11.7% 
1:2:1 1000 1 0.0% 11.8% 5.9% 47.0% 23.5% 11.8% 
1:2:1 0.001 10 20.3% 23.2% 16.5% 11.6% 15.7% 12.7% 
1:2:1 0.01 10 19.7% 22.7% 16.4% 12.0% 16.1% 13.1% 
1:2:1 0.1 10 15.7% 19.3% 15.7% 14.3% 19.3% 15.7% 
1:2:1 1 10 5.1% 10.3% 13.8% 20.6% 27.7% 22.5% 
1:2:1 10 10 0.7% 6.5% 13.0% 23.2% 31.2% 25.4% 
1:2:1 100 10 0.1% 6.0% 12.9% 23.6% 31.7% 25.8% 
1:2:1 1000 10 0.0% 5.9% 12.9% 23.6% 31.7% 25.8% 
2:1:1 0.001 0.1 40.3% 19.6% 16.4% 9.5% 7.9% 6.3% 
2:1:1 0.01 0.1 40.3% 19.6% 16.4% 9.5% 7.9% 6.3% 
2:1:1 0.1 0.1 40.2% 19.6% 16.4% 9.5% 7.9% 6.3% 
2:1:1 1 0.1 39.4% 19.7% 16.4% 9.8% 8.2% 6.5% 
2:1:1 10 0.1 32.6% 20.4% 16.3% 12.3% 10.2% 8.1% 
2:1:1 100 0.1 12.0% 22.7% 16.1% 19.7% 16.4% 13.1% 
2:1:1 1000 0.1 1.6% 23.9% 16.0% 23.5% 19.5% 15.5% 
2:1:1 0.001 1 43.8% 17.8% 17.8% 6.9% 6.9% 6.9% 
2:1:1 0.01 1 43.7% 17.8% 17.8% 6.9% 6.9% 6.9% 
2:1:1 0.1 1 43.0% 17.9% 17.9% 7.1% 7.1% 7.1% 
2:1:1 1 1 36.4% 18.2% 18.2% 9.1% 9.1% 9.1% 
2:1:1 10 1 14.3% 19.3% 19.3% 15.7% 15.7% 15.7% 
2:1:1 100 1 2.0% 19.9% 19.9% 19.4% 19.4% 19.4% 
2:1:1 1000 1 0.2% 19.9% 19.9% 20.0% 20.0% 20.0% 
2:1:1 0.001 10 50.4% 14.4% 20.5% 1.8% 4.9% 7.9% 
2:1:1 0.01 10 49.8% 14.3% 20.7% 1.9% 5.1% 8.2% 
2:1:1 0.1 10 44.1% 13.5% 22.0% 2.5% 6.8% 11.0% 
2:1:1 1 10 20.6% 10.3% 27.7% 5.1% 13.8% 22.5% 
2:1:1 10 10 3.2% 7.9% 31.8% 7.1% 19.0% 31.0% 
2:1:1 100 10 0.3% 7.5% 32.5% 7.4% 19.9% 32.4% 
2:1:1 1000 10 0.0% 7.4% 32.6% 7.4% 20.0% 32.5% 
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Table B.5. Four-receptor, one-ligand (4R1L) model predictions. Tabulated model predictions across system configurations. Initial 
receptor concentrations (nR1, etc) expressed in receptors/cell. Predictions reported as % of total dimers formed at steady-state.   
Input Parameter Model Predictions 
kL1/kL2 nR1 nR2 nR3 nR4 D11 D12 D13 D14 D22 D23 D24 D33 D34 D44 
0.001 1000 1000 1000 1000 13.9% 11.3% 11.3% 11.3% 8.7% 8.7% 8.7% 8.7% 8.7% 8.7% 
0.01 1000 1000 1000 1000 13.9% 11.3% 11.3% 11.3% 8.7% 8.7% 8.7% 8.7% 8.7% 8.7% 
0.1 1000 1000 1000 1000 13.4% 11.1% 11.1% 11.1% 8.9% 8.9% 8.9% 8.9% 8.9% 8.9% 
1 1000 1000 1000 1000 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 
10 1000 1000 1000 1000 2.8% 7.6% 7.6% 7.6% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 
100 1000 1000 1000 1000 0.3% 6.8% 6.8% 6.8% 13.2% 13.2% 13.2% 13.2% 13.2% 13.2% 
1000 1000 1000 1000 1000 0.0% 6.7% 6.7% 6.7% 13.3% 13.3% 13.3% 13.3% 13.3% 13.3% 
0.001 2000 1000 1000 1000 30.6% 12.8% 12.8% 12.8% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 
0.01 2000 1000 1000 1000 30.5% 12.8% 12.8% 12.8% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 
0.1 2000 1000 1000 1000 29.9% 12.8% 12.8% 12.8% 5.3% 5.3% 5.3% 5.3% 5.3% 5.3% 
1 2000 1000 1000 1000 25.0% 12.5% 12.5% 12.5% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3% 
10 2000 1000 1000 1000 9.5% 11.6% 11.6% 11.6% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 
100 2000 1000 1000 1000 1.3% 11.2% 11.2% 11.2% 10.9% 10.9% 10.9% 10.9% 10.9% 10.9% 
1000 2000 1000 1000 1000 0.1% 11.1% 11.1% 11.1% 11.1% 11.1% 11.1% 11.1% 11.1% 11.1% 
0.001 10000 1000 1000 1000 75.3% 7.0% 7.0% 7.0% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 
0.01 10000 1000 1000 1000 75.3% 7.0% 7.0% 7.0% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 
0.1 10000 1000 1000 1000 75.1% 7.0% 7.0% 7.0% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 
1 10000 1000 1000 1000 73.5% 7.4% 7.4% 7.4% 0.7% 0.7% 0.7% 0.7% 0.7% 0.7% 
10 10000 1000 1000 1000 60.5% 10.3% 10.3% 10.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 
100 10000 1000 1000 1000 21.8% 18.9% 18.9% 18.9% 3.6% 3.6% 3.6% 3.6% 3.6% 3.6% 
1000 10000 1000 1000 1000 3.0% 23.1% 23.1% 23.1% 4.6% 4.6% 4.6% 4.6% 4.6% 4.6% 
0.001 1000 10000 1000 1000 0.9% 8.0% 0.8% 0.8% 72.8% 7.3% 7.3% 0.7% 0.7% 0.7% 
0.01 1000 10000 1000 1000 0.9% 7.9% 0.8% 0.8% 72.9% 7.3% 7.3% 0.7% 0.7% 0.7% 
0.1 1000 10000 1000 1000 0.8% 7.9% 0.8% 0.8% 72.9% 7.3% 7.3% 0.7% 0.7% 0.7% 
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Table B.5 (cont.) 
1 1000 10000 1000 1000 0.7% 7.4% 0.7% 0.7% 73.5% 7.4% 7.4% 0.7% 0.7% 0.7% 
10 1000 10000 1000 1000 0.3% 5.4% 0.5% 0.5% 75.8% 7.6% 7.6% 0.8% 0.8% 0.8% 
100 1000 10000 1000 1000 0.0% 4.1% 0.4% 0.4% 77.3% 7.7% 7.7% 0.8% 0.8% 0.8% 
1000 1000 10000 1000 1000 0.0% 3.9% 0.4% 0.4% 77.5% 7.7% 7.7% 0.8% 0.8% 0.8% 
0.001 1000 2000 2000 2000 4.1% 7.2% 7.2% 7.2% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 
0.01 1000 2000 2000 2000 4.1% 7.2% 7.2% 7.2% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 
0.1 1000 2000 2000 2000 4.0% 7.1% 7.1% 7.1% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 
1 1000 2000 2000 2000 3.2% 6.5% 6.5% 6.5% 12.9% 12.9% 12.9% 12.9% 12.9% 12.9% 
10 1000 2000 2000 2000 1.1% 4.6% 4.6% 4.6% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 
100 1000 2000 2000 2000 0.1% 3.8% 3.8% 3.8% 14.7% 14.7% 14.7% 14.7% 14.7% 14.7% 
1000 1000 2000 2000 2000 0.0% 3.7% 3.7% 3.7% 14.8% 14.8% 14.8% 14.8% 14.8% 14.8% 
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Table B.6. Two-ligand, one-receptor (2L1R) model predictions. Tabulated model predictions 
across system configurations. DA and DB are the % of total dimers bound to LA and LB, 
respectively, at steady-state. 
Input Parameters Model Predictions 
[LA]/[LB] kLA/kLB DA DB 
0.01 0.001 0.0% 100.0% 
0.01 0.01 0.0% 100.0% 
0.01 0.1 0.1% 99.9% 
0.01 1 1.0% 99.0% 
0.01 10 9.1% 90.9% 
0.01 100 49.5% 50.5% 
0.01 1000 90.6% 9.4% 
0.1 0.001 0.0% 100.0% 
0.1 0.01 0.1% 99.9% 
0.1 0.1 1.0% 99.0% 
0.1 1 9.1% 90.9% 
0.1 10 50.0% 50.0% 
0.1 100 90.9% 9.1% 
0.1 1000 99.0% 1.0% 
1 0.001 0.1% 99.9% 
1 0.01 1.0% 99.0% 
1 0.1 9.1% 90.9% 
1 1 50.0% 50.0% 
1 10 90.9% 9.1% 
1 100 99.0% 1.0% 
1 1000 99.9% 0.1% 
10 0.001 1.0% 99.0% 
10 0.01 9.1% 90.9% 
10 0.1 50.0% 50.0% 
10 1 90.9% 9.1% 
10 10 99.0% 1.0% 
10 100 99.9% 0.1% 
10 1000 100.0% 0.0% 
100 0.001 9% 91% 
100 0.01 50% 50% 
100 0.1 91% 9% 
100 1 99% 1% 
100 10 100% 0% 
100 100 100% 0% 
100 1000 100% 0% 
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Table B.7. Two-ligand, two-receptor, no-overlapping interactions (2L2R0X) model 
predictions. Tabulated model predictions across system configurations. D11, D12, and D22 are % 
homo- and heterodimers of total formed dimers at steady-state. DA and DB are the % of all 
dimers bound to LA and LB, respectively, at steady-state. 
Input Parameters Model Predictions 
[LA]/[LB] kA1/kB2 D11 D12 D22 DA DB 
0.01 0.001 0.0% 99.9% 0.1% 0.0% 100.0% 
0.01 0.01 0.1% 99.8% 0.1% 0.1% 99.9% 
0.01 0.1 0.8% 99.0% 0.1% 0.8% 99.2% 
0.01 1 7.6% 92.3% 0.1% 7.6% 92.4% 
0.01 10 36.1% 63.8% 0.2% 36.2% 63.8% 
0.01 100 27.3% 50.0% 22.7% 50.0% 50.0% 
0.01 1000 4.2% 50.0% 45.7% 50.0% 50.0% 
0.1 0.001 0.1% 99.8% 0.1% 0.1% 99.9% 
0.1 0.01 0.8% 99.0% 0.1% 0.9% 99.2% 
0.1 0.1 7.6% 92.3% 0.1% 7.6% 92.4% 
0.1 1 36.4% 63.4% 0.2% 36.5% 63.5% 
0.1 10 25.2% 50.0% 24.8% 50.0% 50.0% 
0.1 100 3.9% 50.0% 46.0% 50.0% 50.0% 
0.1 1000 0.4% 50.0% 49.5% 50.0% 50.0% 
1 0.001 0.8% 99.0% 0.1% 0.9% 99.2% 
1 0.01 7.6% 92.3% 0.1% 7.6% 92.4% 
1 0.1 36.5% 63.4% 0.2% 36.6% 63.4% 
1 1 25.0% 50.0% 25.0% 50.0% 50.0% 
1 10 3.9% 50.0% 46.1% 50.0% 50.0% 
1 100 0.4% 50.0% 49.5% 50.0% 50.0% 
1 1000 0.0% 50.0% 49.9% 50.0% 50.0% 
10 0.001 7.6% 92.3% 0.1% 7.6% 92.4% 
10 0.01 36.5% 63.4% 0.2% 36.6% 63.4% 
10 0.1 25.0% 50.0% 25.0% 50.0% 50.0% 
10 1 3.9% 50.0% 46.1% 50.0% 50.0% 
10 10 0.4% 50.0% 49.6% 50.0% 50.0% 
10 100 0.0% 50.0% 49.9% 50.0% 50.0% 
10 1000 0.0% 50.0% 50.0% 50.0% 50.0% 
100 0.001 36.5% 63.3% 0.2% 36.6% 63.4% 
100 0.01 25.0% 50.0% 25.0% 50.0% 50.0% 
100 0.1 3.9% 50.0% 46.1% 50.0% 50.0% 
100 1 0.4% 50.0% 49.6% 50.0% 50.0% 
100 10 0.0% 50.0% 49.9% 50.0% 50.0% 
100 100 0.0% 50.0% 50.0% 50.0% 50.0% 
100 1000 0.0% 50.0% 50.0% 50.0% 50.0% 
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Table B.8. Two-ligand, two-receptor, one-overlap (2L2R1X) model predictions. Tabulated 
model predictions across system configurations. D11, D12, and D22 are % homo- and heterodimers 
of total formed dimers at steady-state. DA and DB are the % of all dimers bound to LA and LB, 
respectively, at steady-state. 
Input Parameters Model Predictions 
[LA]/[LB] kA2/kB2 D11 D12 D22 DA DB 
0.01 0.001 7.6% 92.3% 0.1% 7.6% 92.4% 
0.01 0.01 7.6% 92.3% 0.1% 7.6% 92.4% 
0.01 0.1 7.7% 92.2% 0.1% 7.7% 92.3% 
0.01 1 8.4% 91.5% 0.1% 8.4% 91.6% 
0.01 10 14.8% 85.0% 0.2% 14.8% 85.2% 
0.01 100 44.6% 52.2% 3.2% 48.2% 51.8% 
0.01 1000 46.3% 36.3% 17.4% 87.6% 12.4% 
0.1 0.001 36.6% 63.1% 0.3% 36.8% 63.2% 
0.1 0.01 36.6% 63.1% 0.3% 36.8% 63.2% 
0.1 0.1 36.8% 62.9% 0.3% 37.0% 63.0% 
0.1 1 38.5% 61.1% 0.5% 38.8% 61.2% 
0.1 10 46.6% 48.1% 5.3% 53.4% 46.6% 
0.1 100 46.9% 36.1% 17.0% 88.6% 11.4% 
0.1 1000 61.5% 33.7% 4.7% 98.7% 1.3% 
1 0.001 42.4% 43.8% 13.8% 58.3% 41.7% 
1 0.01 42.3% 43.8% 13.9% 58.4% 41.6% 
1 0.1 42.1% 43.5% 14.4% 59.2% 40.8% 
1 1 40.7% 41.0% 18.3% 66.9% 33.1% 
1 10 45.4% 35.6% 19.0% 90.3% 9.7% 
1 100 61.2% 33.7% 5.1% 98.8% 1.2% 
1 1000 66.0% 33.4% 0.6% 99.9% 0.1% 
10 0.001 23.9% 35.8% 40.3% 80.1% 19.9% 
10 0.01 24.0% 35.8% 40.2% 80.4% 19.6% 
10 0.1 25.1% 35.4% 39.5% 83.7% 16.3% 
10 1 34.4% 34.4% 31.2% 94.0% 6.0% 
10 10 56.9% 33.6% 9.5% 99.2% 0.8% 
10 100 65.5% 33.4% 1.2% 99.9% 0.1% 
10 1000 66.5% 33.3% 0.1% 100.0% 0.0% 
100 0.001 5.4% 33.7% 60.9% 86.5% 13.5% 
100 0.01 5.8% 33.7% 60.5% 88.5% 11.5% 
100 0.1 10.1% 33.6% 56.3% 95.4% 4.6% 
100 1 33.4% 33.4% 33.1% 99.3% 0.7% 
100 10 60.2% 33.4% 6.5% 99.9% 0.1% 
100 100 66.0% 33.3% 0.7% 100.0% 0.0% 
100 1000 66.6% 33.3% 0.1% 100.0% 0.0% 
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Table B.9. Two-ligand, two-receptor, two-overlap (2L2R2X) model predictions. Tabulated 
model predictions across system configurations. D11, D12, and D22 are % homo- and heterodimers 
of total formed dimers at steady-state. DA and DB are the % of all dimers bound to LA and LB, 
respectively, at steady-state. 
Input Parameters Model Predictions 
[LA]/[LB] kA2/kB2 D11 D12 D22 DA DB 
0.01 0.001 33.3% 33.3% 33.4% 0.5% 99.5% 
0.01 0.01 33.3% 33.3% 33.4% 0.5% 99.5% 
0.01 0.1 33.3% 33.3% 33.4% 0.5% 99.5% 
0.01 1 33.3% 33.3% 33.3% 1.0% 99.0% 
0.01 10 33.5% 33.3% 33.2% 5.2% 94.8% 
0.01 100 34.9% 33.3% 31.7% 31.8% 68.2% 
0.01 1000 44.0% 33.3% 22.7% 74.7% 25.3% 
0.1 0.001 33.2% 33.3% 33.5% 4.7% 95.3% 
0.1 0.01 33.2% 33.3% 33.5% 4.8% 95.2% 
0.1 0.1 33.2% 33.3% 33.5% 5.2% 94.8% 
0.1 1 33.3% 33.3% 33.3% 9.1% 90.9% 
0.1 10 34.8% 33.3% 31.8% 34.5% 65.5% 
0.1 100 44.7% 33.3% 21.9% 75.8% 24.2% 
0.1 1000 61.3% 33.3% 5.3% 86.1% 13.9% 
1 0.001 31.6% 33.3% 35.0% 32.1% 67.9% 
1 0.01 31.7% 33.3% 35.0% 32.4% 67.6% 
1 0.1 31.8% 33.3% 34.9% 34.6% 65.4% 
1 1 33.3% 33.3% 33.3% 50.0% 50.0% 
1 10 43.5% 33.3% 23.2% 79.8% 20.2% 
1 100 60.9% 33.3% 5.8% 88.2% 11.8% 
1 1000 66.0% 33.3% 0.7% 89.1% 10.9% 
10 0.001 21.7% 33.3% 45.0% 75.4% 24.6% 
10 0.01 21.8% 33.3% 44.8% 75.9% 24.1% 
10 0.1 23.2% 33.3% 43.5% 79.8% 20.2% 
10 1 33.3% 33.3% 33.3% 90.9% 9.1% 
10 10 56.7% 33.3% 10.0% 95.2% 4.8% 
10 100 65.4% 33.3% 1.3% 95.6% 4.4% 
10 1000 66.5% 33.3% 0.1% 95.6% 4.4% 
100 0.001 5.3% 33.3% 61.4% 86.2% 13.8% 
100 0.01 5.7% 33.3% 60.9% 88.2% 11.8% 
100 0.1 10.0% 33.3% 56.7% 95.2% 4.8% 
100 1 33.3% 33.3% 33.3% 99.0% 1.0% 
100 10 60.2% 33.3% 6.5% 99.4% 0.6% 
100 100 65.9% 33.3% 0.7% 99.4% 0.6% 
100 1000 66.6% 33.3% 0.1% 99.4% 0.6% 
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B.2 Model equations 
B.2.1 Two-receptor, one-ligand (2R1L) model 
(1) 
[ ] [ ] [ ]( )L1 L1 L2 L2 L1 1 L2 2
ext
d L 1 ak C ak C k L R k L R
dt V
= + − −  
(2) ( ) [ ] ( )1 L1 L1 dim 11 12 L1 1 dim 1 L1 L2
dR ak C ak D D k L R k R C C
dt
= + + − − +  
(3) ( ) [ ] ( )2 L2 L2 dim 12 22 L2 2 dim 2 L1 L2
dR ak C ak D D k L R k R C C
dt
= + + − − +  
(4) [ ] ( )L1 L1 1 L1 L1 dim 11 12 dim 1 L1 dim 2 L1
dC k L R ak C ak D D k R C k R C
dt
= − + + − −  
(5) [ ] ( )L2 L2 2 L2 L2 dim 12 22 dim 1 L2 dim 2 L2
dC k L R ak C ak D D k R C k R C
dt
= − + + − −  
(6) 11 dim 1 L1 dim 11
dD k R C ak D
dt
= −  
(7) 12 dim 1 L2 dim 2 L1 dim 12
dD k R C k R C 2 ak D
dt
= + − ⋅  
(8) 22 dim 2 L2 dim 22
dD k R C ak D
dt
= −  
 
B.2.2 Three-receptor, one-ligand (3R1L) model 
(1) 
[ ] [ ] [ ] [ ]( )L1 L1 L2 L2 L3 L3 L1 1 L2 2 L3 3
ext
d L 1 ak C ak C ak C k L R k L R k L R
dt V
= + + − − −  
(2) [ ] ( ) ( )1 L1 L1 L1 1 dim 11 12 13 dim 1 L1 L2 L3
dR ak C k L R ak D D D k R C C C
dt
= − + + + − + +  
(3) [ ] ( ) ( )2 L2 L2 L2 2 dim 12 22 23 dim 2 L1 L2 L3
dR ak C k L R ak D D D k R C C C
dt
= − + + + − + +  
(4) [ ] ( ) ( )3 L3 L3 L3 3 dim 13 23 33 dim 3 L1 L2 L3
dR ak C k L R ak D D D k R C C C
dt
= − + + + − + +  
(5) [ ] ( ) ( )L1 L1 1 L1 L1 dim 11 12 13 dim L1 1 2 3
dC k L R ak C ak D D D k C R R R
dt
= − + + + − + +  
(6) [ ] ( ) ( )L2 L2 2 L2 L2 dim 12 22 23 dim L2 1 2 3
dC k L R ak C ak D D D k C R R R
dt
= − + + + − + +  
(7) [ ] ( ) ( )L3 L3 3 L3 L3 dim 13 23 33 dim L3 1 2 3
dC k L R ak C ak D D D k C R R R
dt
= − + + + − + +  
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(8) 11 dim 1 L1 dim 11
dD k R C ak D
dt
= −  
(9) 12 dim 1 L2 dim 2 L1 dim 12
dD k R C k R C 2 ak D
dt
= + − ⋅  
(10) 13 dim 1 L3 dim 3 L1 dim 13
dD k R C k R C 2 ak D
dt
= + − ⋅  
(11) 22 dim 2 L2 dim 22
dD k R C ak D
dt
= −  
(12) 23 dim 2 L3 dim 3 L2 dim 23
dD k R C k R C 2 ak D
dt
= + − ⋅  
(13)  33 dim 3 L3 dim 33
dD k R C ak D
dt
= −  
 
B.2.3 Four-receptor, one-ligand (4R1L) model 
(1) 
[ ] [ ]
[ ] [ ] [ ]
L1 L1 L2 L2 L3 L3 L4 L4 L1 1
ext L2 2 L3 3 L4 4
ak C ak C ak C ak C k L Rd L 1
dt V k L R k L R k L R
 + + + −
=   − − − 
 
(2) [ ] ( )
( )
1
L1 L1 L1 1 dim 11 12 13 14
dim 1 L1 L2 L3 L4
dR ak C k L R ak D D D D
dt
k R C C C C
= − + + + +
− + + +
 
(3) [ ] ( )
( )
2
L2 L2 L2 2 dim 12 22 23 24
dim 2 L1 L2 L3 L4
dR ak C k L R ak D D D D
dt
k R C C C C
= − + + + +
− + + +
 
(4) [ ] ( )
( )
3
L3 L3 L3 3 dim 13 23 33 34
dim 3 L1 L2 L3 L4
dR ak C k L R ak D D D D
dt
k R C C C C
= − + + + +
− + + +
 
(5) [ ] ( )
( )
4
L4 L4 L4 4 dim 14 24 34 44
dim 4 L1 L2 L3 L4
dR ak C k L R ak D D D D
dt
k R C C C C
= − + + + +
− + + +
 
(6) [ ] ( )
( )
L1
L1 1 L1 L1 dim 11 12 13 14
dim L1 1 2 3 4
dC k L R ak C ak D D D D
dt
k C R R R R
= − + + + +
− + + +
 
(7) [ ] ( )
( )
L2
L2 2 L2 L2 dim 12 22 23 24
dim L2 1 2 3 4
dC k L R ak C ak D D D D
dt
k C R R R R
= − + + + +
− + + +
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(8) [ ] ( )
( )
L3
L3 3 L3 L3 dim 13 23 33 34
dim L3 1 2 3 4
dC k L R ak C ak D D D D
dt
k C R R R R
= − + + + +
− + + +
 
(9) [ ] ( )
( )
L4
L4 4 L4 L4 dim 14 24 34 44
dim L4 1 2 3 4
dC k L R ak C ak D D D D
dt
k C R R R R
= − + + + +
− + + +
 
(10) 11 dim 1 L1 dim 11
dD k R C ak D
dt
= −  
(11) 12 dim 1 L2 dim 2 L1 dim 12
dD k R C k R C 2 ak D
dt
= + − ⋅  
(12) 13 dim 1 L3 dim 3 L1 dim 13
dD k R C k R C 2 ak D
dt
= + − ⋅  
(13) 14 dim 1 L4 dim 4 L1 dim 14
dD k R C k R C 2 ak D
dt
= + − ⋅   
(14) 22 dim 2 L2 dim 22
dD k R C ak D
dt
= −  
(15) 23 dim 2 L3 dim 3 L2 dim 23
dD k R C k R C 2 ak D
dt
= + − ⋅  
(16) 24 dim 2 L4 dim 4 L2 dim 24
dD k R C k R C 2 ak D
dt
= + − ⋅  
(17)  33 dim 3 L3 dim 33
dD k R C ak D
dt
= −  
(18) 34 dim 3 L4 dim 4 L3 dim 34
dD k R C k R C 2 ak D
dt
= + − ⋅  
(19) 44 dim 4 L4 dim 44
dD k R C ak D
dt
= −  
 
B.2.4 Two-ligand, one-receptor (2L1R) model 
(1) 
[ ] [ ]( )A A1 A1 A1 A 1
ext
d L 1 ak C k L R
dt V
= −  
(2) 
[ ] [ ]( )B B1 B1 B1 B 1
ext
d L 1 ak C k L R
dt V
= −  
(3) [ ] [ ]1 A1 A1 A1 A 1 B1 B1 B1 B 1
dR ak C k L R ak C k L R
dt
= − + −  
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(4) [ ]A1 A1 A 1 A1 A1 dim A dim 1 A1
dC k L R ak C ak D k R C
dt
= − + −  
(5) [ ]B1 B1 B 1 B1 B1 dim B dim 1 B1
dC k L R ak C ak D k R C
dt
= − + −  
(6) A dim 1 A1 dim A
dD k R C ak D
dt
= −  
(7) B dim 1 B1 dim B
dD k R C ak D
dt
= −  
 
B.2.5 Two-ligand, two-receptor, no-overlap (2L2R0X) model 
(1) 
[ ] [ ]( )A A1 A1 A1 A 1
ext
d L 1 ak C k L R
dt V
= −  
(2) 
[ ] [ ]( )B B2 B2 B2 B 2
ext
d L 1 ak C k L R
dt V
= −  
(3) [ ] ( ) ( )1 A1 A1 A1 A 1 dim 1 A1 B2 dim A11 B12dR ak C k L R k R C C ak D Ddt = − + + − +  
(4) [ ] ( ) ( )2 B2 B2 B2 B 2 dim 2 B2 A1 dim A12 B22
dR ak C k L R k R C C ak D D
dt
= − + + − +  
(5) [ ]A1 A1 A 1 A1 A1 dim A11 dim 1 A1 dim A12 dim 2 A1
dC k L R ak C ak D k R C ak D k R C
dt
= − + − + −  
(6) [ ]B2 B2 B 2 B2 B2 dim B22 dim 2 B2 dim B12 dim 1 B2
dC k L R ak C ak D k R C ak D k R C
dt
= − + − + −  
(7) A11 dim 1 A1 dim A11
dD k R C ak D
dt
= −  
(8) A12 dim 2 A1 dim A12
dD k R C ak D
dt
= −  
(9) B12 dim 1 B2 dim B12
dD k R C ak D
dt
= −  
(10) B22 dim 2 B2 dim B22
dD k R C ak D
dt
= −  
B.2.6 Two-ligand, two-receptor, one-overlap (2L2R1X) model 
(1) 
[ ] [ ] [ ]( )A A1 A1 A1 A 1 A2 A2 A2 A 2
ext
d L 1 ak C k L R ak C k L R
dt V
= − + −  
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(2) 
[ ] [ ]( )B B2 B2 B2 B 2
ext
d L 1 ak C k L R
dt V
= −  
(3) [ ] ( ) ( )1 A1 A1 A1 A 1 dim 1 A1 A2 B2 dim A11 A12 B12
dR ak C k L R k R C C C ak D D D
dt
= − + + + − + +  
(4) [ ] [ ] ( )
( )
2
B2 B2 B2 B 2 A2 A2 A2 A 2 dim 2 B2 A1 A2
dim A12 B22 A22
dR ak C k L R ak C k L R k R C C C
dt
ak D D D
= − + − + + +
− + +
 
(5) [ ] ( ) ( )A1 A1 A 1 A1 A1 dim A11 A12 dim A1 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(6) [ ] ( ) ( )A2 A2 A 2 A2 A2 dim A12 A22 dim A2 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(7) [ ] ( ) ( )B2 B2 B 2 B2 B2 dim B12 B22 dim B2 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(8) A11 dim 1 A1 dim A11
dD k R C ak D
dt
= −  
(9) A12 dim 1 A1 dim A12 dim 1 A2 dim A12
dD k R C ak D k R C ak D
dt
= − + −  
(10) A22 dim 2 A2 dim A22
dD k R C ak D
dt
= −  
(11) B12 dim 1 B2 dim B12
dD k R C ak D
dt
= −  
(12) B22 dim 2 B2 dim B22
dD k R C ak D
dt
= −  
 
B.2.7 Two-ligand, two-receptor, one-overlap (2L2R2X) model 
(1) 
[ ] [ ] [ ]( )A A1 A1 A1 A 1 A2 A2 A2 A 2
ext
d L 1 ak C k L R ak C k L R
dt V
= − + −  
(2) 
[ ] [ ] [ ]( )B B1 B1 B1 B 1 B2 B2 B2 B 2
ext
d L 1 ak C k L R ak C k L R
dt V
= − + −  
(3) [ ] [ ] [ ]
( ) ( )
1
A1 A1 A1 A 1 B1 B1 B1 B 1 B1 B1 B1 B 1
dim 1 A1 A2 B1 B2 dim A11 A12 B11 B12
dR ak C k L R ak C k L R ak C k L R
dt
k R C C C C ak D D D D
= − + − + −
+ + + + − + + +
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(4) [ ] [ ] ( )
( )
2
B2 B2 B2 B 2 A2 A2 A2 A 2 dim 2 B1 B2 A1 A2
dim A12 B12 B22 A22
dR ak C k L R ak C k L R k R C C C C
dt
ak D D D D
= − + − + + + +
− + + +
 
(5) [ ] ( ) ( )A1 A1 A 1 A1 A1 dim A11 A12 dim A1 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(6) [ ] ( ) ( )A2 A2 A 2 A2 A2 dim A12 A22 dim A2 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(7) [ ] ( ) ( )B1 B1 B 1 B1 B1 dim B11 B12 dim B1 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(8) [ ] ( ) ( )B2 B2 B 2 B2 B2 dim B12 B22 dim B2 1 2
dC k L R ak C ak D D k C R R
dt
= − + + − +  
(9) A11 dim 1 A1 dim A11
dD k R C ak D
dt
= −  
(10) A12 dim 1 A2 dim A12 dim 1 A2 dim A12
dD k R C ak D k R C ak D
dt
= − + −  
(11) A22 dim 2 A2 dim A22
dD k R C ak D
dt
= −  
(12) B11 dim 1 B1 dim B11
dD k R C ak D
dt
= −  
(13) B12 dim 1 B2 dim B12 dim 2 B1 dim B12
dD k R C ak D k R C ak D
dt
= − + −  
(14) B22 dim 2 B2 dim B22
dD k R C ak D
dt
= −  
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B.3 Supplementary Figures 
 
 
Figure B.1. Comparison of dimerization regimes at higher order models. Plots depict steady 
state dimer levels for the (A) – (C) three receptor and (D) – (F) four receptor models varying 
kinetic rate parameters under different initial receptor level configurations.  
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Figure B.2. Two-ligand, one-receptor model parameter space. Compares fractional dimers 
activated by ligand A with dimers activated by ligand B across different ligand concentrations 
while varying the ratio of the binding constants. (A) 1 kA1:1000 kB2, (B) 1 kA1:100 kB2, (C) 1 
kA1:10 kB2, (D) 1 kA1:1 kB2, (E) 10 kA1:1 kB2, (F) 100 kA1:1 kB2, (G) 1000 kA1:1 kB2. 
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Figure B.3. Two receptor model with no overlap. Compares the fractional dimers of 
homodimers made with receptor 1 and receptor 2, as well as heterodimers made with receptors 1-
2 across different ligand concentrations while varying the ratios between the binding rates. (A) 1 
kA1:1000 kB2, (B) 1 kA1:100 kB2, (C) 1 kA1:10 kB2, (D) 1 kA1:1 kB2, (E) 10 kA1:1 kB2, (F) 100 kA1:1 
kB2, (G) 1000 kA1:1 kB2 
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Figure B.4. Two receptor model with two overlaps. Compares the fractional dimers of 
homodimers made with receptor 1 and receptor 2, as well as heterodimers made with receptors 1-
2 across different ligand concentrations while varying the ratios between the binding rates. (A) 1 
kA1:1000 kB2, (B) 1 kA1:100 kB2, (C) 1 kA1:10 kB2, (D) 1 kA1:1 kB2, (E) 10 kA1:1 kB2, (F) 100 kA1:1 
kB2, (G) 1000 kA1:1 kB2 
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Figure B.5. Two-receptor, two-ligand, two-overlapping interactions (2R2L2X) model 
parameter space. Compares the fractional dimers of homodimers made with receptor 1 and 
receptor 2, as well as heterodimers made with receptors 1-2 across different ligand 
concentrations while varying the ratios between the binding rates. (A) 1 kA1:1000 kB2, (B) 1 
kA1:100 kB2, (C) 1 kA1:10 kB2, (D) 1 kA1:1 kB2, (E) 10 kA1:1 kB2, (F) 100 kA1:1 kB2, (G) 1000 kA1:1 
kB2.
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APPENDIX C 
SUPPLEMENTAL– VEGF-A SPLICE VARIANT BINDING 
 
C.1 Supplementary Tables 
Table C.1. VEGF-Axxx:VEGFR binding kinetics and affinities. Kinetic constants were obtained by performing global kinetic 
analysis using the BIAevaluation software across binding sensograms obtained at 10 nM, 20 nM, and 40 nM for each ligand-receptor 
pair. Affinity constants were calculated as the ratio of the association and dissociation rates. Rate constants where the χ2-to-Rmax ratio 
exceeds 1.0 are shown in italics, indicating interactions that are dominated by non-specific interactions. Ligand-receptor pairs that 
produced negative association curves were not analyzed with global fitting (indicated by “NI” for no interaction). All values are 
presented as the arithmetic mean ± standard error of the mean (SEM). (*p < 0.05, **p < 0.01, ***p < 0.001; each concentration series 
was performed in triplicate). 
 
 
 
 
 
 
VEGFR1 VEGFR2 
ka (M
-1 s-1) kd (s
-1) KD (M) ka (M
-1 s-1) kd (s
-1) KD (M) 
VEGF-A165 4.0 ± 0.04 * 105 4.0 ± 0.1 * 10-7 1.0 ± 0.3 * 10-12 9.7 ± 0.3 * 105 9.5 ± 0.2 * 10-6 9.8 ± 0.4 * 10-12 
VEGF-A121 4.1 ± 0.3 * 105 1.9 ± 0.07 * 10-3 3.7 ± 0.3 * 10-9 4.5 ± 1.4 * 105 3.0 ± 0.5 * 10-4 6.6 ± 2.0 * 10-10 
VEGF-A-165b 4.9 ± 0.8 * 103 1.1 ± 0.3 * 10-5 2.3 ± 0.7 * 10-9 1.2 ± 0.9 * 106 9.7 ± 0.1 * 10-7 8.1 ± 0.6 * 10-13 
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Table C.2. χ2-to-Rmax quality-of-fit for VEGFAxxx:VEGFR global kinetic fitting. The ratio 
reflects how well a global kinetic analysis of a multi-concentration sensogram series can fit to a 
simple 1:1 Langmuir interaction model can fit. True interactions were distinguished from those 
due to non-specific binding patterns where χ2-to-Rmax < 1.0. Fitted curves where χ2-to-Rmax > 1.0 
were considered to be dominated by non-specific binding. Ligand-receptor pairs that produced 
negative association curves were not analyzed with global fitting (indicated by “NI” for no 
interaction). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VEGFR1 VEGFR2 
VEGF-A165 0.17 0.52 
VEGF-A121 0.13 0.029 
VEGF-A165b 0.039 0.12 
